#BEGIN_DRUGCARD DB04272

# AHFS_Codes:
Not Available

# ATC_Codes:
A09AB04

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
77-92-9

# ChEBI_ID:
30769

# Chemical_Formula:
C6H8O7

# Chemical_IUPAC_Name:
2-hydroxypropane-1,2,3-tricarboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A key intermediate in metabolism.  It is an acid compound found in citrus fruits.  The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anticoagulants
Chelating Agents

# Drug_Interactions:
Azilsartan medoxomil	Increases serum potassium.
Eltrombopag	Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
Lithium	The urine alkalizer decreases the effect of lithium

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.64

# Experimental_Logs:
0.51

# Experimental_Water_Solubility:
5.92E+005 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Citric Acid

# HET_ID:
CIT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

# InChI_Key:
InChIKey=KRKNYBCHXYNGOX-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00158

# KEGG_Drug_ID:
D00037

# LIMS_Drug_ID:
4272

# Mechanism_Of_Action:
Not Available

# Melting_Point:
153 °C

# Molecular_Weight_Avg:
192.1235

# Molecular_Weight_Mono:
192.02700261

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1HTO

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449021

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-0.26

# Predicted_Water_Solubility:
1.06e+02 g/l

# Primary_Accession_No:
DB04272

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00922

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)CC(O)(CC(O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:09 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
2.79

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
AB013300

# Drug_Target_10_GenBank_ID_Protein:
3434984

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
dxr

# Drug_Target_10_Gene_Sequence:
>1197 bp
ATGAAGCAACTCACCATTCTGGGCTCGACCGGCTCGATTGGTTGCAGCACGCTGGACGTG
GTGCGCCATAATCCCGAACACTTCCGCGTAGTTGCGCTGGTGGCAGGCAAAAATGTCACT
CGCATGGTAGAACAGTGCCTGGAATTCTCTCCCCGCTATGCCGTAATGGACGATGAAGCG
AGTGCGAAACTTCTTAAAACGATGCTACAGCAACAGGGTAGCCGCACCGAAGTCTTAAGT
GGGCAACAAGCCGCTTGCGATATGGCAGCGCTTGAGGATGTTGATCAGGTGATGGCAGCC
ATTGTTGGCGCTGCTGGGCTGTTACCTACGCTTGCTGCGATCCGCGCGGGTAAAACCATT
TTGCTGGCCAATAAAGAATCACTGGTTACCTGCGGACGTCTGTTTATGGACGCCGTAAAG
CAGAGCAAAGCGCAATTGTTACCGGTCGATAGCGAACATAACGCCATTTTTCAGAGTTTA
CCGCAACCTATCCAGCATAATCTGGGATACGCTGACCTTGAGCAAAATGGCGTGGTGTCC
ATTTTACTTACCGGGTCTGGTGGCCCTTTCCGTGAGACGCCATTGCGCGATTTGGCAACA
ATGACGCCGGATCAAGCCTGCCGTCATCCGAACTGGTCGATGGGGCGTAAAATTTCTGTC
GATTCGGCTACCATGATGAACAAAGGTCTGGAATACATTGAAGCGCGTTGGCTGTTTAAC
GCCAGCGCCAGCCAGATGGAAGTGCTGATTCACCCGCAGTCAGTGATTCACTCAATGGTG
CGCTATCAGGACGGCAGTGTTCTGGCGCAGCTGGGGGAACCGGATATGCGTACGCCAATT
GCCCACACCATGGCATGGCCGAATCGCGTGAACTCTGGCGTGAAGCCGCTCGATTTTTGC
AAACTAAGTGCGTTGACATTTGCCGCACCGGATTATGATCGTTATCCATGCCTGAAACTG
GCGATGGAGGCGTTCGAACAAGGCCAGGCAGCGACGACAGCATTGAATGCCGCAAACGAA
ATCACCGTTGCTGCTTTTCTTGCGCAACAAATCCGCTTTACGGATATCGCTGCGTTGAAT
TTATCCGTACTGGAAAAAATGGATATGCGCGAACCACAATGTGTGGACGATGTGTTATCT
GTTGATGCGAACGCGCGTGAAGTCGCCAGAAAAGAGGTGATGCGTCTCGCAAGCTGA

# Drug_Target_10_General_Function:
Lipid transport and metabolism

# Drug_Target_10_General_References:
10631325	Radykewicz T, Rohdich F, Wungsintaweekul J, Herz S, Kis K, Eisenreich W, Bacher A, Zenk MH, Arigoni D: Biosynthesis of terpenoids: 1-deoxy-D-xylulose-5-phosphate reductoisomerase from Escherichia coli is a class B dehydrogenase. FEBS Lett. 2000 Jan 14;465(2-3):157-60.
10787409	Kuzuyama T, Takahashi S, Takagi M, Seto H: Characterization of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme involved in isopentenyl diphosphate biosynthesis, and identification of its catalytic amino acid residues. J Biol Chem. 2000 Jun 30;275(26):19928-32.
1447125	Yamanaka K, Ogura T, Niki H, Hiraga S: Identification and characterization of the smbA gene, a suppressor of the mukB null mutant of Escherichia coli. J Bacteriol. 1992 Dec;174(23):7517-26.
7567469	Borodovsky M, McIninch JD, Koonin EV, Rudd KE, Medigue C, Danchin A: Detection of new genes in a bacterial genome using Markov models for three gene classes. Nucleic Acids Res. 1995 Sep 11;23(17):3554-62.
8202364	Fujita N, Mori H, Yura T, Ishihama A: Systematic sequencing of the Escherichia coli genome: analysis of the 2.4-4.1 min (110,917-193,643 bp) region. Nucleic Acids Res. 1994 May 11;22(9):1637-9.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9707569	Takahashi S, Kuzuyama T, Watanabe H, Seto H: A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9879-84.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
2869

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
43389

# Drug_Target_10_Name:
1-deoxy-D-xylulose 5-phosphate reductoisomerase

# Drug_Target_10_Number_of_Residues:
398

# Drug_Target_10_PDB_ID:
1ONP

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF02670	DXP_reductoisom
PF08436	DXP_redisom_C

# Drug_Target_10_Protein_Sequence:
>1-deoxy-D-xylulose 5-phosphate reductoisomerase
MKQLTILGSTGSIGCSTLDVVRHNPEHFRVVALVAGKNVTRMVEQCLEFSPRYAVMDDEA
SAKLLKTMLQQQGSRTEVLSGQQAACDMAALEDVDQVMAAIVGAAGLLPTLAAIRAGKTI
LLANKESLVTCGRLFMDAVKQSKAQLLPVDSEHNAIFQSLPQPIQHNLGYADLEQNGVVS
ILLTGSGGPFRETPLRDLATMTPDQACRHPNWSMGRKISVDSATMMNKGLEYIEARWLFN
ASASQMEVLIHPQSVIHSMVRYQDGSVLAQLGEPDMRTPIAHTMAWPNRVNSGVKPLDFC
KLSALTFAAPDYDRYPCLKLAMEAFEQGQAATTALNAANEITVAAFLAQQIRFTDIAALN
LSVLEKMDMREPQCVDDVLSVDANAREVARKEVMRLAS

# Drug_Target_10_Reaction:
2-C-methyl-D-erythritol 4-phosphate + NADP+ = 1-deoxy-D-xylulose 5-phosphate + NADPH + H+

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP)

# Drug_Target_10_SwissProt_ID:
P45568

# Drug_Target_10_SwissProt_Name:
DXR_ECOLI

# Drug_Target_10_Synonyms:
1-deoxyxylulose-5-phosphate reductoisomerase
2-C- methyl-D-erythritol 4-phosphate synthase
DXP reductoisomerase
EC 1.1.1.267

# Drug_Target_10_Theoretical_pI:
5.88

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
M32108

# Drug_Target_11_GenBank_ID_Protein:
155133

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
trpA

# Drug_Target_11_Gene_Sequence:
>816 bp
GTGACCACCCTCGAGGCCTTCGCCAAGGCCCGGTCCGAGGGCCGGGCCGCCCTCATCCCT
TACCTCACCGCGGGCTTCCCCAGCCGGGAGGGCTTTTTGCAGGCGGTGGAGGAGGTCCTC
CCCTATGCCGACCTTCTGGAGATCGGCCTCCCCTACTCCGACCCCCTGGGGGACGGCCCC
GTGATCCAGCGGGCAAGCGAACTGGCCCTGAGGAAGGGGATGAGCGTCCAAGGCGCTTTG
GAGCTCGTCCGCGAGGTGCGCGCCCTCACGGAGAAACCCCTCTTCCTCATGACCTACCTG
AACCCCGTCCTGGCCTGGGGGCCGGAGCGCTTCTTCGGCCTCTTCAAGCAGGCGGGGGCC
ACGGGGGTGATCCTTCCCGACCTTCCCCCCGACGAGGACCCAGGCCTCGTGCGCCTCGCC
CAGGAGATCGGCCTGGAGACGGTCTTCCTTCTCGCCCCCACCTCCACGGACGCCCGCATC
GCCACCGTGGTCCGCCACGCCACGGGCTTCTCGTACGCCGTCTCCGTCACCGGGGTCACG
GGGATGCGGGAAAGGCTTCCCGAGGAGGTCAAGGACCTGGTGCGGCGCATCAAGGCCAGG
ACCGCCCTCCCCGTGGCCGTGGGCTTCGGGGTTTCCGGCAAGGCCACGGCCGCGCAGGCG
GCGGTGGCGGACGGGGTGGTGGTGGGAAGCGCCTTGGTCCGGGCCTTGGAGGAGGGGAGG
TCCCTTGCGCCCCTTCTCCAGGAGATCCGCCAGGGCCTCCAGCGCCTCGAGGCCAACCCC
GGCCTGAAGGAAAGCTCAAAGAAGCCGTTGTCCTGA

# Drug_Target_11_General_Function:
Amino acid transport and metabolism

# Drug_Target_11_General_References:
2188962	Koyama Y, Furukawa K: Cloning and sequence analysis of tryptophan synthetase genes of an extreme thermophile, Thermus thermophilus HB27: plasmid transfer from replica-plated Escherichia coli recombinant colonies to competent T. thermophilus cells. J Bacteriol. 1990 Jun;172(6):3490-5.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
3132

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
28937

# Drug_Target_11_Name:
Tryptophan synthase alpha chain

# Drug_Target_11_Number_of_Residues:
271

# Drug_Target_11_PDB_ID:
1UJP

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00290	Trp_syntA

# Drug_Target_11_Protein_Sequence:
>Tryptophan synthase alpha chain
MTTLEAFAKARSEGRAALIPYLTAGFPSREGFLQAVEEVLPYADLLEIGLPYSDPLGDGP
VIQRASELALRKGMSVQGALELVREVRALTEKPLFLMTYLNPVLAWGPERFFGLFKQAGA
TGVILPDLPPDEDPGLVRLAQEIGLETVFLLAPTSTDARIATVVRHATGFVYAVSVTGVT
GMRERLPEEVKDLVRRIKARTALPVAVGFGVSGKATAAQAAVADGVVVGSALVRALEEGR
SLAPLLQEIRQGLQRLEANPGLKESSKKPLS

# Drug_Target_11_Reaction:
L-serine + 1-C-(indol-3-yl)glycerol 3-phosphate = L-tryptophan + glyceraldehyde 3-phosphate + H2O

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
The alpha subunit is responsible for the aldol cleavage of indoleglycerol phosphate to indole and glyceraldehyde 3- phosphate

# Drug_Target_11_SwissProt_ID:
P16608

# Drug_Target_11_SwissProt_Name:
TRPA_THET2

# Drug_Target_11_Synonyms:
EC 4.2.1.20

# Drug_Target_11_Theoretical_pI:
6.09

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Secreted protein

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
D01045

# Drug_Target_12_GenBank_ID_Protein:
216784

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
nedA

# Drug_Target_12_Gene_Sequence:
>1944 bp
ATGACTGCGAATCCGTACCTCCGCCGCCTGCCCCGGCGCCGAGCCGTCAGCTTCCTGCTC
GCACCAGCGCTGGCGGCCGCCACGGTCGCCGGCGCGTCCCCCGCACAGGCCATCGCCGGG
GCACCCGTCCCGCCCGGCGGCGAGCCGCTCTACACGGAGCAGGACCTCGCCGTGAACGGC
AGGGAGGGCTTTCCGAACTACCGCATCCCAGCGCTGACCGTCACGCCCGACGGGGACCTG
CTGGCCTCGTACGACGGCCGCCCGACCGGTATCGACGCGCCCGGCCCCAACTCCATCCTC
CAACGCCGCAGCACCGACGGCGGCCGGACGTGGGGCGAGCAACAGGTCGTCAGCGCCGGC
CAGACCACCGCGCCGATCAAGGGGTTCTCCGACCCCAGCTACCTTGTCGACCGGGAAACC
GGGACCATCTTCAACTTCCACGTCTACTCCCAGCGGCAGGGCTTCGCCGGCAGCCGGCCC
GGCACCGACCCGGCAGACCCCAACGTGCTCCACGCCAACGTCGCGACCTCGACCGACGGC
GGTCTGACCTGGTCGCACCGGACCATCACGGCCGACATCACCCCGGATCCGGGCTGGCGC
AGCCGCTTCGCCGCCTCCGGCGAAGGCATCCAGCTCCGCTATGGACCCCACGCCGGTCGA
CTCATCCAGCAGTACACGATCATCAACGCTGCCGGCGCCTTCCAGGCGGTGAGCGTGTAC
AGCGACGACCACGGAAGGACCTGGCGCGCCGGCGAAGCCGTCGGGGTCGGCATGGACGAG
AACAAGACCGTGGAACTCTCCGATGGCCGGGTCCTGCTCAACAGCCGCGACTCGGCCCGC
AGCGGATACCGTAAGGTGGCCGTCTCCACTGACGGCGGCCACAGCTACGGCCCGGTGACC
ATCGACCGCGACCTCCCCGACCCGACGAACAACGCATCGATCATCCGGGCCTTCCCTGAC
GCCCCGGCCGGCTCCGCGCGGGCCAAGGTCCTGCTCTTCTCCAACGCCGCCAGCCAGACC
TCGCGCAGTCAGGGCACCATCCGGATGTCCTGCGACGATGGCCAGACCTGGCCGGTTTCG
AAGGTCTTCCAGCCCGGCTCGATGTCGTACTCCACCCTGACCGCACTGCCCGACGGCACC
TACGGGCTGCTGTACGAGCCGGGCACCGGCATCAGATACGCCAACTTCAACCTCGCCTGG
CTGGGCGGCATCTGCGCGCCCTTCACGATTCCGGATGTGGCGCTCGAGCCGGGCCAGCAG
GTCACTGTTCCGGTGGCCGTCACGAACCAGTCCGGTATCGCGGTACCGAAGCCGAGCCTT
CAGCTCGACGCATCGCCGGACTGGCAGGTTCAGGGTTCCGTCGAGCCCCTCATGCCCGGA
CGGCAGGCCAAGGGCCAGGTGACCATCACGGTTCCCGCCGGCACCACCCCCGGTCGCTAC
CGGGTCGGTGCGACGCTGCGCACCTCCGCGGGTAACGCGTCGACGACCTTCACGGTCACG
GTTGGACTGCTCGACCAGGCCCGGATGAGCATCGCGGACGTCGACAGCGAGGAGACCGCC
CGCGAAGACGGGCGGGCGAGCAACGTGATCGACGGCAACCCCTCGACGTTCTGGCACACC
GAATGGTCGCGTGCCGATGCTCCTGGCTACCCGCACCGCATCAGCCTCGACCTCGGTGGC
ACGCACACGATCAGCGGCCTCCAGTACACCCGACGGCAGAACAGCGCCAACGAGCAGGTC
GCGGACTACGAGATCTACACCAGCCTGAACGGCACGACCTGGGATGGCCCGGTTGCCAGC
GGGCGCTTCACCACGTCCCTCGCGCCGCAGCGCGCGGTCTTCCCGGCGCGGGACGCCAGG
TACATCCGGTTGGTGGCCCTCAGCGAGCAGACCGGGCACAAGTACGCCGCGGTCGCTGAG
CTGGAGGTGGAAGGCCAGCGCTGA

# Drug_Target_12_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_12_General_References:
1400240	Sakurada K, Ohta T, Hasegawa M: Cloning, expression, and characterization of the Micromonospora viridifaciens neuraminidase gene in Streptomyces lividans. J Bacteriol. 1992 Nov;174(21):6896-903.
8591030	Gaskell A, Crennell S, Taylor G: The three domains of a bacterial sialidase: a beta-propeller, an immunoglobulin module and a galactose-binding jelly-roll. Structure. 1995 Nov 15;3(11):1197-205.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
3546

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
68831

# Drug_Target_12_Name:
Sialidase

# Drug_Target_12_Number_of_Residues:
647

# Drug_Target_12_PDB_ID:
1EUU

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00754	F5_F8_type_C
PF02012	BNR

# Drug_Target_12_Protein_Sequence:
>Sialidase precursor
MTANPYLRRLPRRRAVSFLLAPALAAATVAGASPAQAIAGAPVPPGGEPLYTEQDLAVNG
REGFPNYRIPALTVTPDGDLLASYDGRPTGIDAPGPNSILQRRSTDGGRTWGEQQVVSAG
QTTAPIKGFSDPSYLVDRETGTIFNFHVYSQRQGFAGSRPGTDPADPNVLHANVATSTDG
GLTWSHRTITADITPDPGWRSRFAASGEGIQLRYGPHAGRLIQQYTIINAAGAFQAVSVY
SDDHGRTWRAGEAVGVGMDENKTVELSDGRVLLNSRDSARSGYRKVAVSTDGGHSYGPVT
IDRDLPDPTNNASIIRAFPDAPAGSARAKVLLFSNAASQTSRSQGTIRMSCDDGQTWPVS
KVFQPGSMSYSTLTALPDGTYGLLYEPGTGIRYANFNLAWLGGICAPFTIPDVALEPGQQ
VTVPVAVTNQSGIAVPKPSLQLDASPDWQVQGSVEPLMPGRQAKGQVTITVPAGTTPGRY
RVGATLRTSAGNASTTFTVTVGLLDQARMSIADVDSEETAREDGRASNVIDGNPSTFWHT
EWSRADAPGYPHRISLDLGGTHTISGLQYTRRQNSANEQVADYEIYTSLNGTTWDGPVAS
GRFTTSLAPQRAVFPARDARYIRLVALSEQTGHKYAAVAELEVEGQR

# Drug_Target_12_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_12_Signals:
1-37

# Drug_Target_12_Specific_Function:
To release sialic acids for use as carbon and energy sources for this non-pathogenic bacterium while in pathogenic microorganisms, sialidases have been suggested to be pathogenic factors

# Drug_Target_12_SwissProt_ID:
Q02834

# Drug_Target_12_SwissProt_Name:
NANH_MICVI

# Drug_Target_12_Synonyms:
EC 3.2.1.18
Neuraminidase
Sialidase precursor

# Drug_Target_12_Theoretical_pI:
6.52

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasmic

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
RNASE4

# Drug_Target_13_GenBank_ID_Gene:
CR407633

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
RNASE4

# Drug_Target_13_Gene_Sequence:
>441 bp
ATGGTGATGGGCCTGGGCGTTTTGTTGTTGGTCTTCGTGCTGGGTCTGGGTCTGACCCCA
CCGACCCTGGCTCAGGATAACTCCAGGTACACACACTTCCTGACCCAGCACTATGATGCC
AAACCACAGGGCCGGGATGACAGATACTGTGAAAGCATCATGAGGAGACGGGGCCTGACC
TCACCCTGCAAAGACATCAACACATTTATTCATGGCAACAAGCGCAGCATCAAGGCCATC
TGTGAAAACAAGAATGGAAACCCTCACAGAGAAAACCTAAGAATAAGCAAGTCTTCTTTC
CAGGTCACCACTTGCAAGCTACATGGAGGTTCCCCCTGGCCTCCATGCCAGTACCGAGCC
ACAGCGGGGTTCAGAAACGTTGTTGTTGCTTGTGAAAATGGCTTACCTGTCCACTTGGAT
CAGTCAATTTTCCGTCGTCCG

# Drug_Target_13_General_Function:
Involved in nucleic acid binding

# Drug_Target_13_General_References:
Not Available

# Drug_Target_13_HGNC_ID:
HGNC:483

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
5006

# Drug_Target_13_Locus:
14q11.1

# Drug_Target_13_Molecular_Weight:
16550

# Drug_Target_13_Name:
RNASE4 protein

# Drug_Target_13_Number_of_Residues:
147

# Drug_Target_13_PDB_ID:
2ANG

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_13_Protein_Sequence:
>RNASE4 protein
MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLT
SPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRA
TAGFRNVVVACENGLPVHLDQSIFRRP

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
Q53X86

# Drug_Target_13_SwissProt_Name:
Q53X86_HUMAN

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
10.09

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
Not Available

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
Not Available

# Drug_Target_14_Gene_Sequence:
Not Available

# Drug_Target_14_General_Function:
Involved in iron ion binding

# Drug_Target_14_General_References:
Not Available

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
4992

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
35355

# Drug_Target_14_Name:
Cytochrome c peroxidase

# Drug_Target_14_Number_of_Residues:
326

# Drug_Target_14_PDB_ID:
1RZ6

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF03150	CCP_MauG

# Drug_Target_14_Protein_Sequence:
>Cytochrome c peroxidase
DNLMERANSMFEPIPKYPPVIDGNELTQAKVELGKMEFFEPRLSSSHLISCNTCHNVGLG
GDDELPTSIGHGWQKGPRNSPTVFNAVFNAAQFWDGRAADLAEQAKGPVQAGVEMSSTPD
RVVATLKSMPEYIERFEDAFPGQENPVTFDNMAVAIEAYEATLITPEAPFDKYLRGDTSA
LNESEKEGLALFMDRGCTACHSGVNLGGQNYYPFGLVAKPGAEILPEGDKGRFSVTETAS
DEYVFRASPLRNIELTAPYFHSGAVWSLEEAVAVMGTAQLGTELNNDEVKSIVAFLKTLT
GNVPEVTYPVLPPSTANTPKPVDMIP

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Not Available

# Drug_Target_14_SwissProt_ID:
P83787

# Drug_Target_14_SwissProt_Name:
P83787_MARHY

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
4.30

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Not Available

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
Not Available

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
HGS

# Drug_Target_15_Gene_Sequence:
Not Available

# Drug_Target_15_General_Function:
Not Available

# Drug_Target_15_General_References:
Not Available

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
7135

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
Not Available

# Drug_Target_15_Name:
Hepatocyte growth factor-regulated tyrosine kinase substrate

# Drug_Target_15_Number_of_Residues:
0

# Drug_Target_15_PDB_ID:
Not Available

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
Not Available

# Drug_Target_15_Protein_Sequence:
Not Available

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
Not Available

# Drug_Target_15_Specific_Function:
Not Available

# Drug_Target_15_SwissProt_ID:
O14964

# Drug_Target_15_SwissProt_Name:
HGS_HUMAN

# Drug_Target_15_Synonyms:
Not Available

# Drug_Target_15_Theoretical_pI:
Not Available

# Drug_Target_15_Transmembrane_Regions:
Not Available

# Drug_Target_16_Cellular_Location:
Cell surface

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
Not Available

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
M17448

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
YPTB1668

# Drug_Target_16_Gene_Sequence:
>2958 bp
ATGGTTTTCCAGCCAATCAGTGAGTTTCTCTTGATAAGGAATGCGGGAATGTCTATGTAT
TTTAATAAAATAATTTCATTTAATATTATTTCACGAATAGTTATTTGTATCTTTTTGATA
TGTGGAATGTTCATGGCTGGGGCTTCAGAAAAATATGATGCTAACGCACCGCAACAGGTC
CAGCCTTATTCTGTCTCTTCATCTGCATTTGAAAATCTCCATCCTAATAATGAAATGGAG
AGTTCAATCAATCCCTTTTCCGCATCGGATACAGAAAGAAATGCTGCAATAATAGATCGC
GCCAATAAGGAGCAGGAGACTGAAGCGGTGAATAAGATGATAAGCACCGGGGCCAGGTTA
GCTGCATCAGGCAGGGCATCTGATGTTGCTCACTCAATGGTGGGCGATGCGGTTAATCAA
GAAATCAAACAGTGGTTAAATCGATTCGGTACGGCTCAAGTTAATCTGAATTTTGACAAA
AATTTTTCGCTAAAAGAAAGCTCTCTTGATTGGCTGGCTCCTTGGTATGACTCTGCTTCA
TTCCTCTTTTTTAGTCAGTTAGGTATTCGCAATAAAGACAGCCGCAACACACTTAACCTT
GGCGTCGGGATACGTACATTGGAGAACGGTTGGCTGTACGGACTTAATACTTTTTATGAT
AATGATTTGACCGGCCACAACCACCGTATCGGTCTTGGTGCCGAGGCCTGGACCGATTAT
TTACAGTTGGCTGCCAATGGGTATTTTCGCCTCAATGGATGGCACTCGTCGCGTGATTTC
TCCGACTATAAAGAGCGCCCAGCCACTGGGGGGGATTTGCGCGCGAATGCTTATTTACCT
GCACTCCCACAACTGGGGGGGAAGTTGATGTATGAGCAATACACCGGTGAGCGTGTTGCT
TTATTTGGTAAAGATAATCTGCAACGCAACCCTTATGCCGTGACTGCCGGGATCAATTAC
ACCCCCGTGCCTCTACTCACTGTCGGGGTAGATCAGCGTATGGGGAAAAGCAGTAAGCAT
GAAACACAGTGGAACCTCCAAATGAACTATCGCCTGGGCGAGAGTTTTCAGTCGCAACTT
AGCCCTTCAGCGGTGGCAGGAACACGTCTACTGGCGGAGAGCCGCTATAACCTTGTCGAT
CGTAACAATAATATCGTGTTGGAGTATCAGAAACAGCAGGTGGTTAAACTGACATTATCG
CCAGCAACTATCTCCGGCCTGCCGGGTCAGGTTTATCAGGTGAACGCACAAGTACAAGGG
GCATCTGCTGTAAGGGAAATTGTCTGGAGTGATGCCGAACTGATTGCCGCTGGCGGCACA
TTAACACCACTGAGTACCACACAATTCAACTTGGTTTTACCGCCTTATAAACGCACAGCA
CAAGTGAGTCGGGTAACGGACGACCTGACAGCCAACTTTTATTCGCTTAGTGCGCTCGCG
GTTGATCACCAAGGAAACCGATCTAACTCATTCACATTGAGCGTCACCGTTCAGCAGCCT
CAGTTGACATTAACGGCGGCCGTCATTGGTGATGGCGCACCGGCTAATGGGAAAACTGCA
ATCACCGTTGAGTTCACCGTTGCTGATTTTGAGGGGAAACCCTTAGCCGGGCAGGAGGTG
GTGATAACCACCAATAATGGTGCGCTACCGAATAAAATCACGGAAAAGACAGATGCAAAT
GGCGTCGCGCGCATTGCATTAACCAATACGACAGATGGCGTGACGGTAGTCACAGCAGAA
GTGGAGGGGCAACGGCAAAGTGTTGATACCCACTTTGTTAAGGGTACTATCGCGGCGGAT
AAATCCACTCTGGCTGCGGTACCGACATCTATCATCGCTGATGGTCTAATGGCTTCAACC
ATCACGTTGGAGTTGAAGGATACCTATGGGGACCCGCAGGCTGGCGCGAATGTGGCTTTT
GACACAACCTTAGGCAATATGGGCGTTATCACGGATCACAATGACGGCACTTATAGCGCA
CCATTGACCAGTACCACGTTGGGGGTAGCAACAGTAACGGTGAAAGTGGATGGGGCTGCG
TTCAGTGTGCCGAGTGTGACGGTTAATTTCACGGCAGATCCTATTCCAGATGCTGGCCGC
TCCAGTTTCACCGTCTCCACACCGGATATCTTGGCTGATGGCACGATGAGTTCCACATTA
TCCTTTGTCCCTGTCGATAAGAATGGCCATTTTATCAGTGGGATGCAGGGCTTGAGTTTT
ACTCAAAACGGTGTGCCGGTGAGTATTAGCCCCATTACCGAGCAGCCAGATAGCTATACC
GCGACGGTGGTTGGGAATAGTGTCGGTGATGTCACAATCACGCCGCAGGTTGATACCCTG
ATACTGAGTACATTGCAGAAAAAAATATCCCTATTCCCGGTACCTACGCTGACCGGTATT
CTGGTTAACGGGCAAAATTTCGCTACGGATAAAGGGTTCCCGAAAACGATCTTTAAAAAC
GCCACATTCCAGTTACAGATGGATAACGATGTTGCTAATAATACTCAGTATGAGTGGTCG
TCGTCATTCACACCCAATGTATCGGTTAACGATCAGGGTCAGGTGACGATTACCTACCAA
ACCTATAGCGAAGTGGCTGTGACGGCGAAAAGTAAAAAATTCCCAAGTTATTCGGTGAGT
TATCGGTTCTACCCAAATCGGTGGATATACGATGGCGGCAGATCGCTGGTATCCAGTCTC
GAGGCCAGCAGACAATGCCAAGGTTCAGATATGTCTGCGGTTCTTGAATCCTCACGTGCA
ACCAACGGAACGCGTGCGCCTGACGGGACATTGTGGGGCGAGTGGGGGAGCTTGACCGCG
TATAGTTCTGATTGGCAATCTGGTGAATATTGGGTCAAAAAGACCAGCACGGATTTTGAA
ACCATGAATATGGACACAGGCGCACTGCAACCAGGGCCTGCATACTTGGCGTTCCCGCTC
TGTGCGCTGTCAATATAA

# Drug_Target_16_General_Function:
Involved in binding

# Drug_Target_16_General_References:
10514372	Hamburger ZA, Brown MS, Isberg RR, Bjorkman PJ: Crystal structure of invasin: a bacterial integrin-binding protein. Science. 1999 Oct 8;286(5438):291-5.
1693333	Leong JM, Fournier RS, Isberg RR: Identification of the integrin binding domain of the Yersinia pseudotuberculosis invasin protein. EMBO J. 1990 Jun;9(6):1979-89.
3304658	Isberg RR, Voorhis DL, Falkow S: Identification of invasin: a protein that allows enteric bacteria to penetrate cultured mammalian cells. Cell. 1987 Aug 28;50(5):769-78.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
5574

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
106545

# Drug_Target_16_Name:
Invasin

# Drug_Target_16_Number_of_Residues:
985

# Drug_Target_16_PDB_ID:
1CWV

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF02369	Big_1
PF07979	Intimin_C
PF09134	Invasin_D3

# Drug_Target_16_Protein_Sequence:
>Invasin
MVFQPISEFLLIRNAGMSMYFNKIISFNIISRIVICIFLICGMFMAGASEKYDANAPQQV
QPYSVSSSAFENLHPNNEMESSINPFSASDTERNAAIIDRANKEQETEAVNKMISTGARL
AASGRASDVAHSMVGDAVNQEIKQWLNRFGTAQVNLNFDKNFSLKESSLDWLAPWYDSAS
FLFFSQLGIRNKDSRNTLNLGVGIRTLENGWLYGLNTFYDNDLTGHNHRIGLGAEAWTDY
LQLAANGYFRLNGWHSSRDFSDYKERPATGGDLRANAYLPALPQLGGKLMYEQYTGERVA
LFGKDNLQRNPYAVTAGINYTPVPLLTVGVDQRMGKSSKHETQWNLQMNYRLGESFQSQL
SPSAVAGTRLLAESRYNLVDRNNNIVLEYQKQQVVKLTLSPATISGLPGQVYQVNAQVQG
ASAVREIVWSDAELIAAGGTLTPLSTTQFNLVLPPYKRTAQVSRVTDDLTANFYSLSALA
VDHQGNRSNSFTLSVTVQQPQLTLTAAVIGDGAPANGKTAITVEFTVADFEGKPLAGQEV
VITTNNGALPNKITEKTDANGVARIALTNTTDGVTVVTAEVEGQRQSVDTHFVKGTIAAD
KSTLAAVPTSIIADGLMASTITLELKDTYGDPQAGANVAFDTTLGNMGVITDHNDGTYSA
PLTSTTLGVATVTVKVDGAAFSVPSVTVNFTADPIPDAGRSSFTVSTPDILADGTMSSTL
SFVPVDKNGHFISGMQGLSFTQNGVPVSISPITEQPDSYTATVVGNTAGDVTITPQVDTL
ILSTLQKKISLFPVPTLTGILVNGQNFATDKGFPKTIFKNATFQLQMDNDVANNTQYEWS
SSFTPNVSVNDQGQVTITYQTYSEVAVTAKSKKFPSYSVSYRFYPNRWIYDGGTSLVSSL
EASRQCQGSDMSAVLESSRATNGTRAPDGTLWGEWGSLTAYSSDWQSGEYWVKKTSTDFE
TMNMDTGALVQGPAYLAFPLCALAI

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Invasin is a protein that allows enteric bacteria to penetrate cultured mammalian cells. The entry of invasin in the cell is mediated by binding several beta-1 chain integrins

# Drug_Target_16_SwissProt_ID:
P11922

# Drug_Target_16_SwissProt_Name:
INVA_YERPS

# Drug_Target_16_Synonyms:
Not Available

# Drug_Target_16_Theoretical_pI:
4.84

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Cytoplasmic

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
Not Available

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
M12742

# Drug_Target_17_GenBank_ID_Protein:
Not Available

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
ITEVIR

# Drug_Target_17_Gene_Sequence:
>738 bp
ATGAAAAGCGGAATTTATCAGATTAAAAATACTTTAAACAATAAAGTATATGTAGGAAGT
GCTAAAGATTTTGAAAAGAGATGGAAGAGGCATTTTAAAGATTTAGAAAAAGGATGCCAT
TCTTCTATAAAACTTCAGAGGTCTTTTAACAAACATGGTAATGTGTTTGAATGTTCTATT
TTGGAAGAAATTCCATATGAGAAAGATTTGATTATTGAACGAGAAAATTTTTGGATTAAA
GAGCTTAATTCTAAAATTAATGGATACAATATTGCTGATGCAACGTTTGGTGATACATGT
TCTACGCATCCATTAAAAGAAGAAATTATTAAGAAACGTTCTGAAACTGTTAAAGCTAAG
ATGCTTAAACTTGGACCTGATGGTCGGAAAGCTCTTTACAGTAAACCCGGAAGTAAAAAC
GGGCGTTGGAATCCAGAAACCCATAAGTTTTGTAAGTGCGGTGTTCGCATACAAACTTCT
GCTTATACTTGTAGTAAATGCAGAAATCGTTCAGGTGAAAATAATTCATTCTTTAATCAT
AAGCATTCAGACATAACTAAATCTAAAATATCAGAAAAGATGAAAGGTAAAAAGCCTAGT
AATATTAAAAAGATTTCATGTGATGGGGTTATTTTTGATTGTGCAGCAGATGCAGCTAGA
CATTTTAAAATTTCGTCTGGATTAGTTACTTATCGTGTAAAATCTGATAAATGGAATTGG
TTCTACATAAATGCCTAA

# Drug_Target_17_General_Function:
Involved in endonuclease activity

# Drug_Target_17_General_References:
12626685	Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Ruger W: Bacteriophage T4 genome. Microbiol Mol Biol Rev. 2003 Mar;67(1):86-156, table of contents.
2543665	West DK, Changchien LM, Maley GF, Maley F: Evidence that the intron open reading frame of the phage T4 td gene encodes a specific endonuclease. J Biol Chem. 1989 Jun 25;264(18):10343-6.
3698096	Chu FK, Maley GF, West DK, Belfort M, Maley F: Characterization of the intron in the phage T4 thymidylate synthase gene and evidence for its self-excision from the primary transcript. Cell. 1986 Apr 25;45(2):157-66.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
5060

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
28233

# Drug_Target_17_Name:
Intron-associated endonuclease 1

# Drug_Target_17_Number_of_Residues:
245

# Drug_Target_17_PDB_ID:
1I3J

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF01541	GIY-YIG
PF07460	NUMOD3

# Drug_Target_17_Protein_Sequence:
>Intron-associated endonuclease 1
MKSGIYQIKNTLNNKVYVGSAKDFEKRWKRHFKDLEKGCHSSIKLQRSFNKHGNVFECSI
LEEIPYEKDLIIERENFWIKELNSKINGYNIADATFGDTCSTHPLKEEIIKKRSETVKAK
MLKLGPDGRKALYSKPGSKNGRWNPETHKFCKCGVRIQTSAYTCSKCRNRSGENNSFFNH
KHSDITKSKISEKMKGKKPSNIKKISCDGVIFDCAADAARHFKISSGLVTYRVKSDKWNW
FYINA

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
This endonuclease is specific to the thymidylate synthase (td) gene splice junction and is involved in intron homing

# Drug_Target_17_SwissProt_ID:
P13299

# Drug_Target_17_SwissProt_Name:
TEV1_BPT4

# Drug_Target_17_Synonyms:
EC 3.1.-.-
I-TevI
IRF protein

# Drug_Target_17_Theoretical_pI:
10.26

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
Not Available

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
X06792

# Drug_Target_18_GenBank_ID_Protein:
Not Available

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
12

# Drug_Target_18_Gene_Sequence:
>1584 bp
ATGAGTAATAATACATATCAACACGTTTCTAATGAATCTCGTTATGTAAAATTTGATCCT
ACCGATACGAATTTTCCACCGGAGATTACTGATGTTCACGCTGCTATAGCAGCCATTTCT
CCTGCTGGAGTAAATGGAGTTCCTGATGCATCGTCAACAACAAAGGGAATTCTATTTATT
CCCACTGAACAGGAAGTTATAGATGGAACTAATAATACCAAAGCAGTTACACCAGCAACG
TTGGCAACAAGATTATCTTATCCAAATGCAACTGAAACTGTTTACGGATTAACAAGATAT
TCAACCAATGATGAAGCCATTGCCGGAGTTAATAATGAATCTTCTATAACTCCAGCTAAA
TTTACTGTCGCCCTTAATAATGCGTTTGAAACGCGAGTTTCAACTGAATCCTCAAATGGT
GTTATTAAAATTTCATCTCTACCGCAAGCATTAGCTGGTGCAGATGATACTACTGCAATG
ACTCCATTAAAAACACAGCAGTTAGCTATTAAATTAATTGCGCAAATTGCTCCTTCTGAA
ACCACAGCTACCGAATCGGACCAAGGTGTTGTTCAATTAGCAACAGTAGCGCAGGTTCGT
CAGGGAACTTTAAGAGAAGGCTATGCAATTTCTCCTTATACGTTTATGAATTCATCTTCT
ACTGAAGAATATAAAGGCGTAATTAAATTAGGAACACAATCAGAAGTTAACTCGAATAAT
GCTTCTGTTGCGGTTACTGGCGCAACTCTTAATGGTCGTGGTTCTACGACGTCAATGAGA
GGCGTAGTTAAATTAACTACAACCGCCGGTTCACAGAGTGGAGGCGATGCTTCATCAGCC
TTAGCTTGGAATGCTGACGTTATCCAGCAAAGAGGTGGTCAAATTATCTATGGAACACTC
CGCATTGAAGACACATTTACAATAGCTAATGGTGGAGCAAATATTACGGGTACCGTCAGA
ATGACTGGCGGTTATATTCAAGGTAACCGCATCGTAACACAAAATGAAATTGATAGAACT
ATTCCTGTCGGAGCTATTATGATGTGGGCCGCTGATAGTCTTCCTAGTGATGCTTGGCGC
TTCTGCCATGGTGGAACTGTTTCAGCGTCAGATTGTCCATTATATGCTTCTAGAATTGGA
ACAAGATATGGCGGAAACCCATCAAATCCTGGATTGCCTGACATGCGTGGTCTTTTTGTT
CGTGGTTCTGGTCGTGGTTCTCACTTAACAAATCCAAATGTTAATGGTAATGACCAATTT
GGTAAACCTAGATTAGGTGTAGGTTGTACCGGTGGATATGTTGGTGAAGTACAGATACAA
CAGATGTCTTATCATAAACATGCTGGTGGATTTGGTGAGCATGATGATCTGGGGGCATTC
GGTAATACCCGTAGATCAAATTTTGTTGGTACACGTAAAGGACTTGACTGGGATAACCGT
TCATACTTCACCAATGACGGATATGAAATTGACCCAGAATCACAACGAAATTCCAAATAT
ACATTAAATCGTCCTGAATTAATTGGAAATGAAACACGTCCATGGAACATTTCTTTAAAC
TACATAATTAAGGTAAAAGAATGA

# Drug_Target_18_General_Function:
Not Available

# Drug_Target_18_General_References:
11743729	van Raaij MJ, Schoehn G, Burda MR, Miller S: Crystal structure of a heat and protease-stable part of the bacteriophage T4 short tail fibre. J Mol Biol. 2001 Dec 14;314(5):1137-46.
12626685	Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Ruger W: Bacteriophage T4 genome. Microbiol Mol Biol Rev. 2003 Mar;67(1):86-156, table of contents.
2548819	Barrett BK, Berget PB: Using transposon Tn5 insertions to sequence bacteriophage T4 gene 11. DNA. 1989 May;8(4):287-95.
2726468	Prilipov AG, Selivanov NA, Efimov VP, Marusich EI, Mesyanzhinov VV: Nucleotide sequences of bacteriophage T4 genes 9, 10 and 11. Nucleic Acids Res. 1989 Apr 25;17(8):3303.
3357780	Selivanov NA, Prilipov AG, Mesyanzhinov VV: Nucleotide and deduced amino acid sequence of bacteriophage T4 gene 12. Nucleic Acids Res. 1988 Mar 25;16(5):2334.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
5575

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
56215

# Drug_Target_18_Name:
Short tail fiber protein

# Drug_Target_18_Number_of_Residues:
527

# Drug_Target_18_PDB_ID:
1H6W

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF07484	Collar
PF09089	gp12-short_mid

# Drug_Target_18_Protein_Sequence:
>Short tail fiber protein
MSNNTYQHVSNESRYVKFDPTDTNFPPEITDVHAAIAAISPAGVNGVPDASSTTKGILFI
PTEQEVIDGTNNTKAVTPATLATRLSYPNATETVYGLTRYSTNDEAIAGVNNESSITPAK
FTVALNNAFETRVSTESSNGVIKISSLPQALAGADDTTAMTPLKTQQLAIKLIAQIAPSE
TTATESDQGVVQLATVAQVRQGTLREGYAISPYTFMNSSSTEEYKGVIKLGTQSEVNSNN
ASVAVTGATLNGRGSTTSMRGVVKLTTTAGSQSGGDASSALAWNADVIQQRGGQIIYGTL
RIEDTFTIANGGANITGTVRMTGGYIQGNRIVTQNEIDRTIPVGAIMMWAADSLPSDAWR
FCHGGTVSASDCPLYASRIGTRYGGNPSNPGLPDMRGLFVRGSGRGSHLTNPNVNGNDQF
GKPRLGVGCTGGYVGEVQIQQMSYHKHAGGFGEHDDLGAFGNTRRSNFVGTRKGLDWDNR
SYFTNDGYEIDPESQRNSKYTLNRPELIGNETRPWNISLNYIIKVKE

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Structural component of the short tail fiber (baseplate)

# Drug_Target_18_SwissProt_ID:
P10930

# Drug_Target_18_SwissProt_Name:
VG12_BPT4

# Drug_Target_18_Synonyms:
Protein Gp12
p12

# Drug_Target_18_Theoretical_pI:
6.19

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
MDH2

# Drug_Target_19_GenBank_ID_Gene:
AF047470

# Drug_Target_19_GenBank_ID_Protein:
2906146

# Drug_Target_19_GeneCard_ID:
MDH2

# Drug_Target_19_Gene_Name:
MDH2

# Drug_Target_19_Gene_Sequence:
>1017 bp
ATGCTCTCCGCCCTCGCCCGGCCTGTCAGCGCTGCTCTCCGCCGCAGCTTCAGCACCTCA
GCCCAGAACAATGCTAAAGTAGCTGTGCTAGGGGCCTCTGGAGGCATCGGGCAGCCACTT
TCACTTCTCCTGAAGAACAGCCCCTTGGTGAGCCGCCTGACCCTCTATGATATCGCGCAC
ACACCCGGAGTGGCCGCAGATCTGAGCCACATCGAGACCAAAGCCGCTGTGAAAGGCTAC
CTCGGACCTGAACAGCTGCCTGACTGCCTGAAAGGTTGTGATGTGGTAGTTATTCCGGCT
GGAGTCCCCAGAAAGCCAGGCATGACCCGGGACGACCTGTTCAACACCAATGCCACGATT
GTGGCCACCCTGACCGCTGCCTGTGCCCAGCACTGCCCGGAAGCCATGATCTGCGTCATT
GCCAATCCGGTTAATTCCACCATCCCCATCACAGCAGAAGTTTTCAAGAAGCATGGAGTG
TACAACCCCAACAAAATCTTCGGCGTGACGACCCTGGACATCGTCAGAGCCAACACCTTT
GTTGCAGAGCTGAAGGGTTTGGATCCAGCTCGAGTCAACGTCCCTGTCATTGGTGGCCAT
GCTGGGAAGACCATCATCCCCCTGATCTCTCAGTGCACCCCCAAGGTGGACTTTCCCCAG
GACCAGCTGACAGCACTCACTGGGCGGATCCAGGAGGCCGGCACGGAGGTGGTCAAGGCT
AAAGCCGGAGCAGGCTCTGCCACCCTCTCCATGGCGTATGCCGGCGCCCGCTTTGTCTTC
TCCCTTGTGGATGCAATGAATGGAAAGGAAGGTGTTGTGGAATGTTCCTTCGTTAAGTCA
CAGGAAACGGAATGTACCTACTTCTCCACACCGCTGCTGCTTGGGAAAAAGGGCATCGAG
AAGAACCTGGGCATCGGCAAAGTCTCCTCTTTTGAGGAGAAGATGATCTCGGATGCCATC
CCCGAGCTGAAGGCCTCCATCAAGAAGGGGGAAGATTTCGTGAAGACCCTGAAGTGA

# Drug_Target_19_General_Function:
Energy production and conversion

# Drug_Target_19_General_References:
Not Available

# Drug_Target_19_HGNC_ID:
HGNC:6971

# Drug_Target_19_HPRD_ID:
01099

# Drug_Target_19_ID:
857

# Drug_Target_19_Locus:
7p12.3-q11.2

# Drug_Target_19_Molecular_Weight:
35532

# Drug_Target_19_Name:
Malate dehydrogenase, mitochondrial

# Drug_Target_19_Number_of_Residues:
338

# Drug_Target_19_PDB_ID:
1MLD

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00056	Ldh_1_N
PF02866	Ldh_1_C

# Drug_Target_19_Protein_Sequence:
>Malate dehydrogenase, mitochondrial precursor
MLSALARPVSAALRRSFSTSAQNNAKVAVLGASGGIGQPLSLLLKNSPLVSRLTLYDIAH
TPGVAADLSHIETKAAVKGYLGPEQLPDCLKGCDVVVIPAGVPRKPGMTRDDLFNTNATI
VATLTAACAQHCPEAMICVIANPVNSTIPITAEVFKKHGVYNPNKIFGVTTLDIVRANTF
VAELKGLDPARVNVPVIGGHAGKTIIPLISQCTPKVDFPQDQLTALTGRIQEAGTEVVKA
KAGAGSATLSMAYAGARFVFSLVDAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKGIE
KNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK

# Drug_Target_19_Reaction:
(S)-malate + NAD+ = oxaloacetate + NADH + H+

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Not Available

# Drug_Target_19_SwissProt_ID:
P40926

# Drug_Target_19_SwissProt_Name:
MDHM_HUMAN

# Drug_Target_19_Synonyms:
EC 1.1.1.37
Malate dehydrogenase, mitochondrial precursor

# Drug_Target_19_Theoretical_pI:
8.90

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68871

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
eda

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
11274385	Allard J, Grochulski P, Sygusch J: Covalent intermediate trapped in 2-keto-3-deoxy-6- phosphogluconate (KDPG) aldolase structure at 1.95-A resolution. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3679-84.
11342129	Wymer N, Buchanan LV, Henderson D, Mehta N, Botting CH, Pocivavsek L, Fierke CA, Toone EJ, Naismith JH: Directed evolution of a new catalytic site in 2-keto-3-deoxy-6-phosphogluconate aldolase from Escherichia coli. Structure. 2001 Jan 10;9(1):1-9.
1339418	Patil RV, Dekker EE: Cloning, nucleotide sequence, overexpression, and inactivation of the Escherichia coli 2-keto-4-hydroxyglutarate aldolase gene. J Bacteriol. 1992 Jan;174(1):102-7.
1624451	Egan SE, Fliege R, Tong S, Shibata A, Wolf RE Jr, Conway T: Molecular characterization of the Entner-Doudoroff pathway in Escherichia coli: sequence analysis and localization of promoters for the edd-eda operon. J Bacteriol. 1992 Jul;174(14):4638-46.
1978721	Vlahos CJ, Dekker EE: Active-site residues of 2-keto-4-hydroxyglutarate aldolase from Escherichia coli. Bromopyruvate inactivation and labeling of glutamate 45. J Biol Chem. 1990 Nov 25;265(33):20384-9.
3136164	Vlahos CJ, Dekker EE: The complete amino acid sequence and identification of the active-site arginine peptide of Escherichia coli 2-keto-4-hydroxyglutarate aldolase. J Biol Chem. 1988 Aug 25;263(24):11683-91.
8344525	Carter AT, Pearson BM, Dickinson JR, Lancashire WE: Sequence of the Escherichia coli K-12 edd and eda genes of the Entner-Doudoroff pathway. Gene. 1993 Aug 16;130(1):155-6.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3792

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
22284

# Drug_Target_1_Name:
KHG/KDPG aldolase [Includes: 4-hydroxy-2-oxoglutarate aldolase

# Drug_Target_1_Number_of_Residues:
213

# Drug_Target_1_PDB_ID:
1FQ0

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01081	Aldolase

# Drug_Target_1_Protein_Sequence:
>KHG/KDPG aldolase [Includes: 4-hydroxy-2-oxoglutarate aldolase
MKNWKTSAESILTTGPVVPVIVVKKLEHAVPMAKALVAGGVRVLEVTLRTECAVDAIRAI
AKEVPEAIVGAGTVLNPQQLAEVTEAGAQFAISPGLTEPLLKAATEGTIPLIPGISTVSE
LMLGMDYGLKEFKFFPAEANGGVKALQAIAGPFSQVRFCPTGGISPANYRDYLALKSVLC
IGGSWLVPADALEAGDYDRITKLAREAVEGAKL

# Drug_Target_1_Reaction:
4-hydroxy-2-oxoglutarate = pyruvate + glyoxylate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
4-hydroxy-2-oxoglutarate = pyruvate + glyoxylate

# Drug_Target_1_SwissProt_ID:
P0A955

# Drug_Target_1_SwissProt_Name:
ALKH_ECOLI

# Drug_Target_1_Synonyms:
2- dehydro-3-deoxy-phosphogluconate aldolase
2-keto-3-deoxy-6-phosphogluconate aldolase
2-keto-4-hydroxyglutarate aldolase
EC 4.1.2.14
EC 4.1.3.16
KDPG- aldolase]
KHG-aldolase
Phospho-2- dehydro-3-deoxygluconate aldolase
Phospho-2-keto-3-deoxygluconate aldolase

# Drug_Target_1_Theoretical_pI:
5.35

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
Not Available

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
DQ059549

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
purE

# Drug_Target_20_Gene_Sequence:
>549 bp
GTGAGCGAAACCGCCCCCCTGCCCTCTGCTTCCAGTGCTTTAGAAGATAAAGCAGCCTCT
GCCCCCGTTGTGGGCATTATCATGGGCAGCCAGTCAGACTGGGAAACCATGCGCCATGCA
GACGCATTGCTGACAGAGCTGGAAATTCCGCATGAAACCCTCATTGTTTCAGCACATCGT
ACGCCAGACCGGTTGGCGGATTATGCGCGTACGGCAGCCGAACGCGGCCTGAATGTGATT
ATTGCTGGGGCCGGTGGAGCTGCACATCTGCCGGGTATGTGTGCGGCATGGACACGCCTG
CCCGTGCTGGGTGTTCCAGTAGAATCTCGCGCTCTTAAAGGCATGGACAGCCTGCTTTCC
ATTGTGCAGATGCCCGGCGGCGTGCCTGTGGGCACTTTGGCTATTGGGGCATCCGGCGCC
AAAAATGCCGCCTTGCTGGCCGCCTCCATTCTTGCACTGTATAACCCGGCCCTTGCCGCA
CGCCTTGAAACATGGCGCGCATTGCAGACGGCCTCTGTCCCCAACTCTCCCATTACCGAA
GATAAATGA

# Drug_Target_20_General_Function:
Involved in phosphoribosylaminoimidazole carboxylase activity

# Drug_Target_20_General_References:
Not Available

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
5577

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
18735

# Drug_Target_20_Name:
N5-carboxyaminoimidazole ribonucleotide mutase

# Drug_Target_20_Number_of_Residues:
182

# Drug_Target_20_PDB_ID:
1U11

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00731	AIRC

# Drug_Target_20_Protein_Sequence:
>N5-carboxyaminoimidazole ribonucleotide mutase
MSETAPLPSASSALEDKAASAPVVGIIMGSQSDWETMRHADALLTELEIPHETLIVSAHR
TPDRLADYARTAAERGLNVIIAGAGGAAHLPGMCAAWTRLPVLGVPVESRALKGMDSLLS
IVQMPGGVPVGTLAIGASGAKNAALLAASILALYNPALAARLETWRALQTASVPNSPITE
DK

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Not Available

# Drug_Target_20_SwissProt_ID:
Q2QJL3

# Drug_Target_20_SwissProt_Name:
Q2QJL3_ACEAC

# Drug_Target_20_Synonyms:
Not Available

# Drug_Target_20_Theoretical_pI:
5.60

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
Not Available

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
Not Available

# Drug_Target_21_GenBank_ID_Gene:
Z21677

# Drug_Target_21_GenBank_ID_Protein:
Not Available

# Drug_Target_21_GeneCard_ID:
Not Available

# Drug_Target_21_Gene_Name:
rplD

# Drug_Target_21_Gene_Sequence:
>708 bp
ATGGCTCAGGTTGATCTGTTGAATGTGAAGGGAGAAAAAGTAGGGACCCTGGAAATCAGT
GATTTCGTTTTCAACATCGATCCCAACTACGACGTGATGTGGAGATACGTGGATATGCAG
CTCTCCAACAGGAGAGCTGGAACTGCCTCTACGAAAACAAGAGGAGAAGTCTCCGGTGGT
GGCAGAAAACCCTGGCCGCAGAAACACACTGGAAGAGCAAGTCACGGATCCATAAGATCT
CCCATCTGGAGACATGGAGGAGTAGTACACGGACCTAAACCGAGAGATTGGAGCAAAAAG
CTCAACAAAAAAATGAAGAAACTCGCTTTGCGATCTGCCCTTTCTGTGAAGTACAGAGAA
AACAAACTCCTTGTACTCGATCATCTGAAACTCGAAAGACCCAAGACAAAGTCTCTGAAG
GAAATTCTCCAGAACCTTCAGCTTTCCGACAAGAAAACACTGATGGTCCTTCCGTGGAAA
GAGGAAGGATATATGAATGTGAAACTCTCTGGAAGAAACCTTCCCGACGTGAAGGTAATA
ATTGCGGACAATCCGAACAACAGCAAAAATGGTGAGAAGGCGGTAAGAATAGATGGACTC
AATGTTTTTGACATGCTCAAGTACGATTACCTTGTTCTCACCAGGGACATGGTTTCCAAG
ATAGAGGAGGTGCTCGGAAATGAAGCAGGAAAAGCTCTCACTGCATGA

# Drug_Target_21_General_Function:
Involved in structural constituent of ribosome

# Drug_Target_21_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
8002596	Sanangelantoni AM, Bocchetta M, Cammarano P, Tiboni O: Phylogenetic depth of S10 and spc operons: cloning and sequencing of a ribosomal protein gene cluster from the extremely thermophilic bacterium Thermotoga maritima. J Bacteriol. 1994 Dec;176(24):7703-10.

# Drug_Target_21_HGNC_ID:
Not Available

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
5578

# Drug_Target_21_Locus:
Not Available

# Drug_Target_21_Molecular_Weight:
26631

# Drug_Target_21_Name:
50S ribosomal protein L4

# Drug_Target_21_Number_of_Residues:
235

# Drug_Target_21_PDB_ID:
1DMG

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00573	Ribosomal_L4

# Drug_Target_21_Protein_Sequence:
>50S ribosomal protein L4
MAQVDLLNVKGEKVGTLEISDFVFNIDPNYDVMWRYVDMQLSNRRAGTASTKTRGEVSGG
GRKPWPQKHTGRARHGSIRSPIWRHGGVVHGPKPRDWSKKLNKKMKKLALRSALSVKYRE
NKLLVLDDLKLERPKTKSLKEILQNLQLSDKKTLIVLPWKEEGYMNVKLSGRNLPDVKVI
IADNPNNSKNGEKAVRIDGLNVFDMLKYDYLVLTRDMVSKIEEVLGNEAGKALTA

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Forms part of the polypeptide exit tunnel (By similarity)

# Drug_Target_21_SwissProt_ID:
P38516

# Drug_Target_21_SwissProt_Name:
RL4_THEMA

# Drug_Target_21_Synonyms:
TmaL4

# Drug_Target_21_Theoretical_pI:
10.62

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Secreted protein

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
Not Available

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
CPB1

# Drug_Target_22_GenBank_ID_Gene:
M81057

# Drug_Target_22_GenBank_ID_Protein:
Not Available

# Drug_Target_22_GeneCard_ID:
Not Available

# Drug_Target_22_Gene_Name:
CPB1

# Drug_Target_22_Gene_Sequence:
>1251 bp
ATGTTGGCACTCTTGGTTCTGGTGACTGTGGCCCTGGCATCTGCTCATCATGGTGGTGAG
CACTTTGAAGGCGAGAAGGTGTTCCGTGTTAACGTTGAAGATGAAAATCACATTAACATA
ATCCGCGAGTTGGCCAGCACGACCCAGATTGACTTCTGGAAGCCAGATTCTGTCACACAA
ATCAAACCTCACAGTACAGTTGACTTCCGTGTTAAAGCAGAAGATACTGTCACTGTGGAG
AATGTTCTAAAGCAGAATGAACTACAATACAAGGTACTGATAAGCAACCTGAGAAATGTG
GTGGAGGCTCAGTTTGATAGCCGGGTTCGTGCAACAGGACACAGTTATGAGAAGTACAAC
AAGTGGGAAACGATAGAGGCTTGGACTCAACAAGTCGCCACTGAGAATCCAGCCCTCATC
TCTCGCAGTGTTATCGGAACCACATTTGAGGGACGCGCTATTTACCTCCTGAAGGTTGGC
AAAGCTGGACAAAATAAGCCTGCCATTTTCATGGACTGTGGTTTCCATGCCAGAGAGTGG
ATTTCTCCTGCATTCTGCCAGTGGTTTGTAAGAGAGGCTGTTCGTACCTATGGACGTGAG
ATCCAAGTGACAGAGCTTCTCGACAAGTTAGACTTTTATGTCCTGCCTGTGCTCAATATT
GATGGCTACATCTACACCTGGACCAAGAGCCGATTTTGGAGAAAGACTCGCTCCACCCAT
ACTGGATCTAGCATTGGCACAGACCCCAACAGAAATTTTGATGCTGGTTGGTGTGAAATT
GGAGCCTCTCGAAACCCCTGTGATGAAACTTACTGTGGACCTGCCGCAGAGTCTGAAAAG
GAGACCAAGGCCCTGGCTGATTTCATCCGCAACAAACTCTCTTCCATCAAGGCATATCTG
ACAATCCACTCGTACTCCCAAATGATGATCTACCCTTACTCATATGCTTACAAACTCGGT
GAGAACAATGCTGAGTTGAATGCCCTGGCTAAAGCTACTGTGAAAGAACTTGCCTCACTG
CACGGCACCAAGTACACATATGGCCCGGGAGCTACAACAATCTATCCTGCTGCTGGGGGC
TCTGACGACTGGGCTTATGACCAAGGAATCAGATATTCCTTCACCTTTGAACTTCGAGAT
ACAGGCAGATATGGCTTTCTCCTTCCAGAATCCCAGATCCGGGCTACCTGCGAGGAGACC
TTCCTGGCAATCAAGTATGTTGCCAGCTACGTCCTGGAACACCTGTACTAG

# Drug_Target_22_General_Function:
Involved in carboxypeptidase A activity

# Drug_Target_22_General_References:
12162965	Barbosa Pereira PJ, Segura-Martin S, Oliva B, Ferrer-Orta C, Aviles FX, Coll M, Gomis-Ruth FX, Vendrell J: Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol. 2002 Aug 16;321(3):537-47.
1370825	Yamamoto KK, Pousette A, Chow P, Wilson H, el Shami S, French CK: Isolation of a cDNA encoding a human serum marker for acute pancreatitis. Identification of pancreas-specific protein as pancreatic procarboxypeptidase B. J Biol Chem. 1992 Feb 5;267(4):2575-81.
2920728	Pascual R, Burgos FJ, Salva M, Soriano F, Mendez E, Aviles FX: Purification and properties of five different forms of human procarboxypeptidases. Eur J Biochem. 1989 Feb 15;179(3):609-16.
9524066	Aloy P, Catasus L, Villegas V, Reverter D, Vendrell J, Aviles FX: Comparative analysis of the sequences and three-dimensional models of human procarboxypeptidases A1, A2 and B. Biol Chem. 1998 Feb;379(2):149-55.

# Drug_Target_22_HGNC_ID:
HGNC:2299

# Drug_Target_22_HPRD_ID:
Not Available

# Drug_Target_22_ID:
5579

# Drug_Target_22_Locus:
3q24

# Drug_Target_22_Molecular_Weight:
47368

# Drug_Target_22_Name:
Carboxypeptidase B

# Drug_Target_22_Number_of_Residues:
417

# Drug_Target_22_PDB_ID:
1KWM

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00246	Peptidase_M14
PF02244	Propep_M14

# Drug_Target_22_Protein_Sequence:
>Carboxypeptidase B
MLALLVLVTVALASAHHGGEHFEGEKVFRVNVEDENHINIIRELASTTQIDFWKPDSVTQ
IKPHSTVDFRVKAEDTVTVENVLKQNELQYKVLISNLRNVVEAQFDSRVRATGHSYEKYN
KWETIEAWTQQVATENPALISRSVIGTTFEGRAIYLLKVGKAGQNKPAIFMDCGFHAREW
ISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWTKSRFWRKTRSTH
TGSSCIGTDPNRNFDAGWCEIGASRNPCDETYCGPAAESEKETKALADFIRNKLSSIKAY
LTIHSYSQMMIYPYSYAYKLGENNAELNALAKATVKELASLHGTKYTYGPGATTIYPAAG
GSDDWAYDQGIRYSFTFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVLEHLY

# Drug_Target_22_Reaction:
Not Available

# Drug_Target_22_Signals:
1-15

# Drug_Target_22_Specific_Function:
Preferential release of a C-terminal lysine or arginine amino acid

# Drug_Target_22_SwissProt_ID:
P15086

# Drug_Target_22_SwissProt_Name:
CBPB1_HUMAN

# Drug_Target_22_Synonyms:
Carboxypeptidase B precursor
EC 3.4.17.2
PASP
Pancreas-specific protein

# Drug_Target_22_Theoretical_pI:
6.59

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Not Available

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
Not Available

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
Not Available

# Drug_Target_23_GenBank_ID_Gene:
AB126656

# Drug_Target_23_GenBank_ID_Protein:
Not Available

# Drug_Target_23_GeneCard_ID:
Not Available

# Drug_Target_23_Gene_Name:
Not Available

# Drug_Target_23_Gene_Sequence:
>1626 bp
ATGGAGGGGGAAAGGATGAACGCGTTCCCAAGCACCATGATGGACGAGGAGCTGAACCTC
TGGGACTTTTTGGAGCGGGCGGCGGCGCTTTTCGGTAGGAAGGAGGTGGTCTCCCGCCTC
CACACCGGGGAGGTCCACCGCACCACCTACGCCGAGGTCTACCAAAGGGCCAGGAGGCTC
ATGGGGGGGCTTAGGGCCCTCGGGGTGGGCGTGGGGGACCGGGTGGCCACCCTGGGCTTC
AACCACTTCCGCCACCTCGAGGCCTACTTCGCCGTCCCCGGCATGGGGGCGGTGCTCCAC
ACCGCCAACCCCCGCCTCTCCCCCAAGGAGATCGCCTACATCCTGAACCACGCCGAGGAC
AAGGTCCTCCTCTTTGACCCCAACCTCCTGCCCCTGGTGGAGGCCATACGGGGCGAGCTC
AAGACGGTGCAGCACTTCGTGGTCATGGACGAGAAGGCCCCGGAGGGCTACCTGGCCTAC
GAGGAGGCCCTGGGGGAGGAGGCGGACCCCGTGCGGGTGCCGGAGCGGGCCGCCTGCGGC
ATGGCCTACACCACGGGGACCACGGGCCTCCCCAAGGGGGTGGTCTACAGCCACCGGGCT
TTGGTCCTCCACTCCCTGGCGGCAAGCCTCGTTGACGGCACCGCCCTCTCGGAGAAGGAC
GTGGTCTTGCCGGTGGTCCCCATGTTCCACGTGAACGCCTGGTGCCTGCCCTACGCCGCC
ACCCTGGTGGGGGCCAAACAGGTCCTGCCCGGGCCCAGGCTGGACCCCGCCTCCCTGGTG
GAGCTCTTTGACGGGGAGGGGGTGACCTTCACCGCCGGGGTGCCCACGGTCTGGCTCGCC
CTGGCGGACTACCTGGAAAGCACGGGCCACCGCCTGAAGACCCTGAGGCGGCTCGTGGTG
GGGGGCTCGGCCGCGCCCAGGAGCCTCATCGCCCGCTTTGAGCGGATGGGCGTGGAGGTG
CGCCAGGGCTACGGCCTCACCGAGACCTCCCCGGTGGTGGTGCAGAACTTCGTAAAAAGC
CACCTGGAGTCCCTCTCCGAGGAGGAGAAGCTCACCCTCAAGGCCAAGACGGGCCTCCCC
ATCCCCCTGGTGCGCCTAAGGGTGGCGGACGAGGAGGGCCGCCCCGTGCCCAAGGACGGG
AAGGCCCTGGGGGAGGTCCAGCTCAAGGGCCCCTGGATCACCGGGGGCTACTACGGAAAC
GAGGAGGCCACGCGGAGCGCCCTCACCCCGGACGGCTTCTTCCGCACCGGGGACATCGCC
GTCTGGGACGAGGAGGGGTACGTTGAGATCAAGGACCGGCTCAAGGACCTGATCAAGTCG
GGCGGGGAGTGGATCTCCAGCGTGGACCTGGAGAACGCCCTCATGGGCCACCCCAAGGTG
AAGGAGGCGGCGGTGGTGGCCATCCCCCACCCCAAGTGGCAGGAGAGGCCCCTGGCGGTG
GTGGTGCCCAGGGGCGAGAAGCCCACCCCGGAGGAGCTGAACGAGCACCTCCTAAAGGCC
GGCTTCGCCAAGTGGCAGCTCCCCGACGCCTACGTCTTCGCGGAGGAGATCCCGAGGACA
TCCGCGGGCAAGTTCCTCAAGCGGGCCTTAAGGGAGCAGTACAAGAACTACTACGGAGGC
GCCTGA

# Drug_Target_23_General_Function:
Involved in catalytic activity

# Drug_Target_23_General_References:
Not Available

# Drug_Target_23_HGNC_ID:
Not Available

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
4373

# Drug_Target_23_Locus:
Not Available

# Drug_Target_23_Molecular_Weight:
59572

# Drug_Target_23_Name:
Medium-chain-fatty-acid--CoA ligase

# Drug_Target_23_Number_of_Residues:
541

# Drug_Target_23_PDB_ID:
1V26

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00501	AMP-binding

# Drug_Target_23_Protein_Sequence:
>Medium-chain-fatty-acid--CoA ligase
MEGERMNAFPSTMMDEELNLWDFLERAAALFGRKEVVSRLHTGEVHRTTYAEVYQRARRL
MGGLRALGVGVGDRVATLGFNHFRHLEAYFAVPGMGAVLHTANPRLSPKEIAYILNHAED
KVLLFDPNLLPLVEAIRGELKTVQHFVVMDEKAPEGYLAYEEALGEEADPVRVPERAACG
MAYTTGTTGLPKGVVYSHRALVLHSLAASLVDGTALSEKDVVLPVVPMFHVNAWCLPYAA
TLVGAKQVLPGPRLDPASLVELFDGEGVTFTAGVPTVWLALADYLESTGHRLKTLRRLVV
GGSAAPRSLIARFERMGVEVRQGYGLTETSPVVVQNFVKSHLESLSEEEKLTLKAKTGLP
IPLVRLRVADEEGRPVPKDGKALGEVQLKGPWITGGYYGNEEATRSALTPDGFFRTGDIA
VWDEEGYVEIKDRLKDLIKSGGEWISSVDLENALMGHPKVKEAAVVAIPHPKWQERPLAV
VVPRGEKPTPEELNEHLLKAGFAKWQLPDAYVFAEEIPRTSAGKFLKRALREQYKNYYGG
A

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Not Available

# Drug_Target_23_SwissProt_ID:
Q6L8F0

# Drug_Target_23_SwissProt_Name:
Q6L8F0_THETH

# Drug_Target_23_Synonyms:
Not Available

# Drug_Target_23_Theoretical_pI:
6.47

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Not Available

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
Not Available

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
J01917

# Drug_Target_24_GenBank_ID_Protein:
Not Available

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
PII

# Drug_Target_24_Gene_Sequence:
>2907 bp
ATGGCTACCCCTTCGATGATGCCGCAGTGGTCTTACATGCACATCTCGGGCCAGGACGCC
TCGGAGTACCTGAGCCCCGGGCTGGTGCAGTTTGCCCGCGCCACCGAGACGTACTTCAGC
CTGAATAACAAGTTTAGAAACCCCACGGTGGCACCTACGCACGACGTAACCACAGACCGG
TCCCAGCGTTTGACGCTGCGGTTCATCCCTGTGGACCGCGAGGATACCGCGTACTCGTAC
AAAGCGCGGTTCACCCTGGCTGTGGGTGACAACCGTGTGCTTGATATGGCTTCCACGTAC
TTTGACATCCGCGGCGTGCTGGACAGGGGGCCTACTTTTAAGCCCTACTCCGGCACTGCC
TACAACGCTCTAGCTCCCAAGGGCGCTCCTAACTCCTGTGAGTGGGAACAAACCGAAGAT
AGCGGCCGGGCAGTTGCCGAGGATGAAGAAGAGGAAGATGAAGATGAAGAAGAGGAAGAA
GAAGAGCAAAACGCTCGAGATCAGGCTACTAAGAAAACACATGTCTATGCCCAGGCTCCT
TTGTCTGGAGAAACAATTACAAAAAGCGGGCTACAAATAGGATCAGACAATGCAGAAACA
CAAGCTAAACCTGTATACGCAGATCCTTCCTATCAACCAGAACCTCAAATTGGCGAATCT
CAGTGGAACGAAGCTGATGCTAATGCGGCAGGAGGGAGAGTGCTTAAAAAAACAACTCCC
ATGAAACCATGCTATGGATCTTATGCCAGGCCTACAAATCCTTTTGGTGGTCAATCCGTT
CTGGTTCCGGATGAAAAAGGGGTGCCTCTTCCAAAGGTTGACTTGCAATTCTTCTCAAAT
ACTACCTCTTTGAACGACCGGCAAGGCAATGCTACTAAACCAAAAGTGGTTTTGTACAGT
GAAGATGTAAATATGGAAACCCCAGACACACATCTGTCTTACAAACCTGGAAAAGGTGAT
GAAAATTCTAAAGCTATGTTGGGTCAACAATCTATGCCAAACAGACCCAATTACATTGCT
TTCAGGGACAATTTTATTGGCCTAATGTATTATAACAGCACTGGCAACATGGGTGTTCTT
GCTGGTCAGGCATCGCAGCTAAATGCCGTGGTAGATTTGCAAGACAGAAACACAGAGCTG
TCCTATCAACTCTTGCTTGATTCCATAGGTGATAGAACCAGATATTTTTCTATGTGGAAT
CAGGCTGTAGACAGCTATGATCCAGATGTTAGAATCATTGAAAACCATGGAACTGAGGAT
GAATTGCCAAATTATTGTTTTCCTCTTGGGGGTATTGGGGTAACTGACACCTATCAAGCT
ATTAAGGCTAATGGCAATGGCTCAGGCGATAATGGAGATACTACATGGACAAAAGATGAA
ACTTTTGCAACACGTAATGAAATAGGAGTGGGTAACAACTTTGCCATGGAAATTAACCTA
AATGCCAACCTATGGAGAAATTTCCTTTACTCCAATATTGCGCTGTACCTGCCAGACAAG
CTAAAATACAACCCCACCAATGTGGAAATATCTGACAACCCCAACACCTACGACTACATG
AACAAGCGAGTGGTGGCTCCCGGGCTTGTAGACTGCTACATTAACCTTGGGGCGCGCTGG
TCTCTGGACTACATGGACAACGTTAATCCCTTTAACCACCACCGCAATGCGGGCCTCCGT
TATCGCTCCATGTTGTTGGGAAACGGCCGCTACGTGCCCTTTCACATTCAGGTGCCCCAA
AAGTTTTTTGCCATTAAAAACCTCCTCCTCCTGCCAGGCTCATATACATATGAATGGAAC
TTCAGGAAGGATGTTAACATGGTTCTGCAGAGCTCTCTGGGAAACGATCTTAGAGTTGAC
GGGGCTAGCATTAAGTTTGACAGCATTTGTCTTTACGCCACCTTCTTCCCCATGGCCCAC
AACACGGCCTCCACGCTGGAAGCCATGCTCAGAAATGACACCAACGACCAGTCCTTTAAT
GACTACCTTTCCGCCGCCAACATGCTATACCCCATACCCGCCAACGCCACCAACGTGCCC
ATCTCCATCCCATCGCGCAACTGGGCAGCATTTCGCGGTTGGGCCTTCACACGCTTGAAG
ACAAAGGAAACCCCTTCCCTGGGATCAGGCTACGACCCTTACTACACCTACTCTGGCTCC
ATACCATACCTTGACGGAACCTTCTATCTTAATCACACCTTTAAGAAGGTGGCCATTACC
TTTGACTCTTCTGTTAGCTGGCCGGGCAACGACCGCCTGCTTACTCCCAATGAGTTTGAG
ATTAAACGCTCAGTTGACGGGGAGGGCTACAACGTAGCTCAGTGCAACATGACCAAGGAC
TGGTTCCTGGTGCAGATGTTGGCCAACTACAATATTGGCTACCAGGGCTTCTACATTCCA
GAAAGCTACAAGGACCGCATGTACTCGTTCTTCAGAAACTTCCAGCCCATGAGCCGGCAA
GTGGTTGACGATACTAAATACAAGGAGTATCAGCAGGTTGGAATTCTTCACCAGCATAAC
AACTCAGGATTCGTAGGCTACCTCGCTCCCACCATGCGCGAGGGACAGGCTTACCCCGCC
AACGTGCCCTACCCACTAATAGGCAAAACCGCGGTTGACAGTATTACCCAGAAAAAGTTT
CTTTGCGATCGCACCCTTTGGCGCATCCCATTCTCCAGTAACTTTATGTCCATGGGCGCA
CTCACAGACCTGGGCCAAAACCTTCTCTACGCCAACTCCGCCCACGCGCTAGACATGACT
TTTGAGGTGGATCCCATGGACGAGCCCACCCTTCTTTATGTTTTGTTTGAAGTCTTTGAC
GTGGTCCGTGTGCACCAGCCGCACCGCGGCGTCATCGAGACCGTGTACCTGCGCACGCCC
TTCTCGGCCGGCAACGCCACAACATAA

# Drug_Target_24_General_Function:
Involved in structural molecule activity

# Drug_Target_24_General_References:
4823869	Jornvall H, Ohlsson H, Philipson L: An acetylated N-terminus of adenovirus type 2 hexon protein. Biochem Biophys Res Commun. 1974 Jan 23;56(2):304-10.
6259616	Akusjarvi G, Zabielski J, Perricaudet M, Pettersson U: The sequence of the 3' non-coding region of the hexon mRNA discloses a novel adenovirus gene. Nucleic Acids Res. 1981 Jan 10;9(1):1-17.
6263909	Jornvall H, Akusjarvi G, Alestrom P, von Bahr-Lindstrom H, Pettersson U, Appella E, Fowler AV, Philipson L: The adenovirus hexon protein. The primary structure of the polypeptide and its correlation with the hexon gene. J Biol Chem. 1981 Jun 25;256(12):6181-6.
6501284	Akusjarvi G, Alestrom P, Pettersson M, Lager M, Jornvall H, Pettersson U: The gene for the adenovirus 2 hexon polypeptide. J Biol Chem. 1984 Nov 25;259(22):13976-9.
7932702	Athappilly FK, Murali R, Rux JJ, Cai Z, Burnett RM: The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol. 1994 Sep 30;242(4):430-55.

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
5580

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
109154

# Drug_Target_24_Name:
Hexon protein

# Drug_Target_24_Number_of_Residues:
968

# Drug_Target_24_PDB_ID:
1P2Z

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF01065	Adeno_hexon
PF03678	Adeno_hexon_C

# Drug_Target_24_Protein_Sequence:
>Hexon protein
MATPSMMPQWSYMHISGQDASEYLSPGLVQFARATETYFSLNNKFRNPTVAPTHDVTTDR
SQRLTLRFIPVDREDTAYSYKARFTLAVGDNRVLDMASTYFDIRGVLDRGPTFKPYSGTA
YNALAPKGAPNSCEWEQTEDSGRAVAEDEEEEDEDEEEEEEEQNARDQATKKTHVYAQAP
LSGETITKSGLQIGSDNAETQAKPVYADPSYQPEPQIGESQWNEADANAAGGRVLKKTTP
MKPCYGSYARPTNPFGGQSVLVPDEKGVPLPKVDLQFFSNTTSLNDRQGNATKPKVVLYS
EDVNMETPDTHLSYKPGKGDENSKAMLGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVL
AGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPDVRIIENHGTED
ELPNYCFPLGGIGVTDTYQAIKANGNGSGDNGDTTWTKDETFATRNEIGVGNNFAMEINL
NANLWRNFLYSNIALYLPDKLKYNPTNVEISDNPNTYDYMNKRVVAPGLVDCYINLGARW
SLDYMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKNLLLLPGSYTYEWN
FRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTNDQSFN
DYLSAANMLYPIPANATNVPISIPSRNWAAFRGWAFTRLKTKETPSLGSGYDPYYTYSGS
IPYLDGTFYLNHTFKKVAITFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKD
WFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFQPMSRQVVDDTKYKEYQQVGILHQHN
NSGFVGYLAPTMREGQAYPANVPYPLIGKTAVDSITQKKFLCDRTLWRIPFSSNFMSMGA
LTDLGQNLLYANSAHALDMTFEVDPMDEPTLLYVLFEVFDVVRVHQPHRGVIETVYLRTP
FSAGNATT

# Drug_Target_24_Reaction:
Not Available

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
This protein is one of the structural proteins in the viral coat and is synthesized during late infection

# Drug_Target_24_SwissProt_ID:
P03277

# Drug_Target_24_SwissProt_Name:
HEX_ADE02

# Drug_Target_24_Synonyms:
Late protein 2

# Drug_Target_24_Theoretical_pI:
4.84

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Not Available

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
Not Available

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
Not Available

# Drug_Target_25_GenBank_ID_Gene:
AE000512

# Drug_Target_25_GenBank_ID_Protein:
Not Available

# Drug_Target_25_GeneCard_ID:
Not Available

# Drug_Target_25_Gene_Name:
TM_0857

# Drug_Target_25_Gene_Sequence:
>882 bp
ATGGTTGTCAGCATCGGAGTTTTCGATGGAGTTCACATCGGGCATCAGAAGGTCTTGAGG
ACCATGAAGGAAATAGCATTTTTCAGGAAGGACGATAGCCTTATCTACACCATATCTTAT
CCCCCCGAATATTTCTTACCGGATTTTCCCGGTCTTCTCATGACGGTAGAAAGCAGGGTG
GAGATGCTTTCTCGTTACGCCAGAACCGTTGTTCTGGATTTTTTCAGAATAAAAGATCTC
ACCCCAGAAGGGTTCGTCGAGAGGTATCTATCTGGAGTATCGGCTGTTGTTGTTGGAAGG
GATTTCAGATTTGGCAAGAACGCGAGCGGAAACGCGTCTTTTCTCAGAAAGAAAGGTGTG
GAAGTCTATGAAATTGAAGATGTCGTTGTTCAGGGAAAAAGAGTGAGCAGTTCTCTGATC
AGAAACCTCGTTCAGGAGGGAAGAGTGGAGGAAATTCCTGCATATCTCGGCAGATATTTC
GAAATCGAAGGAATCGTCCACAAAGATAGGGAATTTGGAAGAAAACTGGGATTTCCAACT
GCCAACATCGATAGAGGAAATGAAAAACTCGTAGATCTGAAAAGAGGAGTTTATCTGGTG
AGAGTTCATCTGCCGGATGGAAAGAAAAAATTCGGTGTTATGAACGTGGGTTTCAGGCCC
ACCGTGGGTGATGCGAGAAACGTGAAGTACGAGGTGTACATCCTGGATTTCGAAGGGGAT
CTTTACGGGCAGAGACTGAAACTGGAAGTATTGAAATTCATGAGGGATGAGAAGAAATTT
GATTCAATCGAGGAGCTGAAGGCTGCTATTGACCAGGATGTAAAGAGCGCCAGAAACATG
ATAGATGATATAATCAATTCGAAGTTCGAAAAAGAGGGGTGA

# Drug_Target_25_General_Function:
Involved in FMN adenylyltransferase activity

# Drug_Target_25_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
12910462	Wang W, Kim R, Jancarik J, Yokota H, Kim SH: Crystal structure of a flavin-binding protein from Thermotoga maritima. Proteins. 2003 Sep 1;52(4):633-5.

# Drug_Target_25_HGNC_ID:
Not Available

# Drug_Target_25_HPRD_ID:
Not Available

# Drug_Target_25_ID:
4366

# Drug_Target_25_Locus:
Not Available

# Drug_Target_25_Molecular_Weight:
33614

# Drug_Target_25_Name:
Riboflavin kinase/FMN adenylyltransferase

# Drug_Target_25_Number_of_Residues:
293

# Drug_Target_25_PDB_ID:
1T6Z

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF01687	Flavokinase
PF06574	FAD_syn

# Drug_Target_25_Protein_Sequence:
>Riboflavin kinase/FMN adenylyltransferase
MVVSIGVFDGVHIGHQKVLRTMKEIAFFRKDDSLIYTISYPPEYFLPDFPGLLMTVESRV
EMLSRYARTVVLDFFRIKDLTPEGFVERYLSGVSAVVVGRDFRFGKNASGNASFLRKKGV
EVYEIEDVVVQGKRVSSSLIRNLVQEGRVEEIPAYLGRYFEIEGIVHKDREFGRKLGFPT
ANIDRGNEKLVDLKRGVYLVRVHLPDGKKKFGVMNVGFRPTVGDARNVKYEVYILDFEGD
LYGQRLKLEVLKFMRDEKKFDSIEELKAAIDQDVKSARNMIDDIINSKFEKEG

# Drug_Target_25_Reaction:
Not Available

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Not Available

# Drug_Target_25_SwissProt_ID:
Q9WZW1

# Drug_Target_25_SwissProt_Name:
Q9WZW1_THEMA

# Drug_Target_25_Synonyms:
Not Available

# Drug_Target_25_Theoretical_pI:
9.26

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Cytoplasmic

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
Not Available

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
Not Available

# Drug_Target_26_GenBank_ID_Gene:
AJ001073

# Drug_Target_26_GenBank_ID_Protein:
Not Available

# Drug_Target_26_GeneCard_ID:
Not Available

# Drug_Target_26_Gene_Name:
bfrA

# Drug_Target_26_Gene_Sequence:
>1299 bp
ATGTTCAAGCCGAATTATCACTTTTTCCCGATAACAGGCTGGATGAACGATCCGAACGGT
TTGATCTTCTGGAAGGGAAAATATCATATGTTCTATCAGTATAATCCCAGAAAACCTGAG
TGGGGAAACATCTGCTGGGGCCACGCGGTGAGCGACGATCTCGTTCACTGGAGACACCTT
CCCGTTGCTCTATATCCCGACGATGAAACACACGGAGTGTTCTCTGGAAGCGCTGTCGAG
AAAGATGGGAAAATGTTTCTCGTGTACACCTACTACCGCGATCCGACACACAACAAAGGA
GAAAAAGAAACCCAGTGTGTGGCTATGAGTGAAAACGGATTGGATTTCGTAAAGTACGAT
GGAAACCCGGTCATATCTAAACCCCCAGAGGAAGGGACGCACGCCTTCAGAGACCCGAAG
GTGAACAGAAGCAACGGTGAGTGGCGAATGGTACTGGGATCTGGTAAAGATGAGAAGATT
GGAAGAGTGCTTCTCTATACCTCAGATGACCTTTTTCACTGGAAGTACGAGGGTGTGATC
TTCGAAGATGAAACCACAAAAGAAATAGAGTGTCCCGATCTTGTGAGAATTGGAGAGAAA
GATATCCTCATATACTCGATAACGAGTACAAACAGCGTTCTGTTTTCCATGGGAGAGTTA
AAGGAAGGAAAACTGAATGTCGAAAAGCGGGGGCTTCTCGATCACGGAACGGATTTCTAC
GCTGCTCAAACTTTCTTTGGAACAGACAGAGTTGTAGTTATCGGATGGCTTCAAAGCTGG
TTGAGAACAGGGCTTTACCCGACAAAACGAGAAGGATGGAACGGTGTCATGAGTCTTCCT
AGGGAGCTGTATGTAGAAAACAACGAGTTGAAGGTGAAACCGGTGGATGAACTCTTGGCT
CTCAGAAAGAGAAAGGTTTTCGAAACTGCAAAGTCCGGAACATTTCTGCTGGATGTCAAG
GAAAACAGTTATGAAATTGTGTGTGAATTCAGCGGAGAAATCGAACTTCGAATGGGAAAT
GAATCTGAAGAAGTGGTGATAACGAAGAGTCGAGACGAATTAATCGTGGATACAACGAGA
TCTGGTGTTTCAGGTGGAGAAGTTAGAAAGTCGACAGTCGAAGATGAAGCTACAAATAGA
ATACGAGCTTTCTTGGATTCGTGTTCTGTAGAATTTTTCTTCAACGACTCCATAGCTTTT
TCCTTTAGGATCCATCCAGAGAACGTTTACAACATTCTTTCTGTCAAATCGAACCAAGTG
AAACTCGAAGTCTTTGAACTCGAGAACATATGGTTGTGA

# Drug_Target_26_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_26_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
9720201	Liebl W, Brem D, Gotschlich A: Analysis of the gene for beta-fructosidase (invertase, inulinase) of the hyperthermophilic bacterium Thermotoga maritima, and characterisation of the enzyme expressed in Escherichia coli. Appl Microbiol Biotechnol. 1998 Jul;50(1):55-64.

# Drug_Target_26_HGNC_ID:
Not Available

# Drug_Target_26_HPRD_ID:
Not Available

# Drug_Target_26_ID:
5581

# Drug_Target_26_Locus:
Not Available

# Drug_Target_26_Molecular_Weight:
49842

# Drug_Target_26_Name:
Beta-fructosidase

# Drug_Target_26_Number_of_Residues:
432

# Drug_Target_26_PDB_ID:
1UYP

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00251	Glyco_hydro_32N
PF08244	Glyco_hydro_32C

# Drug_Target_26_Protein_Sequence:
>Beta-fructosidase
MFKPNYHFFPITGWMNDPNGLIFWKGKYHMFYQYNPRKPEWGNICWGHAVSDDLVHWRHL
PVALYPDDETHGVFSGSAVEKDGKMFLVYTYYRDPTHNKGEKETQCVAMSENGLDFVKYD
GNPVISKPPEEGTHAFRDPKVNRSNGEWRMVLGSGKDEKIGRVLLYTSDDLFHWKYEGVI
FEDETTKEIECPDLVRIGEKDILIYSITSTNSVLFSMGELKEGKLNVEKRGLLDHGTDFY
AAQTFFGTDRVVVIGWLQSWLRTGLYPTKREGWNGVMSLPRELYVENNELKVKPVDELLA
LRKRKVFETAKSGTFLLDVKENSYEIVCEFSGEIELRMGNESEEVVITKSRDELIVDTTR
SGVSGGEVRKSTVEDEATNRIRAFLDSCSVEFFFNDSIAFSFRIHPENVYNILSVKSNQV
KLEVFELENIWL

# Drug_Target_26_Reaction:
Not Available

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Hydrolysis of sucrose, raffinose, inulin and levan. Specific for the fructose moiety and the beta-anomeric configuration of the glycosidic linkages of its substrates. The enzyme released fructose from sucrose and raffinose, and the fructose polymer inulin is hydrolyzed quantitatively in an exo- type fashion

# Drug_Target_26_SwissProt_ID:
O33833

# Drug_Target_26_SwissProt_Name:
BFRA_THEMA

# Drug_Target_26_Synonyms:
EC 3.2.1.26
Invertase
Sucrase

# Drug_Target_26_Theoretical_pI:
5.10

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Not Available

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
Not Available

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
AE009952

# Drug_Target_27_GenBank_ID_Protein:
Not Available

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
sspA

# Drug_Target_27_Gene_Sequence:
>642 bp
TTAGCTCCGAGTTTTCAGATGCATTTCACGTTCAGCTTCAGTCAGTGAAGCCAAGAACGC
ATCACGCTCAAAGACGCGAGTCATATAGCCTTTCAGCTCTTTAGAGCCCGCCCCTGTGAA
CTCAATCCCTAACACCGGTAAACGCCATAGCAACGGAGCTAAGTAACAATCGACCAGACT
GAACTCTTCACTCATAAAGAAAGGTGTTTCGTTAAAGACTGGCGCGATGGACAGTAACTC
TTCACGTAACTGTTTACGTGCCGCTTCAGCTTCCTGTGCATTACCTTGCTCAATTTTATA
CAGCAGGGAATACCAGTCGTGCTCAATACGGTGCATCATCAAGCGGCTGCTACCACGAGC
AACAGGATAGACTGGCATCAATGGTGGGTGAGGGAAACGCTCATCCAAATATTCCATGAT
AATGCGGGATTCATACAGCGTCAGCTCGCGATCAACCAAAGTAGGGACAGTACGGTAGGG
GTTGAGGTCAATCAGGTCCTGTGGCAGGTTATCAGCTTCAACCTGCTCAATCTCAACACT
GACACCTTTCTCTGCCAGTACGATACGTACTTGATGGCTAAAAATGTCGGTCGGGCCGGA
AAACAGCGTCATTACCGAACGTTTGTTGGCAGCGACAGCCAT

# Drug_Target_27_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_27_General_References:
12142430	Deng W, Burland V, Plunkett G 3rd, Boutin A, Mayhew GF, Liss P, Perna NT, Rose DJ, Mau B, Zhou S, Schwartz DC, Fetherston JD, Lindler LE, Brubaker RR, Plano GV, Straley SC, McDonough KA, Nilles ML, Matson JS, Blattner FR, Perry RD: Genome sequence of Yersinia pestis KIM. J Bacteriol. 2002 Aug;184(16):4601-11.

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
5582

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
24526

# Drug_Target_27_Name:
Regulator of transcription; stringent starvation protein A

# Drug_Target_27_Number_of_Residues:
213

# Drug_Target_27_PDB_ID:
1YY7

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
Not Available

# Drug_Target_27_Protein_Sequence:
>Regulator of transcription; stringent starvation protein A
MAVAANKRSVMTLFSGPTDIFSHQVRIVLAEKGVSVEIEQVEADNLPQDLIDLNPYRTVP
TLVDRELTLYESRIIMEYLDERFPHPPLMPVYPVARGSSRLMMHRIEHDWYSLLYKIEQG
NAQEAEAARKQLREELLSIAPVFNETPFFMSEEFSLVDCYLAPLLWRLPVLGIEFTGAGS
KELKGYMTRVFERDAFLASLTEAEREMHLKTRS

# Drug_Target_27_Reaction:
Not Available

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Not Available

# Drug_Target_27_SwissProt_ID:
Q7CL96

# Drug_Target_27_SwissProt_Name:
Q7CL96_YERPE

# Drug_Target_27_Synonyms:
Putative stringent starvation protein A

# Drug_Target_27_Theoretical_pI:
4.89

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Not Available

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
Not Available

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
Not Available

# Drug_Target_28_GenBank_ID_Gene:
AB040146

# Drug_Target_28_GenBank_ID_Protein:
Not Available

# Drug_Target_28_GeneCard_ID:
Not Available

# Drug_Target_28_Gene_Name:
cit

# Drug_Target_28_Gene_Sequence:
>1134 bp
ATGGAAGTGGCACGCGGTCTGGAAGGCGTTCTCTTCACGGAAAGCCGGATGTGCTACATT
GACGGCCAGCAGGGGAAGCTCTACTACTACGGCATTCCCATCCAGGAGCTGGCGGAGAAG
AGCAGCTTTGAGGAAACCACCTTCCTCCTCCTCCACGGGAGACTGCCGCGAAGGCAGGAG
CTGGAGGAGTTCTCGGCCGCCCTCGCCCGGCGCCGCGCCATGCCCGCCCACCTTCTGGAG
TCCTTCAAGCGCTACCCCGTCTCCGCCCACCCCATGAGCTTCCTGCGCACGGCGGTCTCC
GAGTTCGGGATGCTGGACCCCACCGAGGGGGACATCTCCCGGGAGGCCCTCTACGAGAAG
GGGCTTGACCTCATCGCCAAGTTCGCCACCATCGTGGCCGCCAACAAGCGCCTCAAGGAG
GGCAAGGAGCCCATCCCTCCCCGGGAGGACCTCTCCCACGCCGCCAACTTCCTCTACATG
GCGAACGGGGTGGAGCCCTCCCCCGAGCAGGCCCGCCTCATGGACGCGGCCCTCATCCTC
CACGCCGAGCACGGCTTCAACGCCAGCACCTTCACCGCCATCGCCGCCTTCTCCACGGAG
ACCGACCTCTACTCGGCCATCACCGCCGCCGTGGCCTCCCTGAAGGGGCCGCGCCACGGC
GGGGCCAACGAGGCCGTGATGCGCATGATCCAGGAGATCGGCACCCCCGAGCGGGCCCGG
GAGTGGGTGCGGGAGAAGCTGGCCAAGAAGGAGCGCATCATGGGCATGGGCCACCGGGTC
TACAAGGCCTTTGACCCCAGGGCCGGGGTCCTGGAAAAGCTCGCCCGGTTGGTGGCGGAG
AAGCACGGCCACTCCAAGGAGTACCAGATCCTGAAGATCGTGGAGGAGGAGGCGGGGAAG
GTCCTGAACCCCAGGGGCATCTACCCCAACGTGGACTTCTACTCCGGGGTGGTCTACTCC
GACCTGGGCTTCAGCCTGGAGTTCTTCACCCCCATCTTCGCCGTGGCCCGGATCTCGGGC
TGGGTGGGGCACATCCTGGAGTACCAGGAGCTGGACAACCGCCTCCTCCGCCCCGGGGCC
AAGTACGTGGGGGAGCTGGACGTGCCCTACGTCCCCCTCGAGGCCCGGGAGTAG

# Drug_Target_28_General_Function:
Involved in transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer

# Drug_Target_28_General_References:
Not Available

# Drug_Target_28_HGNC_ID:
Not Available

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
4575

# Drug_Target_28_Locus:
Not Available

# Drug_Target_28_Molecular_Weight:
42323

# Drug_Target_28_Name:
Citrate synthase

# Drug_Target_28_Number_of_Residues:
377

# Drug_Target_28_PDB_ID:
1IXE

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00285	Citrate_synt

# Drug_Target_28_Protein_Sequence:
>Citrate synthase
MEVARGLEGVLFTESRMCYIDGQQGKLYYYGIPIQELAEKSSFEETTFLLLHGRLPRRQE
LEEFSAALARRRAMPAHLLESFKRYPVSAHPMSFLRTAVSEFGMLDPTEGDISREALYEK
GLDLIAKFATIVAANKRLKEGKEPIPPREDLSHAANFLYMANGVEPSPEQARLMDAALIL
HAEHGFNASTFTAIAAFSTETDLYSAITAAVASLKGPRHGGANEAVMRMIQEIGTPERAR
EWVREKLAKKERIMGMGHRVYKAFDPRAGVLEKLARLVAEKHGHSKEYQILKIVEEEAGK
VLNPRGIYPNVDFYSGVVYSDLGFSLEFFTPIFAVARISGWVGHILEYQELDNRLLRPGA
KYVGELDVPYVPLEARE

# Drug_Target_28_Reaction:
Not Available

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Not Available

# Drug_Target_28_SwissProt_ID:
Q9LCX9

# Drug_Target_28_SwissProt_Name:
Q9LCX9_THETH

# Drug_Target_28_Synonyms:
Not Available

# Drug_Target_28_Theoretical_pI:
6.60

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Cytoplasm

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
Not Available

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
Not Available

# Drug_Target_29_GenBank_ID_Gene:
U00096

# Drug_Target_29_GenBank_ID_Protein:
Not Available

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
rtcA

# Drug_Target_29_Gene_Sequence:
>1017 bp
TCATTCAATGCTCACCCGCGTTACGCCATCTGTTTCTATCAAACTAAACCGCACCGGCAA
GAAACGCTCCACCACCGCGATATTGGTCAGCAGATGGCATGAGGGATGGGCGACCGTAAA
TTCCCCCGCGCCCGCCAGCGCCATCGGTAGCACCAGTTGGTCAGCAAGATATTCCCCCAC
CGCCGCCGTGCTTGCCAGGTAGCGTTTCACCTCTTTCACCAACTGTGCCGCAACCACCTC
GGCACTGACGCGCTTTTCACCGACGACAAAAAAGCGTTCGGTGATATTTTCACTTTCGAC
TTCAAGCGAGACGGTATTACCCGGCCCCTGGTCGCGCGGCAGGTTATGAATATTCTGTTC
ATGCAGGGAAAAACTCCCCGCCAGTGTAGCGATTTCACGCTCAGCAACATGGCGCGGCAC
ACCAGCTAATAGAACTTCTCCACGCATCTGCACAATGTTCCCGCGCTCGCCAAGTTGCAA
GGTGTTAAACGATGCCACGGGCGAGACTTCCGTTGCCACCACACCGCCTCCGGCAGGGTA
AAAACCGTGGCGTAACAGCGTGGTTTGCTGATGAATTCCTATTTTCGCCAGCAGCGGCTC
CAGCACCCGGCGGATAAAATCCGCAGGCGGCGCCGACGGGTTATCGGTGCCGCCGCTCAC
TTCAACACGCGAAGGTCCATCGGCAAACCACAGCGCGGGCAGCACCGTTTGCAGCACCAG
CGTACAACTTCCGGCGCTACCGATAGCAAAGCGGTAATCGCCGCCGCGCACGGTGCCGGG
CCGGAAGAGCAGACGCTGCGACCCCAGCTCCGCGCCTTCCACGGTTGCTCCGCAAATTTC
CGTCGCCGCCTTTACCGCGGTCAGATGCTGGCGCAACAGCCCCGGTTTCGCCCGCCCGGC
ACGAATGCTGGTGATGGTAAATGGCTGGCCGGTTATCATCGACAGGCTCAGCGCCGAGCG
CAGGATCTGCCCGCCACCTTCGCCCTGTGCGCCATCCAGCGCAATCATCCTTTTCAT

# Drug_Target_29_General_Function:
Involved in ligase activity, forming phosphoric ester bonds

# Drug_Target_29_General_References:
10673421	Palm GJ, Billy E, Filipowicz W, Wlodawer A: Crystal structure of RNA 3'-terminal phosphate cyclase, a ubiquitous enzyme with unusual topology. Structure. 2000 Jan 15;8(1):13-23.
3015733	Cole ST, Raibaud O: The nucleotide sequence of the malT gene encoding the positive regulator of the Escherichia coli maltose regulon. Gene. 1986;42(2):201-8.
9184239	Genschik P, Billy E, Swianiewicz M, Filipowicz W: The human RNA 3'-terminal phosphate cyclase is a member of a new family of proteins conserved in Eucarya, Bacteria and Archaea. EMBO J. 1997 May 15;16(10):2955-67.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9738023	Genschik P, Drabikowski K, Filipowicz W: Characterization of the Escherichia coli RNA 3'-terminal phosphate cyclase and its sigma54-regulated operon. J Biol Chem. 1998 Sep 25;273(39):25516-26.

# Drug_Target_29_HGNC_ID:
Not Available

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
5583

# Drug_Target_29_Locus:
Not Available

# Drug_Target_29_Molecular_Weight:
35904

# Drug_Target_29_Name:
RNA 3'-terminal phosphate cyclase

# Drug_Target_29_Number_of_Residues:
338

# Drug_Target_29_PDB_ID:
1QMH

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF01137	RTC
PF05189	RTC_insert

# Drug_Target_29_Protein_Sequence:
>RNA 3'-terminal phosphate cyclase
MKRMIALDGAQGEGGGQILRSALSLSMITGQPFTITSIRAGRAKPGLLRQHLTAVKAATE
ICGATVEGAELGSQRLLFRPGTVRGGDYRFAIGSAGSCTLVLQTVLPALWFADGPSRVEV
SGGTDNPSAPPADFIRRVLEPLLAKIGIHQQTTLLRHGFYPAGGGVVATEVSPVASFNTL
QLGERGNIVQMRGEVLLAGVPRHVAEREIATLAGSFSLHEQNIHNLPRDQGPGNTVSLEV
ESENITERFFVVGEKRVSAEVVAAQLVKEVKRYLASTAAVGEYLADQLVLPMALAGAGEF
TVAHPSCHLLTNIAVVERFLPVRFSLIETDGVTRVSIE

# Drug_Target_29_Reaction:
Not Available

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Catalyzes the conversion of 3'-phosphate to a 2',3'- cyclic phosphodiester at the end of RNA. The mechanism of action of the enzyme occurs in 3 steps:(A) adenylation of the enzyme by ATP; (B) the enzyme acts on RNA-N3'P to produce RNA-N3'PP5'A; (C) a non catalytic nucleophilic attack by the adjacent 2'hydroxyl on the phosphorus in the diester linkage to produce the cyclic end product. The biological role of this enzyme is unknown but it is likely to function in some aspects of cellular RNA processing

# Drug_Target_29_SwissProt_ID:
P46849

# Drug_Target_29_SwissProt_Name:
RTCA_ECOLI

# Drug_Target_29_Synonyms:
EC 6.5.1.4
RNA cyclase
RNA-3'-phosphate cyclase

# Drug_Target_29_Theoretical_pI:
7.26

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
L19201

# Drug_Target_2_GenBank_ID_Protein:
304962

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
mobA

# Drug_Target_2_Gene_Sequence:
>585 bp
TCATCGTTTTTCCTGCCATCGGGCAAGCTCCTCTGGCGTATTCACGTTAACAAATGCATC
TTTATGATCGCTGAAATCAACCGCATGACCGCCAGCCAGACGCATAAATACCATTACCCG
GCGTTCTCCTGCTTGCAGATATTCCAGTAATAAAGGCTCAATAGCGCGGTTTACCAGAGC
AATAGTCGGGTGATCGCGTTCACCGTCATGGACCCACACGACAGGCGCATCTTTGCGCTG
ATGATTAAGCCTGGCTGCTAAATCAGGGGGAATGTAAGGCGTATCGCACGGGCAAAACAA
AAACCACTCACCAGCTTCCTGCTGCATTACTGAAAGCATTCCTGCCAGAGGGCCTGGGTA
ATCCGCCAGTGAATCTTCAATCACTTTCAGACCGCTTGCCTGATAGATTTCCTGATGACG
ATTAGCATTAACCACGACGTGAGAGAGCTGCGTCATAAGCGCGTCAGCGACATGTTGCCA
TAATGGTTTGCCGTTTAATTCAAGCAATCCTTTATCTACGCCGCCCATTCGTCTGGCTTT
ACCGCCTGCCAGCACAACGCCTGTTATCGTCGTCATCAGATTCAC

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
10978347	Lake MW, Temple CA, Rajagopalan KV, Schindelin H: The crystal structure of the Escherichia coli MobA protein provides insight into molybdopterin guanine dinucleotide biosynthesis. J Biol Chem. 2000 Dec 22;275(51):40211-7.
7551035	Iobbi-Nivol C, Palmer T, Whitty PW, McNairn E, Boxer DH: The mob locus of Escherichia coli K12 required for molybdenum cofactor biosynthesis is expressed at very low levels. Microbiology. 1995 Jul;141 ( Pt 7):1663-71.
8020507	Palmer T, Vasishta A, Whitty PW, Boxer DH: Isolation of protein FA, a product of the mob locus required for molybdenum cofactor biosynthesis in Escherichia coli. Eur J Biochem. 1994 Jun 1;222(2):687-92.
8346018	Plunkett G 3rd, Burland V, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome. III. DNA sequence of the region from 87.2 to 89.2 minutes. Nucleic Acids Res. 1993 Jul 25;21(15):3391-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3085

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
21643

# Drug_Target_2_Name:
Molybdopterin-guanine dinucleotide biosynthesis protein A

# Drug_Target_2_Number_of_Residues:
194

# Drug_Target_2_PDB_ID:
1FRW

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
>Molybdopterin-guanine dinucleotide biosynthesis protein A
MNLMTTITGVVLAGGKARRMGGVDKGLLELNGKPLWQHVADALMTQLSHVVVNANRHQEI
YQASGLKVIEDSLADYPGPLAGMLSVMQQEAGEWFLFCPCDTPYIPPDLAARLNHQRKDA
PVVWVHDGERDHPTIALVNRAIEPLLLEYLQAGERRVMVFMRLAGGHAVDFSDHKDAFVN
VNTPEELARWQEKR

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Links a guanosine 5'-phosphate to molydopterin (MPT) forming molybdopterin guanine dinucleotide (MGD)

# Drug_Target_2_SwissProt_ID:
P32173

# Drug_Target_2_SwissProt_Name:
MOBA_ECOLI

# Drug_Target_2_Synonyms:
Protein FA

# Drug_Target_2_Theoretical_pI:
6.30

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Not Available

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
Not Available

# Drug_Target_30_GenBank_ID_Gene:
Not Available

# Drug_Target_30_GenBank_ID_Protein:
Not Available

# Drug_Target_30_GeneCard_ID:
Not Available

# Drug_Target_30_Gene_Name:
LSM6

# Drug_Target_30_Gene_Sequence:
Not Available

# Drug_Target_30_General_Function:
Not Available

# Drug_Target_30_General_References:
Not Available

# Drug_Target_30_HGNC_ID:
Not Available

# Drug_Target_30_HPRD_ID:
Not Available

# Drug_Target_30_ID:
6944

# Drug_Target_30_Locus:
Not Available

# Drug_Target_30_Molecular_Weight:
Not Available

# Drug_Target_30_Name:
U6 snRNA-associated Sm-like protein LSm6

# Drug_Target_30_Number_of_Residues:
0

# Drug_Target_30_PDB_ID:
Not Available

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
Not Available

# Drug_Target_30_Protein_Sequence:
Not Available

# Drug_Target_30_Reaction:
Not Available

# Drug_Target_30_Signals:
Not Available

# Drug_Target_30_Specific_Function:
Not Available

# Drug_Target_30_SwissProt_ID:
P62312

# Drug_Target_30_SwissProt_Name:
LSM6_HUMAN

# Drug_Target_30_Synonyms:
Not Available

# Drug_Target_30_Theoretical_pI:
Not Available

# Drug_Target_30_Transmembrane_Regions:
Not Available

# Drug_Target_31_Cellular_Location:
Cytoplasm. Cell membrane

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
Not Available

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
PLEKHA1

# Drug_Target_31_GenBank_ID_Gene:
AF286160

# Drug_Target_31_GenBank_ID_Protein:
Not Available

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
PLEKHA1

# Drug_Target_31_Gene_Sequence:
>1215 bp
ATGCCTTATGTGGATCGTCAGAATCGCATTTGTGGTTTTCTAGACATTGAAGAAAATGAA
AACAGTGGGAAATTTCTTCGAAGGTACTTCATACTGGATACCAGAGAAGATAGTTTCGTG
TGGTACATGGATAATCCACAGAACCTACCTTCTGGATCATCACGTGTTGGAGCCATTAAG
CTTACCTACATTTCAAAGGTTAGCGATGCTACTAAGCTAAGGCCAAAGGCGGAGTTCTGT
TTTGTTATGAATGCAGGAATGAGGAAGTACTTCCTACAAGCCAATGATCAGCAGGACCTA
GTGGAATGGGTAAATGTGTTAAACAAAGCTATAAAAATTACAGTACCAAAGCAGTCAGAC
TCACAGCCTAATTCTGATAACCTAAGTCGCCATGGTGAATGTGGGAAAAAGCAAGTGTCT
TACAGAACTGATATTGTTGGTGGCGTACCCATCATTACTCCCACTCAGAAAGAAGAAGTA
AATGAATGTGGTGAAAGTATTGACAGAAATAATCTGAAACGGTCACAAAGCCATCTTCCT
TACTTTACTCCTAAACCACCTCAAGATAGTGCGGTTATCAAAGCTGGATATTGTGTAAAA
CAAGGAGCAGTGATGAAAAACTGGAAGAGAAGATATTTTCAATTGGATGAAAACACAATA
GGCTACTTCAAATCTGAACTGGAAAAGGAACCTCTTCGCGTAATACCACTTAAAGAGGTT
CATAAAGTCCAGGAATGTAAGCAAAGCGACATAATGATGAGGGACAACCTCTTTGAAATT
GTAACAACGTCTCGAACTTTCTATGTGCAGGCTGATAGCCCTGAAGAGATGCACAGTTGG
ATTAAAGCAGTCTCTGGCGCCATTGTAGCACAGCGGGGTCCCGGCAGATCTGCGTCTTCT
GAGCATCCCCCCGGTCCTTCAGAATCCAAACACGCTTTCCGTCCTACCAACGCAGCCGCC
GCCACCTCACATTCCACAGCCTCTCGCAGCAACTCTTTGGTCTCAACCTTTACCATGGAG
AAGCGAGGATTTTACGAGTCTCTTGCCAAGGTCAAGCCAGGGAACTTCAAGGTCCAGACT
GTCTCTCCAAGAGAACCAGCTTCCAAAGTGACTGAACAAGCTCTGTTAAGACCTCAAAGT
AAAAATGGCCCTCAGGAAAAAGATTGTGACCTAGTAGACTTGGACGATGCGAGCCTTCCG
GTCAGTGACGTGTGA

# Drug_Target_31_General_Function:
Not Available

# Drug_Target_31_General_References:
11001876	Dowler S, Currie  RA, Campbell  DG, Deak M, Kular G, Downes CP, Alessi DR: Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. Biochem J. 2000 Oct 1;351(Pt 1):19-31.
11802782	Kimber WA, Trinkle-Mulcahy L, Cheung PC, Deak M, Marsden LJ, Kieloch A, Watt S, Javier RT, Gray A, Downes CP, Lucocq JM, Alessi DR: Evidence that the tandem-pleckstrin-homology-domain-containing protein TAPP1 interacts with Ptd(3,4)P2 and the multi-PDZ-domain-containing protein MUPP1 in vivo. Biochem J. 2002 Feb 1;361(Pt 3):525-36.

# Drug_Target_31_HGNC_ID:
HGNC:14335

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
5586

# Drug_Target_31_Locus:
10q26.13

# Drug_Target_31_Molecular_Weight:
45554

# Drug_Target_31_Name:
Pleckstrin homology domain-containing family A member 1

# Drug_Target_31_Number_of_Residues:
404

# Drug_Target_31_PDB_ID:
1EAZ

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00169	PH

# Drug_Target_31_Protein_Sequence:
>Pleckstrin homology domain-containing family A member 1
MPYVDRQNRICGFLDIEENENSGKFLRRYFILDTREDSFVWYMDNPQNLPSGSSRVGAIK
LTYISKVSDATKLRPKAEFCFVMNAGMRKYFLQANDQQDLVEWVNVLNKAIKITVPKQSD
SQPNSDNLSRHGECGKKQVSYRTDIVGGVPIITPTQKEEVNECGESIDRNNLKRSQSHLP
YFTPKPPQDSAVIKAGYCVKQGAVMKNWKRRYFQLDENTIGYFKSELEKEPLRVIPLKEV
HKVQECKQSDIMMRDNLFEIVTTSRTFYVQADSPEEMHSWIKAVSGAIVAQRGPGRSASS
EHPPGPSESKHAFRPTNAATATSHSTASRSNSLVSTFTMEKRGFYESLAKVKPGNFKVQT
VSPREPASKVTEQALLRPQSKNGPQEKDCDLVDLDDASLPVSDV

# Drug_Target_31_Reaction:
Not Available

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Binds specifically to phosphatidylinositol-3,4- diphosphate (PtdIns3,4P2), but not to other phosphoinositides. May recruit other proteins to the plasma membrane

# Drug_Target_31_SwissProt_ID:
Q9HB21

# Drug_Target_31_SwissProt_Name:
PKHA1_HUMAN

# Drug_Target_31_Synonyms:
TAPP-1
Tandem PH domain-containing protein 1

# Drug_Target_31_Theoretical_pI:
8.78

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Periplasm (Probable)

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
Not Available

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
Not Available

# Drug_Target_32_GenBank_ID_Gene:
M33815

# Drug_Target_32_GenBank_ID_Protein:
Not Available

# Drug_Target_32_GeneCard_ID:
Not Available

# Drug_Target_32_Gene_Name:
fbpA

# Drug_Target_32_Gene_Sequence:
>1017 bp
ATGAAGCTGCGTATTTCATCTCTCGGCCCCGTCGCCCTGCTTGCCTCCTCGATGATGCTG
GCCTTTGGCGCTCAGGCGGCCTCCGCCGACCAGGGCATCGTTATTTACAACGCCCAGCAT
GAAAATCTGGTGAAATCCTGGGTCGACGGGTTTACCAAAGACACCGGCATCAAAGTCACG
CTGCGCAACGGCGGCGACAGCGAGCTGGGCAATCAGCTGGTGCAGGAAGGCAGCGCCTCG
CCTGCCGACGTGTTCCTGACGGAAAACTCCCCGGCGATGGTGTTGGTGGATAACGCCAAG
CTGTTCGCCCCGCTGGACGCCGCCACGCTGGCCCAGGTGGAACCACAATATCGCCCAAGC
CACGGCCGCTGGATCGGCATCGCCGCCCGTTCTACCGTGTTTGTTTATAACCCGGCCAAA
CTGAGCGACGCGCAGTTGCCGAAGTCACTGCTGGATCTGGCCAAACCGGAATGGAAAGGC
CGTTGGGCCGCTTCGCCATCGGGCGCCGATTTCCAGGCGATCGTCAGCGCGCTGCTGGAG
CTGAAAGGCGAGAAAGCCACGCTGGCGTGGCTGAAAGCGATGAAAACCAACTTCACCGCC
TATAAGGGCAACAGCACGGTAATGAAAGCGGTCAATGCCGGCCAGGTCGACAGCGGTGTG
ATCTATCACTACTACCCGTTCGTGGATGGCGCAAAAACCGGCGAAAACAGCAACAACATC
AAGCTGTATTACTTCAAACATCAGGATCCTGGCGCGTTCGTCAGCATCTCCGGCGGCGGC
GTGCTGGCTTCCAGCAAGCATCAGCAGCAGGCGCAGGCGTTCATCAAGTGGATCACCGGC
AAACAGGGCCAGGAAATCCTGCGCACCAACAACGCCTTCGAATACGCCGTCGGCGTCGGC
GCGGCCTCCAACCCGAAACTGGTGCCGCTGAAAGATCTGGACGCACCGAAAGTAGACGCC
GCACAGCTGAACAGTAAAAAAGTTGTCGAACTGATGACCGAGGCCGGCCTGCTGTAA

# Drug_Target_32_General_Function:
Involved in transporter activity

# Drug_Target_32_General_References:
2404942	Angerer A, Gaisser S, Braun V: Nucleotide sequences of the sfuA, sfuB, and sfuC genes of Serratia marcescens suggest a periplasmic-binding-protein-dependent iron transport mechanism. J Bacteriol. 1990 Feb;172(2):572-8.

# Drug_Target_32_HGNC_ID:
Not Available

# Drug_Target_32_HPRD_ID:
Not Available

# Drug_Target_32_ID:
5587

# Drug_Target_32_Locus:
Not Available

# Drug_Target_32_Molecular_Weight:
36158

# Drug_Target_32_Name:
Iron(III)-binding periplasmic protein

# Drug_Target_32_Number_of_Residues:
338

# Drug_Target_32_PDB_ID:
1XVY

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF01547	SBP_bac_1

# Drug_Target_32_Protein_Sequence:
>Iron(III)-binding periplasmic protein
MKLRISSLGPVALLASSMMLAFGAQAASADQGIVIYNAQHENLVKSWVDGFTKDTGIKVT
LRNGGDSELGNQLVQEGSASPADVFLTENSPAMVLVDNAKLFAPLDAATLAQVEPQYRPS
HGRWIGIAARSTVFVYNPAKLSDAQLPKSLLDLAKPEWKGRWAASPSGADFQAIVSALLE
LKGEKATLAWLKAMKTNFTAYKGNSTVMKAVNAGQVDSGVIYHYYPFVDGAKTGENSNNI
KLYYFKHQDPGAFVSISGGGVLASSKHQQQAQAFIKWITGKQGQEILRTNNAFEYAVGVG
AASNPKLVPLKDLDAPKVDAAQLNSKKVVELMTEAGLL

# Drug_Target_32_Reaction:
Not Available

# Drug_Target_32_Signals:
1-26

# Drug_Target_32_Specific_Function:
Part of the ABC transporter complex fbpABC (TC 3.A.1.10.1) involved in Fe(3+) ions import. This protein specifically binds Fe(3+) and is involved in its transmembrane transport (By similarity)

# Drug_Target_32_SwissProt_ID:
P21408

# Drug_Target_32_SwissProt_Name:
FBPA_SERMA

# Drug_Target_32_Synonyms:
Iron(III)-binding periplasmic protein precursor

# Drug_Target_32_Theoretical_pI:
9.48

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Cytoplasmic

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
Not Available

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
Not Available

# Drug_Target_33_GenBank_ID_Gene:
AE000512

# Drug_Target_33_GenBank_ID_Protein:
Not Available

# Drug_Target_33_GeneCard_ID:
Not Available

# Drug_Target_33_Gene_Name:
TM_0570

# Drug_Target_33_Gene_Sequence:
>885 bp
TCATTCTGAAAGCAATACCTCCACAAAGGCCTCAGGATCGAAAGGCCTCAGGTCTTCTGC
CTTTTCTCCGACACCGATGAACTTTATGGGAATTCCCAGTTCCCGGGCAATGGCCAGAGT
TATTCCGCCTTTCGCGGTTCCGTCGAGCTTTGTGAGAATTATACCGGTGACATTCACTGC
TTCTTTGAATATTTTTGCCTGAACAAGTCCGTTTTGGCCGGTGGTGGCGTCTATCACGAG
GAGCGTTTCGTGCGGAGCGTCGGGGATCTTCTTCTTGACAACTCTGTGAACCTTCCGCAA
TTCCTCCATGAGATTCTTCTTCGTGTGAAGTCTTCCGGCGGTGTCTATTATGACCACATC
TTTGTTTCTGGCGAGAGCGTGAGCCACCGCGTCAAAGGCAACGGCGGCCGGATCTGCTCC
TTCCGAGTGGGATATCACCGTGGCACCGACACGTTCTCCCCATATCTTCAGCTGTTCTAT
GGCGGCTGCTCTGAAAGTATCCGCCGCAGCGAGCACCACACTCTTTCCTTCATCCACGAA
CATCTTTGCGAGCTTTCCACAGGAGGTGGTCTTTCCCGTTCCGTTGACACCAACAACCAT
GATCACGAACGGGGGTTCAGGAGGAACGTTCAGCTTCGTATCGAAGTTCAGAATTTCCAG
AATGATTTCCTTGAGAGACTCGAGAGCGTCTCCGTCCTTCTCTTCCAATCTCTCCAGAAT
GTATTCCGTTGTCTCGACTCCCACGTCCGCTTGAATGAGAAGTTCTTCCAGCTCCTCGCG
GGTTTCATCGTCCAGCTTTTTTCCTTTGAGGAGCTTCACCACTCGTCCAAAAAACGTTTC
TTTCGTCTTCTGGAGTCCCTTTTTCAAAAAATCGAAGAGTCCCAT

# Drug_Target_33_General_Function:
Involved in nucleotide binding

# Drug_Target_33_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_33_HGNC_ID:
Not Available

# Drug_Target_33_HPRD_ID:
Not Available

# Drug_Target_33_ID:
5588

# Drug_Target_33_Locus:
Not Available

# Drug_Target_33_Molecular_Weight:
32047

# Drug_Target_33_Name:
Cell division protein FtsY

# Drug_Target_33_Number_of_Residues:
294

# Drug_Target_33_PDB_ID:
1VMA

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF00448	SRP54

# Drug_Target_33_Protein_Sequence:
>Cell division protein FtsY
MGLFDFLKKGLQKTKETFFGRVVKLLKGKKLDDETREELEELLIQADVGVETTEYILERL
EEKDGDALESLKEIILEILNFDTKLNVPPEPPFVIMVVGVNGTGKTTSCGKLAKMFVDEG
KSVVLAAADTFRAAAIEQLKIWGERVGATVISHSEGADPAAVAFDAVAHALARNKDVVII
DTAGRLHTKKNLMEELRKVHRVVKKKIPDAPHETLLVIDATTGQNGLVQAKIFKEAVNVT
GIILTKLDGTAKGGITLAIARELGIPIKFIGVGEKAEDLRPFDPEAFVEVLLSE

# Drug_Target_33_Reaction:
Not Available

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
Q9WZ40

# Drug_Target_33_SwissProt_Name:
Q9WZ40_THEMA

# Drug_Target_33_Synonyms:
Not Available

# Drug_Target_33_Theoretical_pI:
5.32

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Not Available

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
Not Available

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
AE005674

# Drug_Target_34_GenBank_ID_Protein:
Not Available

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
nadD

# Drug_Target_34_Gene_Sequence:
>642 bp
ATGAAATCTTTACAGGCTCTGTTTGGCGGCACCTTTGATCCGGTGCACTATGGTCATCTA
AAACCCGTGGAAACGCTGGCGAATTTGATTGGTCTGACGCGGGTCACAATCATCCCTAAT
AATGTTCCTCCGCATCGTCCCCAGCCGGAAGCGAACAGCGTGCAGCGTAAACACATGCTT
GAACTGGCGATTGCCGACAAGCCATTATTTACTCTTGATGAACGCGAGCTAAAGCGCAAT
GCCCCCTCTTACACTGCGCAAACACTGAAAGAGTGGCGGCAGGAACAAGGACCGGACGTG
CCGCTGGCGTTTATTATTGGTCAGGATTCATTGCTGACCTTTCCGACCTGGTACGAATAC
GAAACGATACTCGACAATGCACATTTGATCGTCTGTCGGCGTCCAGGTTACCCACTTGAA
ATGGCGCAACCGCAATACCAGCAATGGCTGGAAGATCATTTGACACATAACCCGGAAGAT
CTTCACCTTCAGCCTGCCGGTAAAATTTATCTGGCTGAAACGCCGTGGTTTAACATCTCG
GCGACCATCATCCGCGAACGTTTGCAAAACGGTGAATCGTGTGAGGATTTATTGCCGGAA
CCGGTATTGACTTACATTAACCAACAAGGCTTGTATCGCTGA

# Drug_Target_34_General_Function:
Involved in catalytic activity

# Drug_Target_34_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
4469

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
24528

# Drug_Target_34_Name:
Nicotinate-nucleotide adenylyltransferase

# Drug_Target_34_Number_of_Residues:
213

# Drug_Target_34_PDB_ID:
1K4K

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF01467	CTP_transf_2

# Drug_Target_34_Protein_Sequence:
>Nicotinate-nucleotide adenylyltransferase
MKSLQALFGGTFDPVHYGHLKPVETLANLIGLTRVTIIPNNVPPHRPQPEANSVQRKHML
ELAIADKPLFTLDERELKRNAPSYTAQTLKEWRQEQGPDVPLAFIIGQDSLLTFPTWYEY
ETILDNAHLIVCRRPGYPLEMAQPQYQQWLEDHLTHNPEDLHLQPAGKIYLAETPWFNIS
ATIIRERLQNGESCEDLLPEPVLTYINQQGLYR

# Drug_Target_34_Reaction:
Not Available

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD) (By similarity)

# Drug_Target_34_SwissProt_ID:
P0A753

# Drug_Target_34_SwissProt_Name:
NADD_SHIFL

# Drug_Target_34_Synonyms:
Deamido- NAD(+) pyrophosphorylase
Deamido-NAD(+) diphosphorylase
EC 2.7.7.18
NaMN adenylyltransferase
Nicotinate mononucleotide adenylyltransferase

# Drug_Target_34_Theoretical_pI:
5.54

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Cytoplasmic

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
Not Available

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
Not Available

# Drug_Target_35_GenBank_ID_Gene:
AE000512

# Drug_Target_35_GenBank_ID_Protein:
Not Available

# Drug_Target_35_GeneCard_ID:
Not Available

# Drug_Target_35_Gene_Name:
nusB

# Drug_Target_35_Gene_Sequence:
>429 bp
ATGAAAACACCGAGGCGAAGAATGAGGCTTGCTGTCTTCAAAGCCCTGTTTCAGCATGAA
TTCAGAAGAGACGAAGATCTTGAACAAATTCTCGAGGAAATTCTGGACGAAACCTACGAT
AAAAAGGCAAAGGAAGACGCCCGGCGCTACATAAGAGGTATAAAAGAGAACCTTTCCATG
ATAGACGATCTCATTTCCCGATACCTAGAAAAGTGGTCTCTGAACCGATTATCCGTTGTG
GACAGAAACGTTCTGAGACTCGCCACTTATGAACTTCTCTTCGAAAAGGACATCCCCATA
GAAGTGACCATCGATGAAGCCATAGAAATAGCCAAGAGATACGGCACGGAAAACAGTGGA
AAATTCGTCAACGGAATACTGGACAGAATCGCCAAAGAACACGCTCCAAAAGAAAAATTC
GAACTTTGA

# Drug_Target_35_General_Function:
Involved in transcription termination factor activity

# Drug_Target_35_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_35_HGNC_ID:
Not Available

# Drug_Target_35_HPRD_ID:
Not Available

# Drug_Target_35_ID:
5590

# Drug_Target_35_Locus:
Not Available

# Drug_Target_35_Molecular_Weight:
16974

# Drug_Target_35_Name:
N utilization substance protein B homolog

# Drug_Target_35_Number_of_Residues:
142

# Drug_Target_35_PDB_ID:
1TZX

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF01029	NusB

# Drug_Target_35_Protein_Sequence:
>N utilization substance protein B homolog
MKTPRRRMRLAVFKALFQHEFRRDEDLEQILEEILDETYDKKAKEDARRYIRGIKENLSM
IDDLISRYLEKWSLNRLSVVDRNVLRLATYELLFEKDIPIEVTIDEAIEIAKRYGTENSG
KFVNGILDRIAKEHAPKEKFEL

# Drug_Target_35_Reaction:
Not Available

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Involved in the transcription termination process (By similarity)

# Drug_Target_35_SwissProt_ID:
Q9X286

# Drug_Target_35_SwissProt_Name:
NUSB_THEMA

# Drug_Target_35_Synonyms:
Protein nusB

# Drug_Target_35_Theoretical_pI:
6.56

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Secreted protein

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
C8G

# Drug_Target_36_GenBank_ID_Gene:
M17263

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
C8G

# Drug_Target_36_Gene_Sequence:
>609 bp
ATGCTGCCCCCTGGGACTGCGACCCTCTTGACTCTGCTCCTGGCAGCTGGCTCGCTGGGC
CAGAAGCCTCAGAGGCCACGCCGGCCCGCATCCCCCATCAGCACCATCCAGCCCAAGGCC
AATTTTGATGCTCAGCAGTTTGCAGGGACCTGGCTCCTTGTGGCTGTGGGCTCCGCTTGC
CGTTTCCTGCAGGAGCAGGGCCACCGGGCCGAGGCCACCACACTGCATGTGGCTCCCCAG
GGCACAGCCATGGCTGTCAGTACCTTCCGAAAGCTGGATGGGATCTGCTGGCAGGTGCGC
CAGCTCTATGGAGACACAGGGGTCCTCGGCCGCTTCCTGCTTCAAGCCCGAGGCGCCCGA
GGGGCTGTGCACGTGGTTGTCGCTGAGACCGACTACCAGAGTTTCGCTGTCCTGTACCTG
GAGCGGGCGGGGCAGCTGTCAGTGAAGCTCTACGCCCGCTCGCTCCCTGTGAGCGACTCG
GTCCTGAGTGGGTTTGAGCAGCGGGTCCAGGAGGCCCACCTGACTGAGGACCAGATCTTC
TACTTCCCCAAGTACGGCTTCTGCGAGGCTGCAGACCAGTTCCACGTCCTGGACGAAGTG
AGGAGGTGA

# Drug_Target_36_General_Function:
Involved in transporter activity

# Drug_Target_36_General_References:
11058761	Schreck SF, Parker C, Plumb ME, Sodetz JM: Human complement protein C8 gamma. Biochim Biophys Acta. 2000 Oct 18;1482(1-2):199-208.
12033936	Ortlund E, Parker CL, Schreck SF, Ginell S, Minor W, Sodetz JM, Lebioda L: Crystal structure of human complement protein C8gamma at 1.2 A resolution reveals a lipocalin fold and a distinct ligand binding site. Biochemistry. 2002 Jun 4;41(22):7030-7.
1707134	Haefliger JA, Peitsch MC, Jenne DE, Tschopp J: Structural and functional characterization of complement C8 gamma, a member of the lipocalin protein family. Mol Immunol. 1991 Jan-Feb;28(1-2):123-31.
2446620	Hunt LT, Elzanowski A, Barker WC: The homology of complement factor C8 gamma chain and alpha-1-microglobulin. Biochem Biophys Res Commun. 1987 Nov 30;149(1):282-8.
2447883	Haefliger JA, Jenne D, Stanley KK, Tschopp J: Structural homology of human complement component C8 gamma and plasma protein HC: identity of the cysteine bond pattern. Biochem Biophys Res Commun. 1987 Dec 16;149(2):750-4.
3676249	Ng SC, Rao AG, Howard OM, Sodetz JM: The eighth component of human complement: evidence that it is an oligomeric serum protein assembled from products of three different genes. Biochemistry. 1987 Aug 25;26(17):5229-33.
8172891	Kaufman KM, Sodetz JM: Genomic structure of the human complement protein C8 gamma: homology to the lipocalin gene family. Biochemistry. 1994 May 3;33(17):5162-6.

# Drug_Target_36_HGNC_ID:
HGNC:1354

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
5591

# Drug_Target_36_Locus:
9q34.3

# Drug_Target_36_Molecular_Weight:
22278

# Drug_Target_36_Name:
Complement component C8 gamma chain

# Drug_Target_36_Number_of_Residues:
202

# Drug_Target_36_PDB_ID:
1IW2

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00061	Lipocalin

# Drug_Target_36_Protein_Sequence:
>Complement component C8 gamma chain
MLPPGTATLLTLLLAAGSLGQKPQRPRRPASPISTIQPKANFDAQQFAGTWLLVAVGSAC
RFLQEQGHRAEATTLHVAPQGTAMAVSTFRKLDGICWQVRQLYGDTGVLGRFLLQARDAR
GAVHVVVAETDYQSFAVLYLERAGQLSVKLYARSLPVSDSVLSGFEQRVQEAHLTEDQIF
YFPKYGFCEAADQFHVLDEVRR

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
1-20

# Drug_Target_36_Specific_Function:
C8 is a constituent of the membrane attack complex. C8 binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds C9 and acts as a catalyst in the polymerization of C9. The gamma subunit seems to be able to bind retinol

# Drug_Target_36_SwissProt_ID:
P07360

# Drug_Target_36_SwissProt_Name:
CO8G_HUMAN

# Drug_Target_36_Synonyms:
Complement component C8 gamma chain precursor

# Drug_Target_36_Theoretical_pI:
8.48

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
Not Available

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
AL583923

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
nrdF

# Drug_Target_37_Gene_Sequence:
>978 bp
TTAGAAGTCCCAGTCCTCGTCCTCAGTGACGACGGCTTTCCCGATCACATACGACGACCC
CGAGCCGGAGAAAAAGTCATGATTCTCATCGGCGTTGGGAGACAAGGCCGACAGGATCGC
CGGGTTCACGTCGGTCTCGTCCCGCGGGAACAGCGCCTCGTAGCCAAGGTTCATCAACGC
CTTATTTGCGTTGTAGCGCAAGAACTTCTTGACGTCTTCGGTCAACCCGACTCTGTCGTA
GAGATCTTGGGTGTATTCCACCTCGTTGTCGTAGAGCTCAAAGAGCAATTCGTAGGTGTA
TTCCTTGAGTTCTGCCCGCCTGGCGTCGTCGACCAACACCAAGCCACGCTGAAATTTGTA
GCCGATATAGTAACCGTGGACTGCTTCGTCGCGGATGATCAGCCGAATCATATCAGCGGT
GTTGGTCAGCTTGGCCCGACTTGACCAGTACATCGGCAGGTAGAACCCAGAGTAAAACAG
GAAGCTTTCGAGCAAGGTGGAGGCCACCTTGCGCTTGAGCGGTTCGTCGCCTCGATAGTA
CTCCATCACAATCTTAGCTTTGCGCTGCAGGTTGTTGTTCTCCTCCGACCAGCGAAACGC
TTCGTCGATCTCCGCTGTCGAGCACAGCGTGGAAAAGATCGAACTGTAGCTCTTGGCGTG
CACCGACTCCATGAATGCAATGTTGGTGTAGACGGCTTCCTCATGCGGCGTTAGCGCATC
AGGAATAAGGCTGACCGCTCCGACCGTGCCTTGGATCGTGTCGAGCAGCGTCAAACCGGT
GAACACCCGCATTGTCAGCTGCTTTTCACTAGCAGTCAGCGTGCCCCACGACGGGAGATC
GTTGGACACCGGCACCTTCTCGGGCAGCCAGAAGTTTCCAGTCAGCCGGTCCCAGACCTC
GGCGTCCTTGTCGTCTTGCAGCCAGTTCCAATTAATCGCCGAAACGCGGTCAATTAGCTT
CATCTTCCCAGTCAACAA

# Drug_Target_37_General_Function:
Involved in oxidoreductase activity

# Drug_Target_37_General_References:
11234002	Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG: Massive gene decay in the leprosy bacillus. Nature. 2001 Feb 22;409(6823):1007-11.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
5592

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
37316

# Drug_Target_37_Name:
Ribonucleoside-diphosphate reductase subunit beta

# Drug_Target_37_Number_of_Residues:
325

# Drug_Target_37_PDB_ID:
1UZR

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00268	Ribonuc_red_sm

# Drug_Target_37_Protein_Sequence:
>Ribonucleoside-diphosphate reductase subunit beta
MLTGKMKLIDRVSAINWNWLQDDKDAEVWDRLTGNFWLPEKVPVSNDLPSWGTLTASEKQ
LTMRVFTGLTLLDTIQGTVGAVSLIPDALTPHEEAVYTNIAFMESVHAKSYSSIFSTLCS
TAEIDEAFRWSEENNNLQRKAKIVMEYYRGDEPLKRKVASTLLESFLFYSGFYLPMYWSS
RAKLTNTADMIRLIIRDEAVHGYYIGYKFQRGLVLVDDARRAELKEYTYELLFELYDNEV
EYTQDLYDRVGLTEDVKKFLRYNANKALMNLGYEALFPRDETDVNPAILSALSPNADENH
DFFSGSGSSYVIGKAVVTEDEDWDF

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides (By similarity)

# Drug_Target_37_SwissProt_ID:
Q9CBQ2

# Drug_Target_37_SwissProt_Name:
RIR2_MYCLE

# Drug_Target_37_Synonyms:
EC 1.17.4.1
Ribonucleotide reductase small subunit

# Drug_Target_37_Theoretical_pI:
4.43

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
U87280

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
glnA1

# Drug_Target_38_Gene_Sequence:
>1437 bp
GTGACGGAAAAGACGCCCGACGACGTCTTCAAACTTGCCAAGGACGAGAAGGTCGAATAT
GTCGACGTCCGGTTCTGTGACCTGCCTGGCATCATGCAGCACTTCACGATTCCGGCTTCG
GCCTTTGACAAGAGCGTGTTTGACGACGGCTTGGCCTTTGACGGCTCGTCGATTCGCGGG
TTCCAGTCGATCCACGAATCCGACATGTTGCTTCTTCCCGATCCCGAGACGGCGCGCATC
GACCCGTTCCGCGCGGCCAAGACGCTGAATATCAACTTCTTTGTGCACGACCCGTTCACC
CTGGAGCCGTACTCCCGCGACCCGCGCAACATCGCCCGCAAGGCCGAGAACTACCTGATC
AGCACTGGCATCGCCGACACCGCATACTTCGGCGCCGAGGCCGAGTTCTACATTTTCGAT
TCGGTGAGCTTCGACTCGCGCGCCAACGGCTCCTTCTACGAGGTGGACGCCATCTCGGGG
TGGTGGAACACCGGCGCGGCGACCGAGGCCGACGGCAGTCCCAACCGGGGCTACAAGGTC
CGCCACAAGGGCGGGTATTTCCCAGTGGCCCCCAACGACCAATACGTCGACCTGCGCGAC
AAGATGCTGACCAACCTGATCAACTCCGGCTTCATCCTGGAGAAGGGCCACCACGAGGTG
GGCAGCGGCGGACAGGCCGAGATCAACTACCAGTTCAATTCGCTGCTGCACGCCGCCGAC
GACATGCAGTTGTACAAGTACATCATCAAGAACACCGCCTGGCAGAACGGCAAAACGGTC
ACGTTCATGCCCAAGCCGCTGTTCGGCGACAACGGGTCCGGCATGCACTGTCATCAGTCG
CTGTGGAAGGACGGGGCCCCGCTGATGTACGACGAGACGGGTTATGCCGGTCTGTCGGAC
ACGGCCCGTCATTACATCGGCGGCCTGTTACACCACGCGCCGTCGCTGCTGGCCTTCACC
AACCCGACGGTGAACTCCTACAAGCGGCTGGTTCCCGGTTACGAGGCCCCGATCAACCTG
GTCTATAGCCAGCGCAACCGGTCGGCATGCGTGCGCATCCCGATCACCGGCAGCAACCCG
AAGGCCAAGCGGCTGGAGTTCCGAAGCCCCGACTCGTCGGGCAACCCGTATCTGGCGTTC
TCGGCCATGCTGATGGCAGGCCTGGACGGTATCAAGAACAAGATCGAGCCGCAGGCGCCC
GTCGACAAGGATCTCTACGAGCTGCCGCCGGAAGAGGCCGCGAGTATCCCGCAGACTCCG
ACCCAGCTGTCAGATGTGATCGACCGTCTCGAGGCCGACCACGAATACCTCACCGAAGGA
GGGGTGTTCACAAACGACCTGATCGAGACGTGGATCAGTTTCAAGCGCGAAAACGAGATC
GAGCCGGTCAACATCCGGCCGCATCCCTACGAATTCGCGCTGTACTACGACGTTTAA

# Drug_Target_38_General_Function:
Involved in glutamate-ammonia ligase activity

# Drug_Target_38_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9278431	Harth G, Horwitz MA: Expression and efficient export of enzymatically active Mycobacterium tuberculosis glutamine synthetase in Mycobacterium smegmatis and evidence that the information for export is contained within the protein. J Biol Chem. 1997 Sep 5;272(36):22728-35.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
4375

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
53570

# Drug_Target_38_Name:
Glutamine synthetase 1

# Drug_Target_38_Number_of_Residues:
478

# Drug_Target_38_PDB_ID:
1HTQ

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00120	Gln-synt_C
PF03951	Gln-synt_N

# Drug_Target_38_Protein_Sequence:
>Glutamine synthetase 1
MTEKTPDDVFKLAKDEKVEYVDVRFCDLPGIMQHFTIPASAFDKSVFDDGLAFDGSSIRG
FQSIHESDMLLLPDPETARIDPFRAAKTLNINFFVHDPFTLEPYSRDPRNIARKAENYLI
STGIADTAYFGAEAEFYIFDSVSFDSRANGSFYEVDAISGWWNTGAATEADGSPNRGYKV
RHKGGYFPVAPNDQYVDLRDKMLTNLINSGFILEKGHHEVGSGGQAEINYQFNSLLHAAD
DMQLYKYIIKNTAWQNGKTVTFMPKPLFGDNGSGMHCHQSLWKDGAPLMYDETGYAGLSD
TARHYIGGLLHHAPSLLAFTNPTVNSYKRLVPGYEAPINLVYSQRNRSACVRIPITGSNP
KAKRLEFRSPDSSGNPYLAFSAMLMAGLDGIKNKIEPQAPVDKDLYELPPEEAASIPQTP
TQLSDVIDRLEADHEYLTEGGVFTNDLIETWISFKRENEIEPVNIRPHPYEFALYYDV

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
ATP + L-glutamate + NH(3) = ADP + phosphate + L-glutamine

# Drug_Target_38_SwissProt_ID:
P0A590

# Drug_Target_38_SwissProt_Name:
GLNA1_MYCTU

# Drug_Target_38_Synonyms:
EC 6.3.1.2
Glutamate--ammonia ligase 1

# Drug_Target_38_Theoretical_pI:
4.84

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Not Available

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
Not Available

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
Not Available

# Drug_Target_39_GenBank_ID_Gene:
U85944

# Drug_Target_39_GenBank_ID_Protein:
Not Available

# Drug_Target_39_GeneCard_ID:
Not Available

# Drug_Target_39_Gene_Name:
gltA

# Drug_Target_39_Gene_Sequence:
>1140 bp
ATGACCGAACCAACAATTCATAAGGGCCTTGCCGGCGTCACGGCGGATGTCACCGCCATT
TCGAAGGTCAATTCTGATACCAACTCGCTGCTGTACCGTGGATACCCCGTTCAGGAACTG
GCTGCTAAGTGCAGCTTTGAACAGGTGGCCTACTTGCTGTGGAACAGCGAACTGCCCAAC
GATTCCGAGCTGAAAGCTTTCGTAAATTTCGAACGCTCCCACCGGAAACTGGATGAGAAC
GTCAAAGGGGCAATAGACCTCCTCTCCACTGCCTGTCACCCTATGGACGTTGCGCGGACC
GCCGTCTCAGTTCTGGGAGCCAACCACGCCAGGGCGCAGGATTCCTCCCCGGAAGCAAAT
CTAGAAAAGGCGATGTCGCTGCTGGCAACCTTCCCGTCCGTCGTCGCCTACGACCAAAGG
CGACGACGCGGTGAGGAACTTATCGAACCACGAGAGGATCTCGATTACTCCGCGAACTTC
CTGTGGATGACTTTTGGCGAAGAGGCAGCGCCGGAGGTTGTGGAAGCCTTCAACGTCTCC
ATGATTCTCTACGCGGAGCATTCCTTCAACGCCTCGACGTTCACGGCCCGGGTCATCACC
TCCACCCTGGCGGATCTGCATTCGGCGGTGACCGGAGCCATAGGTGCCCTCAAGGGGCCG
CTGCACGGGGGTGCCAACGAGGCCGTGATGCATACCTTTGAGGAGATTGGGATCCGCAAG
GACGAATCCCTCGATGAGGCAGCCACGCGTTCGAAAGCTTGGATGGTCGATGCCCTTGCG
CAGAAGAAAAAGGTCATGGGTTTTGGGCACCGCGTGTACAAGAATGGTGACTCCCGGGTC
CCCACCATGAAGAGCGCTCTGGACGCCATGATCAAACATTATGATCGTCCGGAAATGCTC
GGCCTGTACAACGGACTCGAAGCCGCTATGGAAGAGGCCAAGCAGATCAAGCCGAATCTC
GACTACCCGGCAGGACCCACCTATAACCTGATGGGCTTTGACACGGAGATGTTCACTCCG
CTCTTCATCGCCGCGCGCATCACCGGTTGGACCGCCCATATCATGGAACAAGTGGCGGAC
AACGCTCTGATCCGCCCACTCAGCGAATATAACGGTCCTGAGCAGCGCCAGGTCCCCTGA

# Drug_Target_39_General_Function:
Involved in transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer

# Drug_Target_39_General_References:
9310359	Gerike U, Danson MJ, Russell NJ, Hough DW: Sequencing and expression of the gene encoding a cold-active citrate synthase from an Antarctic bacterium, strain DS2-3R. Eur J Biochem. 1997 Aug 15;248(1):49-57.
9551556	Russell RJ, Gerike U, Danson MJ, Hough DW, Taylor GL: Structural adaptations of the cold-active citrate synthase from an Antarctic bacterium. Structure. 1998 Mar 15;6(3):351-61.

# Drug_Target_39_HGNC_ID:
Not Available

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
4580

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
41833

# Drug_Target_39_Name:
Citrate synthase

# Drug_Target_39_Number_of_Residues:
379

# Drug_Target_39_PDB_ID:
1A59

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00285	Citrate_synt

# Drug_Target_39_Protein_Sequence:
>Citrate synthase
MTEPTIHKGLAGVTADVTAISKVNSDTNSLLYRGYPVQELAAKCSFEQVAYLLWNSELPN
DSELKAFVNFERSHRKLDENVKGAIDLLSTACHPMDVARTAVSVLGANHARAQDSSPEAN
LEKAMSLLATFPSVVAYDQRRRRGEELIEPREDLDYSANFLWMTFGEEAAPEVVEAFNVS
MILYAEHSFNASTFTARVITSTLADLHSAVTGAIGALKGPLHGGANEAVMHTFEEIGIRK
DESLDEAATRSKAWMVDALAQKKKVMGFGHRVYKNGDSRVPTMKSALDAMIKHYDRPEML
GLYNGLEAAMEEAKQIKPNLDYPAGPTYNLMGFDTEMFTPLFIAARITGWTAHIMEQVAD
NALIRPLSEYNGPEQRQVP

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
Acetyl-CoA + H(2)O + oxaloacetate = citrate + CoA

# Drug_Target_39_SwissProt_ID:
O34002

# Drug_Target_39_SwissProt_Name:
CISY_ABDS2

# Drug_Target_39_Synonyms:
EC 2.3.3.1

# Drug_Target_39_Theoretical_pI:
5.17

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X04065

# Drug_Target_3_GenBank_ID_Protein:
41513

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
fumC

# Drug_Target_3_Gene_Sequence:
>1404 bp
ATGAATACAGTACGCAGCGAAAAAGATTCGATGGGGGCGATTGATGTCCCGGCAGATAAG
CTGTGGGGCGCACAAACTCAACGCTCGCTGGAGCATTTCCGCATTTCGACGGAGAAAATG
CCCACCTCACTGATTCATGCGCTGGCGCTAACCAAGCGTGCAGCGGCAAAAGTTAATGAA
GATTTAGGCTTGTTGTCTGAAGAGAAAGCGAGCGCCATTCGTCAGGCGGCGGATGAAGTA
CTGGCAGGACAGCATGACGACGAATTCCCGCTGGCTATCTGGCAGACCGGCTCCGGCACG
CAAAGTAACATGAACATGAACGAAGTGCTGGCTAACCGGGCCAGTGAATTACTCGGCGGT
GTGCGCGGGATGGAACGTAAAGTTCACCCTAACGACGACGTGAACAAAAGCCAAAGTTCC
AACGATGTCTTTCCGACGGCGATGCACGTTGCGGCGCTGCTGGCGCTGCGCAAGCAACTC
ATTCCTCAGCTTAAAACCCTGACACAGACACTGAATGAGAAATCCCGTGCTTTTGCCGAT
ATCGTCAAAATTGGTCGTACTCACTTGCAGGATGCCACGCCGTTAACGCTGGGGCAGGAG
ATTTCCGGCTGGGTAGCGATGCTCGAGCATAATCTCAAACATATCGAATACAGCCTGCCT
CACGTAGCGGAACTGGCTCTTGGCGGTACAGCGGTGGGTACTGGACTAAATACCCATCCG
GAGTATGCGCGTCGCGTAGCAGATGAACTGGCAGTCATTACCTGTGCACCGTTTGTTACC
GCGCCGAACAAATTTGAAGCGCTGGCGACCTGTGATGCCCTGGTTCAGGCGCACGGCGCG
TTGAAAGGGTTGGCTGCGTCACTGATGAAAATCGCCAATGATGTCCGCTGGCTGGCCTCT
GGCCCGCGCTGCGGAATTGGTGAAATCTCAATCCCGGAAAATGAGCCGGGCAGCTCAATC
ATGCCGGGGAAAGTGAACCCAACACAGTGTGAGGCATTAACCATGCTCTGCTGTCAGGTG
ATGGGGAACGACGTGGCGATCAACATGGGGGGCGCTTCCGGTAACTTTGAACTGAACGTC
TTCCGTCCAATGGTGATCCACAATTTCCTGCAATCGGTGCGCTTGCTGGCAGATGGCATG
GAAAGTTTTAACAAACACTGCGCAGTGGGTATTGAACCGAATCGTGAGCGAATCAATCAA
TTACTCAATGAATCGCTGATGCTGGTGACTGCGCTTAACACCCACATTGGTTATGACAAA
GCCGCCGAGATCGCCAAAAAAGCGCATAAAGAAGGGCTGACCTTAAAAGCTGCGGCCCTT
GCGCTGGGGTATCTTAGCGAAGCCGAGTTTGACAGCTGGGTACGGCCAGAACAGATGGTC
GGCAGTATGAAAGCCGGGCGTTAA

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
12021453	Estevez M, Skarda J, Spencer J, Banaszak L, Weaver TM: X-ray crystallographic and kinetic correlation of a clinically observed human fumarase mutation. Protein Sci. 2002 Jun;11(6):1552-7.
1917897	Ueda Y, Yumoto N, Tokushige M, Fukui K, Ohya-Nishiguchi H: Purification and characterization of two types of fumarase from Escherichia coli. J Biochem (Tokyo). 1991 May;109(5):728-33.
3005475	Guest JR, Miles JS, Roberts RE, Woods SA: The fumarase genes of Escherichia coli: location of the fumB gene and discovery of a new gene (fumC). J Gen Microbiol. 1985 Nov;131(11):2971-84.
3282546	Woods SA, Schwartzbach SD, Guest JR: Two biochemically distinct classes of fumarase in Escherichia coli. Biochim Biophys Acta. 1988 Apr 28;954(1):14-26.
3541901	Woods SA, Miles JS, Roberts RE, Guest JR: Structural and functional relationships between fumarase and aspartase. Nucleotide sequences of the fumarase (fumC) and aspartase (aspA) genes of Escherichia coli K12. Biochem J. 1986 Jul 15;237(2):547-57.
6328431	Miles JS, Guest JR: Complete nucleotide sequence of the fumarase gene fumA, of Escherichia coli. Nucleic Acids Res. 1984 Apr 25;12(8):3631-42.
8496960	Weaver TM, Levitt DG, Banaszak LJ: Purification and crystallization of fumarase C from Escherichia coli. J Mol Biol. 1993 May 5;231(1):141-4.
8909293	Weaver T, Banaszak L: Crystallographic studies of the catalytic and a second site in fumarase C from Escherichia coli. Biochemistry. 1996 Nov 5;35(44):13955-65.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9098893	Weaver T, Lees M, Banaszak L: Mutations of fumarase that distinguish between the active site and a nearby dicarboxylic acid binding site. Protein Sci. 1997 Apr;6(4):834-42.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3486

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
50490

# Drug_Target_3_Name:
Fumarate hydratase class II

# Drug_Target_3_Number_of_Residues:
467

# Drug_Target_3_PDB_ID:
1FUO

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00206	Lyase_1

# Drug_Target_3_Protein_Sequence:
>Fumarate hydratase class II
MNTVRSEKDSMGAIDVPADKLWGAQTQRSLEHFRISTEKMPTSLIHALALTKRAAAKVNE
DLGLLSEEKASAIRQAADEVLAGQHDDEFPLAIWQTGSGTQSNMNMNEVLANRASELLGG
VRGMERKVHPNDDVNKSQSSNDVFPTAMHVAALLALRKQLIPQLKTLTQTLNEKSRAFAD
IVKIGRTHLQDATPLTLGQEISGWVAMLEHNLKHIEYSLPHVAELALGGTAVGTGLNTHP
EYARRVADELAVITCAPFVTAPNKFEALATCDALVQAHGALKGLAASLMKIANDVRWLAS
GPRCGIGEISIPENEPGSSIMPGKVNPTQCEALTMLCCQVMGNDVAINMGGASGNFELNV
FRPMVIHNFLQSVRLLADGMESFNKHCAVGIEPNRERINQLLNESLMLVTALNTHIGYDK
AAEIAKKAHKEGLTLKAAALALGYLSEAEFDSWVRPEQMVGSMKAGR

# Drug_Target_3_Reaction:
(S)-malate = fumarate + H2O

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
(S)-malate = fumarate + H(2)O

# Drug_Target_3_SwissProt_ID:
P05042

# Drug_Target_3_SwissProt_Name:
FUMC_ECOLI

# Drug_Target_3_Synonyms:
EC 4.2.1.2
Fumarase C

# Drug_Target_3_Theoretical_pI:
6.57

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
Not Available

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
Not Available

# Drug_Target_40_GenBank_ID_Protein:
Not Available

# Drug_Target_40_GeneCard_ID:
Not Available

# Drug_Target_40_Gene_Name:
Not Available

# Drug_Target_40_Gene_Sequence:
Not Available

# Drug_Target_40_General_Function:
Involved in catalytic activity

# Drug_Target_40_General_References:
Not Available

# Drug_Target_40_HGNC_ID:
Not Available

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
5593

# Drug_Target_40_Locus:
Not Available

# Drug_Target_40_Molecular_Weight:
43210

# Drug_Target_40_Name:
Transferase

# Drug_Target_40_Number_of_Residues:
408

# Drug_Target_40_PDB_ID:
1J3N

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF00109	ketoacyl-synt
PF02801	Ketoacyl-synt_C

# Drug_Target_40_Protein_Sequence:
>Transferase
MRRVVVTGLGALTPIGVGQEAFHKAQLAGKSGVRPITRFDASALPVRIAAEVDVDPGAYL
DRKELRRLDRFVQYALIAAQLALEDAGLKPEDLDPERVGTLVGTGIGGMETWEAQSRVFL
ERGPNRISPFFIPMMIANMASAHIAMRYGFTGPSSTVVTACATGADALGSALRMIQLGEA
DLVLAGGTEAAITPMAIGAFAVMRALSTRNEEPEKASRPFTLSRDGFVMGEGAGVLVLEA
YEHAKKRGARIYAELVGFGRSADAHHITEPHPEGKGAALAMARALKDAGIAPEQVGYINA
HGTSTPVGDRAEVLAIKRVFGDHAKRLMVSSTKSMIGHLLGAAGAVEAIATVQALYHGVI
PPTINLEDPDPELDLDFVPEPREAKVDYALSNSFAFGGHNAVLAFKRV

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
Not Available

# Drug_Target_40_SwissProt_ID:
Q7SIC5

# Drug_Target_40_SwissProt_Name:
Q7SIC5_THETH

# Drug_Target_40_Synonyms:
Not Available

# Drug_Target_40_Theoretical_pI:
6.60

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
AB034727

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
Tb11.02.2310

# Drug_Target_41_Gene_Sequence:
>831 bp
ATGGCTCTCACTCAATCCCTAAAACTCTCGAATGGAGTGATGATGCCAGTTCTTGGTTTC
GGTATGTGGAAGTTACAGGATGGCAATGAAGCCGAGACGGCGACGATGTGGGCCATAAAA
AGCGGCTATCGTCACATCGATACTGCAGCCATCTATAAAAATGAAGAAAGCGCTGGCAGA
GCCATTGCCTCATGTGGTGTACCGCGGGAAGAGCTATTCGTCACGACGAAGCTTTGGAAC
TCCGACCAGGGATATGAGAGCACGCTGAGCGCATTTGAGAAGAGCATTAAGAAGCTCGGC
CTGGAATATGTTGACCTATACCTCATCCACTGGCCGGGGAAGGACAAGTTTATCGACACA
TGGAAGGCGTTTGAGAAACTGTACGCCGATAAGAAGGTGCGCGCCATTGGCGTTTCCAAC
TTTCACGAGCACCACATCGAGGAACTGCTAAAGCACTGTAAGGTTGCACCGATGGTTAAC
CAGATCGAGCTCCATCCGCTGCTCAATCAGAAGGCACTCTGCGAGTACTGCAAGTCGAAG
AACATCGCCGTCACTGCCTGGTCGCCGCTTGGTCAAGGACATCTCGTCGAAGACGCCCGT
CTGAAAGCTATCGGAGGAAAGTATGGTAAGACAGCTGCGCAGGTGATGCTCCGCTGGGAA
ATACAAGCAGGGGTCATCACGATTCCCAAATCGGGCAACGAGGCCCGCATCAAGGAAAAT
GGCAATATATTTGACTTCGAACTAACTGCGGAGGACATTCAAGTCATCGATGGTATGAAT
GCCGGCCACCGCTACGGCCCCGATCCGGAGGTCTTCATGAACGACTTTTGA

# Drug_Target_41_General_Function:
Involved in oxidoreductase activity

# Drug_Target_41_General_References:
11067881	Kubata BK, Duszenko M, Kabututu Z, Rawer M, Szallies A, Fujimori K, Inui T, Nozaki T, Yamashita K, Horii T, Urade Y, Hayaishi O: Identification of a novel prostaglandin f(2alpha) synthase in Trypanosoma brucei. J Exp Med. 2000 Nov 6;192(9):1327-38.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
5328

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
30993

# Drug_Target_41_Name:
Prostaglandin F synthase

# Drug_Target_41_Number_of_Residues:
276

# Drug_Target_41_PDB_ID:
1VBJ

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_41_Protein_Sequence:
>Prostaglandin F synthase
MALTQSLKLSNGVMMPVLGFGMWKLQDGNEAETATMWAIKSGYRHIDTAAIYKNEESAGR
AIASCGVPREELFVTTKLWNSDQGYESTLSAFEKSIKKLGLEYVDLYLIHWPGKDKFIDT
WKAFEKLYADKKVRAIGVSNFHEHHIEELLKHCKVAPMVNQIELHPLLNQKALCEYCKSK
NIAVTAWSPLGQGHLVEDARLKAIGGKYGKTAAQVMLRWEIQAGVITIPKSGNEARIKEN
GNIFDFELTAEDIQVIDGMNAGHRYGPDPEVFMNDF

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Not Available

# Drug_Target_41_SwissProt_ID:
Q9GV41

# Drug_Target_41_SwissProt_Name:
Q9GV41_9TRYP

# Drug_Target_41_Synonyms:
EC 1.1.-.-

# Drug_Target_41_Theoretical_pI:
6.79

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Cytoplasm. Note=Assembles at the inner surface of the cytoplasmic membrane (By similarity)

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
Not Available

# Drug_Target_42_GenBank_ID_Gene:
BX842578

# Drug_Target_42_GenBank_ID_Protein:
2104328

# Drug_Target_42_GeneCard_ID:
Not Available

# Drug_Target_42_Gene_Name:
ftsZ

# Drug_Target_42_Gene_Sequence:
>1140 bp
TCAGCGGCGCATGAAGGGCGGCACGTCGACATCGTCGTCATCACCGCCGATGCTCAGGGT
TGCGCCGTTGGTGTGCAACGGCACGCTGACGGCGTCGACCGGCTCGAACAAGGTCGAGGT
GAGCTTGCCTGCCTTGGCTGACTCGATCCGGTGGGCGCCGCCGGTCTCGCCCATCACCGG
CTTGCGGCCGGGACCGCTGACGTCGAAGCCGGCCGCGATCACGGTCACCCGCACCTCGTC
ACCGAGCGAATCGTCGATGACGGTGCCGAAGATGATGTTGGCATCGGGGTGAGCGGCGTC
TTGTACCAACGAGGCCGCCTCGTTGATCTCGAACAAGCCCAAGTCGCTGCCGCCGGCGAT
CGACATCAGCACGCCTTGCGCGCCCTCCATCGAGGCTTCCAGCAACGGCGAGTTGATGGC
GATCTCGGCCGCTTTGAGCGACCGGCCTTCGCCCCGGGCCGAGCCGATGCCCATCAGTGC
GGTGCCGGCACCGGACATGATGCCCTTGACGTCGGCGAAGTCGACGTTGATTAGACCCGG
GGTGGTAATCAGGTCGGTGATGCCCTGCACGCCGTTGAGCAGCACCTCGTCGGCGCTACG
GAAAGCATCCATCAGCGATACCGCGGCATCTCCCATCTGCAGCAACCGGTCGTTGGGAAT
CACGATGAGGGTGTCGCAACTCTCCCGCAGCGCCGCGATGCCATTTTCGGCCTGATTGCT
GCGTCGCTTGCCCTCGAACGAGAACGGCCGGGTGACCACACCGACGGTCAACGCGCCCAG
CTTGCGGGCGATGCTGGCGACGACGGGTGCCCCCCCGGTGCCGGTTCCGCCCCCCTCGCC
GGCGGTGACAAACACCATGTCGGCACCGCGCAGCAGCTCTTCGATCTCGTCCTTGGCGTC
CTCGGCGGCCTTACGGCCGACCTCCGGATCGGCGCCGGCGCCCAGCCCGCGGGTGGAGTC
GCGGCCGACGTCGAGTTTGACGTCGGCATCGCTCATCAACAACGCCTGGGCGTCGGTGTT
GATCGCGATGAATTCCACGCCTTTGAGGCCCTGCTCGATCATTCGGTTGACGGCGTTGAC
ACCGCCACCACCGATACCCACGACCTTGATGACGGCCAGGTAGTTGTGCGGGGGGGTCAT

# Drug_Target_42_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_42_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_42_HGNC_ID:
Not Available

# Drug_Target_42_HPRD_ID:
Not Available

# Drug_Target_42_ID:
2521

# Drug_Target_42_Locus:
Not Available

# Drug_Target_42_Molecular_Weight:
38756

# Drug_Target_42_Name:
Cell division protein ftsZ

# Drug_Target_42_Number_of_Residues:
379

# Drug_Target_42_PDB_ID:
1RQ7

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00091	Tubulin
PF03953	Tubulin_C

# Drug_Target_42_Protein_Sequence:
>Cell division protein ftsZ
MTPPHNYLAVIKVVGIGGGGVNAVNRMIEQGLKGVEFIAINTDAQALLMSDADVKLDVGR
DSTRGLGAGADPEVGRKAAEDAKDEIEELLRGADMVFVTAGEGGGTGTGGAPVVASIARK
LGALTVGVVTRPFSFEGKRRSNQAENGIAALRESCDTLIVIPNDRLLQMGDAAVSLMDAF
RSADEVLLNGVQGITDLITTPGLINVDFADVKGIMSGAGTALMGIGSARGEGRSLKAAEI
AINSPLLEASMEGAQGVLMSIAGGSDLGLFEINEAASLVQDAAHPDANIIFGTVIDDSLG
DEVRVTVIAAGFDVSGPGRKPVMGETGGAHRIESAKAGKLTSTLFEPVDAVSVPLHTNGA
TLSIGGDDDDVDVPPFMRR

# Drug_Target_42_Reaction:
Not Available

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
This protein is essential to the cell-division process. It seems to assemble into a dynamic ring on the inner surface of the cytoplasmic membrane at the place where division will occur, and the formation of the ring is the signal for septation to begin. Binds to and hydrolyzes GTP

# Drug_Target_42_SwissProt_ID:
P64170

# Drug_Target_42_SwissProt_Name:
FTSZ_MYCTU

# Drug_Target_42_Synonyms:
Not Available

# Drug_Target_42_Theoretical_pI:
4.31

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Cytoplasm

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
APRT

# Drug_Target_43_GenBank_ID_Gene:
Y00486

# Drug_Target_43_GenBank_ID_Protein:
28819

# Drug_Target_43_GeneCard_ID:
APRT

# Drug_Target_43_Gene_Name:
APRT

# Drug_Target_43_Gene_Sequence:
>543 bp
ATGGCCGACTCCGAGCTGCAGCTGGTTGAGCAGCGGATCCGCAGCTTCCCCGACTTCCCC
ACCCCAGGCGTGGTATTCAGGGACATCTCGCCCGTCCTGAAGGACCCCGCCTCCTTCCGC
GCCGCCATCGGCCTCCTGGCGCGACACCTGAAGGCGACCCACGGGGGCCGCATCGACTAC
ATCGCAGGCCTAGACTCCCGAGGCTTCCTCTTTGGCCCCTCCCTGGCCCAGGAGCTTGGA
CTGGGCTGCGTGCTCATCCGAAAGCGGGGGAAGCTGCCAGGCCCCACTCTGTGGGCCTCC
TATTCCCTGGAGTACGGGAAGGCTGAGCTGGAGATTCAGAAAGACGCCCTGGAGCCAGGA
CAGAGGGTGGTCGTCGTGGATGATCTGCTGGCCACTGGTGGAACCATGAACGCTGCCTGT
GAGCTGCTGGGCCGCCTGCAGGCTGAGGTCCTGGAGTGCGTGAGCCTGGTGGAGCTGACC
TCGCTTAAGGGCAGGGAGAAGCTGGCACCTGTACCCTTCTTCTCTCTCCTGCAGTATGAG
TGA

# Drug_Target_43_General_Function:
Nucleotide transport and metabolism

# Drug_Target_43_General_References:
11243733	Deng L, Yang M, Frund S, Wessel T, De Abreu RA, Tischfield JA, Sahota A: 2,8-Dihydroxyadenine urolithiasis in a patient with considerable residual adenine phosphoribosyltransferase activity in cell extracts but with mutations in both copies of APRT. Mol Genet Metab. 2001 Mar;72(3):260-4.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1353080	Kamatani N, Hakoda M, Otsuka S, Yoshikawa H, Kashiwazaki S: Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients. J Clin Invest. 1992 Jul;90(1):130-5.
1746557	Chen J, Sahota A, Laxdal T, Scrine M, Bowman S, Cui C, Stambrook PJ, Tischfield JA: Identification of a single missense mutation in the adenine phosphoribosyltransferase (APRT) gene from five Icelandic patients and a British patient. Am J Hum Genet. 1991 Dec;49(6):1306-11.
3343350	Hidaka Y, Tarle SA, Fujimori S, Kamatani N, Kelley WN, Palella TD: Human adenine phosphoribosyltransferase deficiency. Demonstration of a single mutant allele common to the Japanese. J Clin Invest. 1988 Mar;81(3):945-50.
3531209	Wilson JM, O'Toole TE, Argos P, Shewach DS, Daddona PE, Kelley WN: Human adenine phosphoribosyltransferase. Complete amino acid sequence of the erythrocyte enzyme. J Biol Chem. 1986 Oct 15;261(29):13677-83.
3554238	Broderick TP, Schaff DA, Bertino AM, Dush MK, Tischfield JA, Stambrook PJ: Comparative anatomy of the human APRT gene and enzyme: nucleotide sequence divergence and conservation of a nonrandom CpG dinucleotide arrangement. Proc Natl Acad Sci U S A. 1987 May;84(10):3349-53.
3680503	Hidaka Y, Palella TD, O'Toole TE, Tarle SA, Kelley WN: Human adenine phosphoribosyltransferase. Identification of allelic mutations at the nucleotide level as a cause of complete deficiency of the enzyme. J Clin Invest. 1987 Nov;80(5):1409-15.
3684585	Hidaka Y, Tarle SA, O'Toole TE, Kelley WN, Palella TD: Nucleotide sequence of the human APRT gene. Nucleic Acids Res. 1987 Nov 11;15(21):9086.
7915931	Sahota A, Chen J, Boyadjiev SA, Gault MH, Tischfield JA: Missense mutation in the adenine phosphoribosyltransferase gene causing 2,8-dihydroxyadenine urolithiasis. Hum Mol Genet. 1994 May;3(5):817-8.

# Drug_Target_43_HGNC_ID:
HGNC:626

# Drug_Target_43_HPRD_ID:
00029

# Drug_Target_43_ID:
128

# Drug_Target_43_Locus:
16q24

# Drug_Target_43_Molecular_Weight:
19477

# Drug_Target_43_Name:
Adenine phosphoribosyltransferase

# Drug_Target_43_Number_of_Residues:
179

# Drug_Target_43_PDB_ID:
1ORE

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00156	Pribosyltran

# Drug_Target_43_Protein_Sequence:
>Adenine phosphoribosyltransferase
ADSELQLVEQRIRSFPDFPTPGVVFRDISPVLKDPASFRAAIGLLARHLKATHGGRIDYI
AGLDSRGFLFGPSLAQELGLGCVLIRKRGKLPGPTLWASYSLEYGKAELEIQKDALEPGQ
RVVVVDDLLATGGTMNAACELLGRLQAEVLECVSLVELTSLKGREKLAPVPFFSLLQYE

# Drug_Target_43_Reaction:
AMP + diphosphate = adenine + 5-phospho-alpha-D-ribose 1-diphosphate

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis

# Drug_Target_43_SwissProt_ID:
P07741

# Drug_Target_43_SwissProt_Name:
APT_HUMAN

# Drug_Target_43_Synonyms:
APRT
EC 2.4.2.7

# Drug_Target_43_Theoretical_pI:
5.82

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Secreted protein

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
ANG

# Drug_Target_44_GenBank_ID_Gene:
M11567

# Drug_Target_44_GenBank_ID_Protein:
178250

# Drug_Target_44_GeneCard_ID:
ANG

# Drug_Target_44_Gene_Name:
ANG

# Drug_Target_44_Gene_Sequence:
>444 bp
ATGGTGATGGGCCTGGGCGTTTTGTTGTTGGTCTTCGTGCTGGGTCTGGGTCTGACCCCA
CCGACCCTGGCTCAGGATAACTCCAGGTACACACACTTCCTGACCCAGCACTATGATGCC
AAACCACAGGGCCGGGATGACAGATACTGTGAAAGCATCATGAGGAGACGGGGCCTGACC
TCACCCTGCAAAGACATCAACACATTTATTCATGGCAACAAGCGCAGCATCAAGGCCATC
TGTGAAAACAAGAATGGAAACCCTCACAGAGAAAACCTAAGAATAAGCAAGTCTTCTTTC
CAGGTCACCACTTGCAAGCTACATGGAGGTTCCCCCTGGCCTCCATGCCAGTACCGAGCC
ACAGCGGGGTTCAGAAACGTTGTTGTTGCTTGTGAAAATGGCTTACCTGTCCACTTGGAT
CAGTCAATTTTCCGTCGTCCGTAA

# Drug_Target_44_General_Function:
Involved in nucleic acid binding

# Drug_Target_44_General_References:
11468363	Leonidas DD, Chavali GB, Jardine AM, Li S, Shapiro R, Acharya KR: Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography. Protein Sci. 2001 Aug;10(8):1669-76.
11851402	Leonidas DD, Shapiro R, Subbarao GV, Russo A, Acharya KR: Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry. 2002 Feb 26;41(8):2552-62.
11919285	Zhang J, Rosenberg HF: Diversifying selection of the tumor-growth promoter angiogenin in primate evolution. Mol Biol Evol. 2002 Apr;19(4):438-45.
12842050	Chavali GB, Papageorgiou AC, Olson KA, Fett JW, Hu G, Shapiro R, Acharya KR: The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody. Structure. 2003 Jul;11(7):875-85.
1400510	Saxena SK, Rybak SM, Davey RT Jr, Youle RJ, Ackerman EJ: Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J Biol Chem. 1992 Oct 25;267(30):21982-6.
2440105	Weiner HL, Weiner LH, Swain JL: Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science. 1987 Jul 17;237(4812):280-2.
2866794	Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL: Amino acid sequence of human tumor derived angiogenin. Biochemistry. 1985 Sep 24;24(20):5486-94.
2866795	Kurachi K, Davie EW, Strydom DJ, Riordan JF, Vallee BL: Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985 Sep 24;24(20):5494-9.
8159679	Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL: Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2915-9.
9311977	Papageorgiou AC, Shapiro R, Acharya KR: Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. EMBO J. 1997 Sep 1;16(17):5162-77.
9461294	Lequin O, Thuring H, Robin M, Lallemand JY: Three-dimensional solution structure of human angiogenin determined by 1H,15N-NMR spectroscopy--characterization of histidine protonation states and pKa values. Eur J Biochem. 1997 Dec 15;250(3):712-26.
9918722	Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K, Acharya KR: Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J Mol Biol. 1999 Jan 22;285(3):1209-33.

# Drug_Target_44_HGNC_ID:
HGNC:483

# Drug_Target_44_HPRD_ID:
00105

# Drug_Target_44_ID:
2149

# Drug_Target_44_Locus:
14q11.1-q11.2

# Drug_Target_44_Molecular_Weight:
16550

# Drug_Target_44_Name:
Angiogenin

# Drug_Target_44_Number_of_Residues:
147

# Drug_Target_44_PDB_ID:
2ANG

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_44_Protein_Sequence:
>Angiogenin precursor
MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLT
SPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRA
TAGFRNVVVACENGLPVHLDQSIFRRP

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
1-24

# Drug_Target_44_Specific_Function:
May function as a tRNA-specific ribonuclease that binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus, thereby promoting the endothelial invasiveness necessary for blood vessel formation. Angiogenin induces vascularization of normal and malignant tissues. Abolishes protein synthesis by specifically hydrolyzing cellular tRNAs

# Drug_Target_44_SwissProt_ID:
P03950

# Drug_Target_44_SwissProt_Name:
ANGI_HUMAN

# Drug_Target_44_Synonyms:
Angiogenin precursor
EC 3.1.27.-
RNase 5
Ribonuclease 5

# Drug_Target_44_Theoretical_pI:
10.09

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
Not Available

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
AE004091

# Drug_Target_45_GenBank_ID_Protein:
Not Available

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
rmlA

# Drug_Target_45_Gene_Sequence:
>882 bp
ATGAAACGCAAGGGCATCATCCTCGCCGGAGGCTCGGGCACCCGCCTGCACCCGGCAACG
CTGGCCATCTCCAAGCAGTTGCTGCCGGTGTACGACAAGCCGATGATCTACTACCCGCTC
AGTACCCTGATGCTGGCGGGCATCCGCGAGATACTGATCATCTCGACCCCACAGGACACC
CCACGCTTCCAGCAGTTGCTGGGCGACGGTTCGAACTGGGGCCTGGACCTGCAATATGCC
GTGCAACCGTCGCCGGACGGCCTGGCCCAGGCCTTCCTGATCGGCGAGTCGTTCATCGGC
AACGACCTCAGCGCGCTGGTCCTGGGCGACAACCTCTATTACGGCCACGACTTCCACGAG
TTGCTCGGCAGCGCTTCGCAGCGCCAGACCGGCGCCAGTGTCTTCGCCTACCACGTGCTG
GACCCGGAGCGCTACGGCGTGGTCGAGTTCGACCAGGGCGGCAAGGCCATCAGCCTGGAA
GAGAAGCCACTGGAGCCGAAGTCGAACTACGCGGTCACCGGCCTGTATTTCTACGACCAG
CAGGTGGTGGACATCGCCAGGGACCTGAAGCCTTCGCCGCGCGGCGAGCTGGAGATCACC
GACGTCAACCGCGCCTATCTGGAGCGCGGCCAGCTCAGCGTGGAGATCATGGGCCGCGGC
TACGCCTGGCTGGATACCGGCACCCACGATTCGCTGCTCGAGGCCGGCCAGTTCATCGCC
ACCCTGGAGAACCGCCAGGGTCTCAAGGTGGCCTGCCCGGAAGAGATCGCCTACCGGCAG
AAGTGGATCGACGCCGCGCAACTGGAAAAACTCGCCGCGCCGCTGGCCAAGAACGGCTAC
GGCCAATACCTCAAGCGCCTGCTGACCGAGACCGTGTACTGA

# Drug_Target_45_General_Function:
Involved in glucose-1-phosphate thymidylyltransferase activity

# Drug_Target_45_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
4277

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
32457

# Drug_Target_45_Name:
Glucose-1-phosphate thymidylyltransferase

# Drug_Target_45_Number_of_Residues:
293

# Drug_Target_45_PDB_ID:
1G3L

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00483	NTP_transferase

# Drug_Target_45_Protein_Sequence:
>Glucose-1-phosphate thymidylyltransferase
MKRKGIILAGGSGTRLHPATLAISKQLLPVYDKPMIYYPLSTLMLAGIREILIISTPQDT
PRFQQLLGDGSNWGLDLQYAVQPSPDGLAQAFLIGESFIGNDLSALVLGDNLYYGHDFHE
LLGSASQRQTGASVFAYHVLDPERYGVVEFDQGGKAISLEEKPLEPKSNYAVTGLYFYDQ
QVVDIARDLKPSPRGELEITDVNRAYLERGQLSVEIMGRGYAWLDTGTHDSLLEAGQFIA
TLENRQGLKVACPEEIAYRQKWIDAAQLEKLAAPLAKNGYGQYLKRLLTETVY

# Drug_Target_45_Reaction:
Not Available

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Not Available

# Drug_Target_45_SwissProt_ID:
Q9HU22

# Drug_Target_45_SwissProt_Name:
Q9HU22_PSEAE

# Drug_Target_45_Synonyms:
Glucose-1-phosphate thymidyltransferase

# Drug_Target_45_Theoretical_pI:
5.02

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Cytoplasmic

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
M11189

# Drug_Target_46_GenBank_ID_Protein:
142604

# Drug_Target_46_GeneCard_ID:
Not Available

# Drug_Target_46_Gene_Name:
blm

# Drug_Target_46_Gene_Sequence:
>774 bp
ATGAAAAAGAATACGTTGTTAAAAGTAGGATTATGTGTAGGTTTACTAGGAACAATTCAA
TTTGTTAGCACAATTTCTTCTGTACAAGCATCACAAAAGGTAGAGAAAACAGTAATAAAA
AATGAGACGGGAACCATTTCAATATCTCAGTTAAACAAGAATGTATGGGTTCATACGGAG
TTAGGTTCTTTTAATGGAGAAGCAGTTCCTTCGAACGGTCTAGTTCTTAATACTTCTAAA
GGGTTAGTACTTGTGGATTCTTCTTGGGATGACAAATTAACGAAGGAACTAATAGAAATG
GTAGAAAAGAAATTTCAGAAGCGCGTAACGGATGTCATTATTACACATGCGCACGCTGAT
CGAATTGGCGGAATAAAAACGTTGAAAGAAAGAGGCATTAAAGCGCATAGTACAGCATTA
ACTGCAGAACTAGCAAAGAAAAATGGATATGAAGAACCGCTTGGAGATTTACAAACCGTT
ACAAATTTGAAGTTTGGAAATATGAAAGTAGAAACATTTTATCCAGGGAAAGGGCATACA
GAAGATAATATTGTCGTATGGTTACCGCAATACAATATTTTAGTTGGAGGCTGTTTAGTG
AAATCTACGTCCGCGAAAGATTTAGGAAACGTTGCGGATGCTTATGTAAATGAATGGTCT
ACATCGATTGAGAATGTGCTGAAGCGATATAGAAATATAAATGCAGTAGTGCCTGGTCAT
GGGGAAGTAGGGGACAAAGGATTACTTTTACATACATTGGATTTATTAAAATAA

# Drug_Target_46_General_Function:
Involved in zinc ion binding

# Drug_Target_46_General_References:
10933508	Chantalat L, Duee E, Galleni M, Frere JM, Dideberg O: Structural effects of the active site mutation cysteine to serine in Bacillus cereus zinc-beta-lactamase. Protein Sci. 2000 Jul;9(7):1402-6.
3124808	Sutton BJ, Artymiuk PJ, Cordero-Borboa AE, Little C, Phillips DC, Waley SG: An X-ray-crystallographic study of beta-lactamase II from Bacillus cereus at 0.35 nm resolution. Biochem J. 1987 Nov 15;248(1):181-8.
3930290	Ambler RP, Daniel M, Fleming J, Hermoso JM, Pang C, Waley SG: The amino acid sequence of the zinc-requiring beta-lactamase II from the bacterium Bacillus cereus 569. FEBS Lett. 1985 Sep 23;189(2):207-11.
3930467	Hussain M, Carlino A, Madonna MJ, Lampen JO: Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J Bacteriol. 1985 Oct;164(1):223-9.
7588620	Carfi A, Pares S, Duee E, Galleni M, Duez C, Frere JM, Dideberg O: The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J. 1995 Oct 16;14(20):4914-21.
9730812	Fabiane SM, Sohi MK, Wan T, Payne DJ, Bateson JH, Mitchell T, Sutton BJ: Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry. 1998 Sep 8;37(36):12404-11.
9761898	Carfi A, Duee E, Galleni M, Frere JM, Dideberg O: 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. Acta Crystallogr D Biol Crystallogr. 1998 May 1;54(Pt 3):313-23.

# Drug_Target_46_HGNC_ID:
Not Available

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
2603

# Drug_Target_46_Locus:
Not Available

# Drug_Target_46_Molecular_Weight:
28093

# Drug_Target_46_Name:
Beta-lactamase II

# Drug_Target_46_Number_of_Residues:
257

# Drug_Target_46_PDB_ID:
1MQO

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_46_Protein_Sequence:
>Beta-lactamase II precursor
MKKNTLLKVGLCVGLLGTIQFVSTISSVQASQKVEKTVIKNETGTISISQLNKNVWVHTE
LGSFNGEAVPSNGLVLNTSKGLVLVDSSWDDKLTKELIEMVEKKFQKRVTDVIITHAHAD
RIGGIKTLKERGIKAHSTALTAELAKKNGYEEPLGDLQTVTNLKFGNMKVETFYPGKGHT
EDNIVVWLPQYNILVGGCLVKSTSAKDLGNVADAYVNEWSTSIENVLKRYRNINAVVPGH
GEVGDKGLLLHTLDLLK

# Drug_Target_46_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_46_Signals:
1-30

# Drug_Target_46_Specific_Function:
Can hydrolyze carbapenem compounds

# Drug_Target_46_SwissProt_ID:
P04190

# Drug_Target_46_SwissProt_Name:
BLA2_BACCE

# Drug_Target_46_Synonyms:
Beta-lactamase II precursor
Cephalosporinase
EC 3.5.2.6
Penicillinase

# Drug_Target_46_Theoretical_pI:
9.29

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Not Available

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
Not Available

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
AE016877

# Drug_Target_47_GenBank_ID_Protein:
Not Available

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
BC_1747

# Drug_Target_47_Gene_Sequence:
>453 bp
TTATTTATTACCGAGTTCTTCTGCTAAACCGATTAAAATTCCTTCGACTCCACGAATGTA
GCAGAGACGATACGAGTTCTCGTACTGAACTACTTCGCCAACGAGCTCTGCACCATGCTT
AGTGAGTCTCGATACCATTTCGTCAATATCCTCGACAGTGAACATGACGCGTAGATAACC
GAGGGCGTTTACAGGAGCTGTTCGGTGATCTGCTATAGTAGGAGGGGTGAGAAATCGCGA
AAGTTCAATTCGGCTGTGGCCATCTGGAGTGACCATCATAGCAATCTCTACGCACTGAGA
ACCGAGTCCAGTTACGCGACCAGCCCATTCACCTTCGACATTTGCTCGACCTTCGAGATT
CAAGCCAATCTCCTCAAAGAAAGAGATTGCGTTATCAAGGGATTCTACAACGATGCTGAC
ATTGTCCATTCGTAGTAATTTGTTTTTTGCCAT

# Drug_Target_47_General_Function:
Amino acid transport and metabolism

# Drug_Target_47_General_References:
12721630	Ivanova N, Sorokin A, Anderson I, Galleron N, Candelon B, Kapatral V, Bhattacharyya A, Reznik G, Mikhailova N, Lapidus A, Chu L, Mazur M, Goltsman E, Larsen N, D'Souza M, Walunas T, Grechkin Y, Pusch G, Haselkorn R, Fonstein M, Ehrlich SD, Overbeek R, Kyrpides N: Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature. 2003 May 1;423(6935):87-91.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
4533

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
16582

# Drug_Target_47_Name:
Glyoxalase family protein

# Drug_Target_47_Number_of_Residues:
150

# Drug_Target_47_PDB_ID:
1SS4

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF00903	Glyoxalase

# Drug_Target_47_Protein_Sequence:
>Glyoxalase family protein
MAKNKLLRMDNVSIVVESLDNAISFFEEIGLNLEGRANVEGEWAGRVTGLGSQCVEIAMM
VTPDGHSRIELSRFLTPPTIADHRTAPVNALGYLRVMFTVEDIDEMVSRLTKHGAELVGE
VVQYENSYRLCYIRGVEGILIGLAEELGNK

# Drug_Target_47_Reaction:
Not Available

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
Not Available

# Drug_Target_47_SwissProt_ID:
Q81F54

# Drug_Target_47_SwissProt_Name:
Q81F54_BACCR

# Drug_Target_47_Synonyms:
Not Available

# Drug_Target_47_Theoretical_pI:
4.59

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Not Available

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
UCK2

# Drug_Target_48_GenBank_ID_Gene:
D78335

# Drug_Target_48_GenBank_ID_Protein:
1655420

# Drug_Target_48_GeneCard_ID:
UCK2

# Drug_Target_48_Gene_Name:
UCK2

# Drug_Target_48_Gene_Sequence:
>786 bp
ATGGCCGGGGACAGCGAGCAGACCCTGCAGAACCACCAGCAGCCCAACGGCGGCGAGCCC
TTCCTTATAGGCGTCAGCGGGGGAACAGCTAGCGGCAAGTCTTCCGTGTGTGCTAAGATC
GTGCAGCTCCTGGGGCAGAATGAGGTGGACTATCGCCAGAAGCAGGTGGTCATCCTGAGC
CAGGATAGCTTCTACCGTGTCCTTACCTCGGAGCAGAAGGCCAAAGCCCTGAAGGGCCAG
TTCAACTTTGACCACCCGGATGCCTTTGACAATGAACTCATTCTCAAAACACTCAAAGAA
ATCACTGAAGGGAAAACAGTCCAGATCCCCGTGTATGACTTTGTCTCCCATTCCCGGAAG
GAGGAGACAGTTACTGTCTATCCCGCAGACGTGGTGCTCTTTGAAGGGATCCTGGCCTTC
TACTCCCAGGAGGTACGAGACCTGTTCCAGATGAAGCTTTTTGTGGATACAGATGCGGAC
ACCCGGCTCTCACGCAGAGTATTAAGGGACATCAGCGAGAGAGGCAGGGATCTTGAGCAG
ATTTTATCTCAGTACATTACGTTCGTCAAGCCTGCCTTTGAGGAATTCTGCTTGCCAACA
AAGAAGTATGCTGATGTGATCATCCCTAGAGGTGCAGATAATCTGGTGGCCATCAACCTC
ATCGTGCAGCACATCCAGGACATCCTGAATGGAGGGCCCTCCAAACGGCAGACCAATGGC
TGTCTCAACGGCTACACCCCTTCACGCAAGAGGCAGGCATCGGAGTCCAGCAGCAGGCCG
CATTGA

# Drug_Target_48_General_Function:
Nucleotide transport and metabolism

# Drug_Target_48_General_References:
11306702	Van Rompay AR, Norda A, Linden K, Johansson M, Karlsson A: Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
11494055	Koizumi K, Shimamoto Y, Azuma A, Wataya Y, Matsuda A, Sasaki T, Fukushima M: Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. Int J Mol Med. 2001 Sep;8(3):273-8.
8812458	Ozaki K, Kuroki T, Hayashi S, Nakamura Y: Isolation of three testis-specific genes (TSA303, TSA806, TSA903) by a differential mRNA display method. Genomics. 1996 Sep 1;36(2):316-9.

# Drug_Target_48_HGNC_ID:
HGNC:12562

# Drug_Target_48_HPRD_ID:
01882

# Drug_Target_48_ID:
2697

# Drug_Target_48_Locus:
1q23

# Drug_Target_48_Molecular_Weight:
29299

# Drug_Target_48_Name:
Uridine-cytidine kinase 2

# Drug_Target_48_Number_of_Residues:
261

# Drug_Target_48_PDB_ID:
1XRJ

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00485	PRK

# Drug_Target_48_Protein_Sequence:
>Uridine-cytidine kinase 2
MAGDSEQTLQNHQQPNGGEPFLIGVSGGTASGKSSVCAKIVQLLGQNEVDYRQKQVVILS
QDSFYRVLTSEQKAKALKGQFNFDHPDAFDNELILKTLKEITEGKTVQIPVYDFVSHSRK
EETVTVYPADVVLFEGILAFYSQEVRDLFQMKLFVDTDADTRLSRRVLRDISERGRDLEQ
ILSQYITFVKPAFEEFCLPTKKYADVIIPRGADNLVAINLIVQHIQDILNGGPSKRQTNG
CLNGYTPSRKRQASESSSRPH

# Drug_Target_48_Reaction:
ATP + uridine = ADP + UMP

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate donor. Can also phosphorylate cytidine and uridine nucleoside analogs such as 6-azauridine, 5-fluorouridine, 4- thiouridine, 5-bromouridine, 4-N-acetylcytidine, 4-N- benzoylcytidine, 5-fluorocytidine, 2-thiocytidine, 5- methylcytidine, and 4-N-anisoylcytidine

# Drug_Target_48_SwissProt_ID:
Q9BZX2

# Drug_Target_48_SwissProt_Name:
UCK2_HUMAN

# Drug_Target_48_Synonyms:
Cytidine monophosphokinase 2
EC 2.7.1.48
UCK 2
Uridine monophosphokinase 2

# Drug_Target_48_Theoretical_pI:
6.68

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Cell membrane
single-pass type II membrane protein. Processed form:Secreted protein. Note=Also exis

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
TNFSF13B

# Drug_Target_49_GenBank_ID_Gene:
AF136293

# Drug_Target_49_GenBank_ID_Protein:
4761612

# Drug_Target_49_GeneCard_ID:
TNFSF13B

# Drug_Target_49_Gene_Name:
TNFSF13B

# Drug_Target_49_Gene_Sequence:
>858 bp
ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAA
GAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGA
TCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGC
CTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGG
GCAGAGCTGCAGGGCCACCACGCGGAGAAGCTGCCAGCAGGAGCAGGAGCCCCCAAGGCC
GGCTTGGAGGAAGCTCCAGCTGTCACCGCGGGACTGAAAATCTTTGAACCACCAGCTCCA
GGAGAAGGCAACTCCAGTCAGAACAGCAGAAATAAGCGTGCCGTTCAGGGTCCAGAAGAA
ACAGTCACTCAAGACTGCTTGCAACTGATTGCAGACAGTGAAACACCAACTATACAAAAA
GGATCTTACACATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGGAAGTGCCCTAGAAGAA
AAAGAGAATAAAATATTGGTCAAAGAAACTGGTTACTTTTTTATATATGGTCAGGTTTTA
TATACTGATAAGACCTACGCCATGGGACATCTAATTCAGAGGAAGAAGGTCCATGTCTTT
GGGGATGAATTGAGTCTGGTGACTTTGTTTCGATGTATTCAAAATATGCCTGAAACACTA
CCCAATAATTCCTGCTATTCAGCTGGCATTGCAAAACTGGAAGAAGGAGATGAACTCCAA
CTTGCAATACCAAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGGT
GCATTGAAACTGCTGTGA

# Drug_Target_49_General_Function:
Involved in tumor necrosis factor receptor binding

# Drug_Target_49_General_References:
10331498	Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999 May;65(5):680-3.
10359578	Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747-56.
10398604	Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3.
10973284	Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE: APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000 Sep;1(3):252-6.
11827482	Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K, Hsu YM, Kalled SL: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol. 2002 Feb 1;315(5):1145-54.
11853672	Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G: Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell. 2002 Feb 8;108(3):383-94.
11862220	Oren DA, Li Y, Volovik Y, Morris TS, Dharia C, Das K, Galperina O, Gentz R, Arnold E: Structural basis of BLyS receptor recognition. Nat Struct Biol. 2002 Apr;9(4):288-92.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_49_HGNC_ID:
HGNC:11929

# Drug_Target_49_HPRD_ID:
04914

# Drug_Target_49_ID:
1467

# Drug_Target_49_Locus:
13q32-34

# Drug_Target_49_Molecular_Weight:
31223

# Drug_Target_49_Name:
Tumor necrosis factor ligand superfamily member 13B

# Drug_Target_49_Number_of_Residues:
285

# Drug_Target_49_PDB_ID:
1OSG

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF00229	TNF

# Drug_Target_49_Protein_Sequence:
>Tumor necrosis factor ligand superfamily member 13B
MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCC
LTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAP
GEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEE
KENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETL
PNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response

# Drug_Target_49_SwissProt_ID:
Q9Y275

# Drug_Target_49_SwissProt_Name:
TN13B_HUMAN

# Drug_Target_49_Synonyms:
B cell-activating factor
B lymphocyte stimulator
BAFF
BLyS
CD257 antigen
Dendritic cell- derived TNF-like molecule
TALL-1
TNF- and APOL- related leukocyte expressed ligand 1

# Drug_Target_49_Theoretical_pI:
6.15

# Drug_Target_49_Transmembrane_Regions:
47-67

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AE000512

# Drug_Target_4_GenBank_ID_Protein:
4981702

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
pgl

# Drug_Target_4_Gene_Sequence:
>663 bp
TTATTTTCCCACAAACCAGACGGTTTTCTCTTTGCCTCTCACGAAGTAAGCGGGAAGTGG
TGTATCTTTTAAGATCTCCGTTAGTCTGTTTATCTTTTCTTTTCCCCTGATGAGAAAGAG
CACGTACAGTGATGTGTTCAGTGCACGAAACGTCAGGGTGACTCTGGGAACCTTAGGGTC
ACCGGAAGGATCTGTGAAAGTCACAAGGTTGTCTTTATTTCCCGTTTCCAAGTCGAATAT
GGACGCGACATGGCCATCGGGACCCATTCCAAGAATAGCGAGGTCGAACTGGTCAGTAGC
TGATCTTATTTCCCTCTCATATTTCTCGCAGGCTTTTTCAATAGGAAGAGAAGTGTCAAC
GTAGTGAACATTACCGGAAGGGATCTTTGCTCTGCTGAAAAGAACCTCGTTTATGTTCCT
GAAATTGCTTTGATCTGAGTCGAGGGGCACGTACCGCTCGTCGCTCAAAAAGAAGTGGAT
GCGATTCCATGGGAACTTCTGTTCTGCCAGTTTCTCATAAACGGGAAGTGGGGTTCTCCC
GCCGGCGAGAACGACGAAGATCTTATCCTTTTCCTCGAGAAGTTTTTCCATCTTTGTGCG
AATTTTCTCGACTACAAAATCAACGTACCCATCTTCGAGCAGGTATATCACAGTTTTCTC
CAT

# Drug_Target_4_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_4_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3583

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
25325

# Drug_Target_4_Name:
6-phosphogluconolactonase

# Drug_Target_4_Number_of_Residues:
220

# Drug_Target_4_PDB_ID:
1VL1

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01182	Glucosamine_iso

# Drug_Target_4_Protein_Sequence:
>6-phosphogluconolactonase
MEKTVIYLLEDGYVDFVVEKIRTKMEKLLEEKDKIFVVLAGGRTPLPVYEKLAEQKFPWN
RIHFFLSDERYVPLDSDQSNFRNINEVLFSRAKIPSGNVHYVDTSLPIEKACEKYEREIR
SATDQFDLAILGMGPDGHVASIFDLETGNKDNLVTFTDPSGDPKVPRVTLTFRALNTSLY
VLFLIRGKEKINRLTEILKDTPLPAYFVRGKEKTVWFVGK

# Drug_Target_4_Reaction:
6-phospho-D-glucono-1,5-lactone + H2O = 6-phospho-D-gluconate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Hydrolysis of 6-phosphogluconolactone to 6- phosphogluconate

# Drug_Target_4_SwissProt_ID:
Q9X0N8

# Drug_Target_4_SwissProt_Name:
6PGL_THEMA

# Drug_Target_4_Synonyms:
6PGL
EC 3.1.1.31

# Drug_Target_4_Theoretical_pI:
6.81

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Not Available

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
Not Available

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
U50134

# Drug_Target_50_GenBank_ID_Protein:
Not Available

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
yfiH

# Drug_Target_50_Gene_Sequence:
>732 bp
ATGAGTAAGCTGATTGTCCCGCAGTGGCCGCAGCCAAAAGGTGTTGCGGCCTGTAGCTCC
ACTCGTATCGGCGGCGTGACGTTGCCCCCGTATGACTCACTCAACCTCGGTGCCCATTGT
GGCGATAACCCGGATCACGTTGAGGAGAATCGCAAGCGACTTTTTGCTGCGGGCAATTTG
CCTTCTAAACCGGTCTGGCTTGAGCAGGTACACGGCAAAGATGTGCTTAAGCTCACTGGC
GAACCTTATGCCTCAAAACGGGCGGATGCCTCTTATAGCAATACGCCCGGCACGGTTTGC
GCAGTGATGACTGCCGACTGCCTCCCTGTGCTGTTTTGCAATCGAGCGGGAACGGAAGTC
GCCGCCGCTCATGCTGGCTGGCGTGGACTGTGCGCAGGCGTGCTGGAAGAGACGGTTTCC
TGTTTTGCTGATAATCCGGAAAATATTCTCGCCTGGTTAGGGCCGGCAATTGGTCCACGC
GCGTTCGAAGTGGGGGGGGAGGTTCGCGAGGCGTTTATGGCAGTAGACGCTAAAGCAAGT
GCAGCTTTCATTCAGCATGGTGATAAGTATCTGGCGGATATTTATCAGCTTGCCCGGCAG
CGTCTGGCGAACGTGGGTGTTGAGCAAATTTTCGGCGGCGACCGTTGTACATATACGGAA
AATGAGACTTTCTTCTCTTATCGTCGCGACAAGACCACCGGTCGTATGGCAAGTTTCATT
TGGCTGATATAA

# Drug_Target_50_General_Function:
Not Available

# Drug_Target_50_General_References:
1906060	Kitagawa M, Wada C, Yoshioka S, Yura T: Expression of ClpB, an analog of the ATP-dependent protease regulatory subunit in Escherichia coli, is controlled by a heat shock sigma factor (sigma 32). J Bacteriol. 1991 Jul;173(14):4247-53.
2066329	Squires CL, Pedersen S, Ross BM, Squires C: ClpB is the Escherichia coli heat shock protein F84.1. J Bacteriol. 1991 Jul;173(14):4254-62.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
4695

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
26339

# Drug_Target_50_Name:
UPF0124 protein yfiH

# Drug_Target_50_Number_of_Residues:
243

# Drug_Target_50_PDB_ID:
1U05

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF02578	DUF152

# Drug_Target_50_Protein_Sequence:
>UPF0124 protein yfiH
MSKLIVPQWPQPKGVAACSSTRIGGVSLPPYDSLNLGAHCGDNPDHVEENRKRLFAAGNL
PSKPVWLEQVHGKDVLKLTGEPYASKRADASYSNTPGTVCAVMTADCLPVLFCNRAGTEV
AAAHAGWRGLCAGVLEETVSCFADNPENILAWLGPAIGPRAFEVGGEVREAFMAVDAKAS
AAFIQHGDKYLADIYQLARQRLANVGVEQIFGGDRCTYTENETFFSYRRDKTTGRMASFI
WLI

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Not Available

# Drug_Target_50_SwissProt_ID:
P33644

# Drug_Target_50_SwissProt_Name:
YFIH_ECOLI

# Drug_Target_50_Synonyms:
Not Available

# Drug_Target_50_Theoretical_pI:
6.65

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Cytoplasm

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
BHMT

# Drug_Target_51_GenBank_ID_Gene:
U50929

# Drug_Target_51_GenBank_ID_Protein:
1522683

# Drug_Target_51_GeneCard_ID:
BHMT

# Drug_Target_51_Gene_Name:
BHMT

# Drug_Target_51_Gene_Sequence:
>1221 bp
ATGCCACCCGTTGGGGGCAAAAAGGCCAAGAAGGGCATCCTAGAACGTTTAAATGCTGGA
GAGATTGTGATTGGAGATGGAGGGTTTGTCTTTGCACTGGAGAAGAGGGGCTACGTAAAG
GCAGGACCCTGGACTCCTGAAGCTGCTGTGGAGCACCCAGAAGCAGTTCGCCAGCTTCAT
CGAGAGTTCCTCAGAGCTGGCTCAAACGTCATGCAGACCTTCACCTTCTATGCGAGTGAA
GACAAGCTGGAGAACAGGGGCAACTATGTCTTAGAGAAGATATCTGGGCAGGAAGTCAAT
GAAGCTGCTTGCGACATCGCCCGACAAGTGGCTGATGAAGGAGATGCTTTGGTAGCAGGA
GGAGTGAGTCAGACACCTTCATACCTTAGCTGCAAGAGTGAAACTGAAGTCAAAAAAGTA
TTTCTGCAACAGTTAGAGGTCTTTATGAAGAAGAACGTGGACTTCTTGATTGCAGAGTAT
TTTGAACACGTTGAAGAAGCTGTGTGGGCAGTTGAAACCTTGATAGCATCCGGTAAACCT
GTGGCAGCAACCATGTGCATTGGCCCAGAAGGAGATTTGCATGGCGTGCCCCCCGGCGAG
TGTGCAGTGCGCCTGGTGAAAGCAGGAGCATCCATCATTGGTGTGAACTGCCACTTTGAC
CCCACCATTAGTTTAAAAACAGTGAAGCTCATGAAGGAGGGCTTGGAGGCTGCCCAACTG
AAAGCTCACCTGATGAGCCAGCCCTTGGCTTACCACACTCCTGACTGCAACAAGCAGGGA
TTCATCGATCTCCCAGAATTCCCATTTGGACTGGAACCCAGAGTTGCCACCAGATGGGAT
ATTCAAAAATACGCCAGAGAGGCCTACAACCTGGGGGTCAGGTACATTGGCGGGTGCTGT
GGATTTGAGCCCTACCACATCAGGGCAATTGCAGAGGAGCTGGCCCCAGAAAGGGGCTTT
TTGCCACCAGCTTCAGAAAAACATGGCAGCTGGGGAAGTGGTTTGGACATGCACACCAAA
CCCTGGGTTAGAGCAAGGGCCAGGAAGGAATACTGGGAGAATCTTCGGATAGCCTCAGGC
CGGCCATACAACCCTTCAATGTCAAAGCCAGATGGCTGGGGAGTGACCAAAGGAACAGCC
GAGCTGATGCAGCAGAAAGAAGCCACAACTGAGCAGCAGCTGAAAGAGCTCTTTGAAAAA
CAAAAATTCAAATCACAGTAG

# Drug_Target_51_General_Function:
Amino acid transport and metabolism

# Drug_Target_51_General_References:
10075673	Park EI, Garrow TA: Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene. J Biol Chem. 1999 Mar 19;274(12):7816-24.
12818402	Weisberg IS, Park E, Ballman KV, Berger P, Nunn M, Suh DS, Breksa AP 3rd, Garrow TA, Rozen R: Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis. 2003 Apr;167(2):205-14.
8798461	Garrow TA: Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase. J Biol Chem. 1996 Sep 13;271(37):22831-8.
9281325	Sunden SL, Renduchintala MS, Park EI, Miklasz SD, Garrow TA: Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys. 1997 Sep 1;345(1):171-4.
9681996	Millian NS, Garrow TA: Human betaine-homocysteine methyltransferase is a zinc metalloenzyme. Arch Biochem Biophys. 1998 Aug 1;356(1):93-8.

# Drug_Target_51_HGNC_ID:
HGNC:1047

# Drug_Target_51_HPRD_ID:
04200

# Drug_Target_51_ID:
941

# Drug_Target_51_Locus:
5q13.1-q15

# Drug_Target_51_Molecular_Weight:
44971

# Drug_Target_51_Name:
Betaine--homocysteine S-methyltransferase 1

# Drug_Target_51_Number_of_Residues:
406

# Drug_Target_51_PDB_ID:
1LT8

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF02574	S-methyl_trans

# Drug_Target_51_Protein_Sequence:
>Betaine--homocysteine S-methyltransferase
MPPVGGKKAKKGILERLNAGEIVIGDGGFVFALEKRGYVKAGPWTPEAAVEHPEAVRQLH
REFLRAGSNVMQTFTFYASEDKLENRGNYVLEKISGQEVNEAACDIARQVADEGDALVAG
GVSQTPSYLSCKSETEVKKVFLQQLEVFMKKNVDFLIAEYFEHVEEAVWAVETLIASGKP
VAATMCIGPEGDLHGVPPGECAVRLVKAGASIIGVNCHFDPTISLKTVKLMKEGLEAAQL
KAHLMSQPLAYHTPDCNKQGFIDLPEFPFGLEPRVATRWDIQKYAREAYNLGVRYIGGCC
GFEPYHIRAIAEELAPERGFLPPASEKHGSWGSGLDMHTKPWVRARARKEYWENLRIASG
RPYNPSMSKPDGWGVTKGTAELMQQKEATTEQQLKELFEKQKFKSQ

# Drug_Target_51_Reaction:
trimethylammonioacetate + L-homocysteine = dimethylglycine + L-methionine

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Involved in the regulation of homocysteine metabolism. Converts betaine and homocysteine to dimethylglycine and methionine, respectively. This reaction is also required for the irreversible oxidation of choline

# Drug_Target_51_SwissProt_ID:
Q93088

# Drug_Target_51_SwissProt_Name:
BHMT1_HUMAN

# Drug_Target_51_Synonyms:
EC 2.1.1.5

# Drug_Target_51_Theoretical_pI:
6.85

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Not Available

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
Not Available

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
Not Available

# Drug_Target_52_GenBank_ID_Gene:
L42023

# Drug_Target_52_GenBank_ID_Protein:
Not Available

# Drug_Target_52_GeneCard_ID:
Not Available

# Drug_Target_52_Gene_Name:
rpiA

# Drug_Target_52_Gene_Sequence:
>660 bp
ATGAATCAATTAGAAATGAAAAAACTCGCCGCACAAGCTGCATTACAATATGTAAAAGCA
GATACGATTGTTGGGGTGGGAAGTGGCTCCACAGTGAACTGCTTTATTGAAGCTTTAGGT
ACAATCAAAGATAAAATTCAAGGTGCCGTTGCGGCTTCAAAAGAATCAGAAGAATTATTA
CGTAAGCAAGGTATCGAAGTATTTAATGCAAATGATGTCTCTAGCTTAGATATTTATGTG
GATGGTGCGGATGAAATCAATCCACAAAAAATGATGATTAAAGGCGGCGGCGCAGCACTC
ACTCGTGAAAAAATAGTCGCTGCATTAGCGAAAAAATTTATTTGTATTGTGGATTCAAGT
AAGCAAGTGGATGTGTTGGGTTCAACTTTCCCATTACCAGTTGAAGTGATTCCTATGGCA
CGCTCACAAGTAGGCAGAAAATTAGCCGCACTTGGTGGCTCACCTGAATATCGTGAAGGG
GTGGTGACTGACAACGGCAATGTGATTTTAGATGTACACAACTTCAGTATTTTAAATCCA
GTCGAAATTGAAAAAGAATTAAACAACGTTGCAGGTGTCGTCACTAATGGGATATTCGCG
TTACGTGGTGCAGATGTTGTGATCGTCGGGACGCCTGAGGGTGCCAAAGTTATTGACTAA

# Drug_Target_52_General_Function:
Involved in ribose-5-phosphate isomerase activity

# Drug_Target_52_General_References:
10675023	Langen H, Takacs B, Evers S, Berndt P, Lahm HW, Wipf B, Gray C, Fountoulakis M: Two-dimensional map of the proteome of Haemophilus influenzae. Electrophoresis. 2000 Jan;21(2):411-29.
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_52_HGNC_ID:
Not Available

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
5595

# Drug_Target_52_Locus:
Not Available

# Drug_Target_52_Molecular_Weight:
23094

# Drug_Target_52_Name:
Ribose-5-phosphate isomerase A

# Drug_Target_52_Number_of_Residues:
219

# Drug_Target_52_PDB_ID:
1M0S

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF06026	Rib_5-P_isom_A

# Drug_Target_52_Protein_Sequence:
>Ribose-5-phosphate isomerase A
MNQLEMKKLAAQAALQYVKADTIVGVGSGSTVNCFIEALGTIKDKIQGAVAASKESEELL
RKQGIEVFNANDVSSLDIYVDGADEINPQKMMIKGGGAALTREKIVAALAKKFICIVDSS
KQVDVLGSTFPLPVEVIPMARSQVGRKLAALGGSPEYREGVVTDNGNVILDVHNFSILNP
VEIEKELNNVAGVVTNGIFALRGADVVIVGTPEGAKVID

# Drug_Target_52_Reaction:
Not Available

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
D-ribose 5-phosphate = D-ribulose 5-phosphate

# Drug_Target_52_SwissProt_ID:
P44725

# Drug_Target_52_SwissProt_Name:
RPIA_HAEIN

# Drug_Target_52_Synonyms:
EC 5.3.1.6
PRI
Phosphoriboisomerase A

# Drug_Target_52_Theoretical_pI:
4.78

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Cytoplasm

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
Not Available

# Drug_Target_53_GenBank_ID_Gene:
M14742

# Drug_Target_53_GenBank_ID_Protein:
143784

# Drug_Target_53_GeneCard_ID:
Not Available

# Drug_Target_53_Gene_Name:
trpS

# Drug_Target_53_Gene_Sequence:
>987 bp
ATGAAAACCATTTTTTCCGGCATTCAGCCAAGCGGCGTCATCACCATTGGCAACTATATT
GGGGCGCTGCGGCAGTTTGTCGAGCTGCAGCATGAATACAACTGCTATTTTTGCATCGTT
GACCAACACGCCATTACCGTTTGGCAAGACCCACACGAACTGCGGCAAAACATCCGCCGC
CTCGCCGCAAAGTATTTGGCCGTCGGCATCGACCCGACGCAAGCGACGTTGTTCATCCAG
TCAGAAGTGCCGGCGCACGCTCAAGCCGCTTGGATGCTGCAGTGCATCGTTTATATCGGC
GAACTTGAGCGGATGACGCAATTTAAAGAAAAATCGGCCGGCAAAGAGGCGGTCAGCGCC
GGGCTGCTCACGTACCCGCCGCTGATGGCCGCTGACATTTTGCTTTATAACACCGACATC
GTCCCGGTCGGCGAAGACCAAAAGCAGCATATCGAATTGACGCGGGATCTGGCCGAGCGC
TTCAACAAACGGTATGGCGAGCTGTTTACGATCCCTGAGGCGCGCATTCCGAAAGTCGGC
GCCCGCATCATGTCGCTTGTCGACCCGACGAAAAAAATGAGCAAATCCGACCCCAACCCG
AAAGCGTACATCACACTGCTTGACGATGCGAAAACGATCGAGAAGAAGATCAAAAGCGCG
GTCACCGACTCGGAAGGAACGATTCGCTACGACAAAGAAGCGAAGCCAGGCATTTCGAAC
TTGCTCAATATTTATTCGACCCTATCCGGTCAATCGATCGAGGAGTTGGAGCGGCAATAC
GAAGGAAAAGGATACGGCGTCTTCAAAGCAGACCTCGCTCAAGTCGTCATCGAAACGCTT
CGACCGATTCAAGAGCGGTATCACCATTGGATGGAAAGCGAGGAGCTTGACCGCGTGTTG
GATGAAGGGGCGGAAAAAGCAAATCGGGTTGCATCGGAAATGGTGCGAAAAATGGAGCAA
GCCATGGGGCTCGGGCGGCGGCGGTAA

# Drug_Target_53_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_53_General_References:
10716174	Ilyin VA, Temple B, Hu M, Li G, Yin Y, Vachette P, Carter CW Jr: 2.9 A crystal structure of ligand-free tryptophanyl-tRNA synthetase: domain movements fragment the adenine nucleotide binding site. Protein Sci. 2000 Feb;9(2):218-31.
3026925	Barstow DA, Sharman AF, Atkinson T, Minton NP: Cloning and complete nucleotide sequence of the Bacillus stearothermophilus tryptophanyl tRNA synthetase gene. Gene. 1986;46(1):37-45.
7743129	Doublie S, Bricogne G, Gilmore C, Carter CW Jr: Tryptophanyl-tRNA synthetase crystal structure reveals an unexpected homology to tyrosyl-tRNA synthetase. Structure. 1995 Jan 15;3(1):17-31.
891985	Winter GP, Hartley BS: The amino acid sequence of tryptophanyl tRNA synthetase from Bacillus stearothermophilus. FEBS Lett. 1977 Aug 15;80(2):340-2.

# Drug_Target_53_HGNC_ID:
Not Available

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
2452

# Drug_Target_53_Locus:
Not Available

# Drug_Target_53_Molecular_Weight:
37193

# Drug_Target_53_Name:
Tryptophanyl-tRNA synthetase

# Drug_Target_53_Number_of_Residues:
328

# Drug_Target_53_PDB_ID:
1MB2

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00579	tRNA-synt_1b

# Drug_Target_53_Protein_Sequence:
>Tryptophanyl-tRNA synthetase
MKTIFSGIQPSGVITIGNYIGALRQFVELQHEYNCYFCIVDQHAITVWQDPHELRQNIRR
LAAKYLAVGIDPTQATLFIQSEVPAHAQAAWMLQCIVYIGELERMTQFKEKSAGKEAVSA
GLLTYPPLMAADILLYNTDIVPVGEDQKQHIELTRDLAERFNKRYGELFTIPEARIPKVG
ARIMSLVDPTKKMSKSDPNPKAYITLLDDAKTIEKKIKSAVTDSEGTIRYDKEAKPGISN
LLNIYSTLSGQSIEELERQYEGKGYGVFKADLAQVVIETLRPIQERYHHWMESEELDRVL
DEGAEKANRVASEMVRKMEQAMGLGRRR

# Drug_Target_53_Reaction:
ATP + L-tryptophan + tRNATrp = AMP + diphosphate + L-tryptophyl-tRNATrp

# Drug_Target_53_Signals:
None

# Drug_Target_53_Specific_Function:
ATP + L-tryptophan + tRNA(Trp) = AMP + diphosphate + L-tryptophyl-tRNA(Trp)

# Drug_Target_53_SwissProt_ID:
P00953

# Drug_Target_53_SwissProt_Name:
SYW_GEOSE

# Drug_Target_53_Synonyms:
EC 6.1.1.2
TrpRS
Tryptophan--tRNA ligase

# Drug_Target_53_Theoretical_pI:
6.64

# Drug_Target_53_Transmembrane_Regions:
None

# Drug_Target_54_Cellular_Location:
Not Available

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
Not Available

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
Not Available

# Drug_Target_54_GenBank_ID_Gene:
M10101

# Drug_Target_54_GenBank_ID_Protein:
Not Available

# Drug_Target_54_GeneCard_ID:
Not Available

# Drug_Target_54_Gene_Name:
guaA

# Drug_Target_54_Gene_Sequence:
>1578 bp
ATGACGGAAAACATTCATAAGCATCGCATCCTCATTCTGGACTTCGGTTCTCAGTACACT
CAACTGGTTGCGCGCCGCGTGCGTGAGCTGGGTGTTTACTGCGAACTGTGGGCGTGGGAT
GTGACAGAAGCACAAATTCGTGACTTCAATCCAAGCGGCATTATTCTTTCCGGCGGCCCG
GAAAGTACTACTGAAGAAAACAGTCCGCGTGCGCCGCAGTATGTCTTTGAAGCAGGCGTA
CCGGTATTCGGCGTTTGCTATGGCATGCAGACCATGGCAATGCAGTTGGGCGGTCACGTT
GAAGCCTCTAACGAACGTGAATTTGGCTACGCGCAGGTTGAAGTCGTAAACGACAGCGCA
CTGGTTCGCGGTATCGAAGATGCGCTGACCGCAGACGGTAAACCGCTGCTCGATGTCTGG
ATGAGCCACGGCGATAAAGTTACCGCTATTCCGTCCGACTTCATCACCGTAGCCAGCACC
GAAAGCTGCCCGTTTGCCATTATGGCTAACGAAGAAAAACGCTTCTATGGCGTACAGTTC
CACCCGGAAGTGACTCATACCCGCCAGGGTATGCGCATGCTGGAGCGTTTTGTGCGTGAT
ATCTGCCAGTGTGAAGCCCTGTGGACGCCAGCGAAAATTATCGACGATGCTGTAGCTCGC
ATCCGCGAGCAGGTAGGCGACGATAAAGTCATCCTCGGCCTCTCTGGTGGTGTGGATTCC
TCCGTAACCGCAATGCTGCTGCACCGCGCTATCGGTAAAAACCTGACTTGCGTATTCGTC
GACAACGGCCTGCTGCGCCTCAACGAAGCAGAGCAGGTTCTGGATATGTTTGGCGATCAC
TTTGGTCTTAACATTGTTCACGTACCGGCAGAAGATCGCTTCCTGTCAGCGCTGGCTGGC
GAAAACGATCCGGAAGCAAAACGTAAAATCATCGGTCGCGTTTTCGTTGAAGTATTCGAT
GAAGAAGCGCTGAAACTGGAAGACGTGAAGTGGCTGGCGCAGGGCACCATCTACCCTGAC
GTTATCGAATCTGCGGCGTCTGCAACCGGTAAAGCACACGTCATCAAATCTCACCACAAC
GTGGGCGGCCTGCCGAAAGAGATGAAGATGGGCCTGGTTGAACCGCTGAAAGAGCTGTTC
AAAGACGAAGTGCGTAAGATTGGTCTGGAGCTGGGCCTGCCGTACGACATGCTGTACCGT
CACCCGTTCCCGGGACCAGGCCTTGGCGTTCGTGTTCTGGGTGAAGTGAAGAAAGAGTAC
TGTGACCTGCTGCGCCGTGCTGACGCCATCTTCATTGAAGAACTGCGTAAAGCGGACCTG
TACGACAAAGTCAGCCAGGCGTTCACTGTGTTCCTGCCGGTACGTTCCGTTGGCGTAATG
GGCGATGGTCGTAAGTATGACTGGGTTGTCTCTCTGCGTGCTGTCGAAACCATCGACTTT
ATGACCGCACACTGGGCGCATCTGCCGTACGATTTCCTCGGTCGCGTTTCCAACCGCATT
ATCAATGAAGTGAACGGTATTTCCCGCGTGGTGTATGACATCAGCGGCAAGCCGCCAGCT
ACCATTGAGTGGGAATGA

# Drug_Target_54_General_Function:
Involved in catalytic activity

# Drug_Target_54_General_References:
10856643	Hutchings MI, Drabble WT: Regulation of the divergent guaBA and xseA promoters of Escherichia coli by the cyclic AMP receptor protein. FEMS Microbiol Lett. 2000 Jun 15;187(2):115-22.
1736096	Tesfa-Selase F, Drabble WT: Regulation of the gua operon of Escherichia coli by the DnaA protein. Mol Gen Genet. 1992 Jan;231(2):256-64.
2982857	Zalkin H, Argos P, Narayana SV, Tiedeman AA, Smith JM: Identification of a trpG-related glutamine amide transfer domain in Escherichia coli GMP synthetase. J Biol Chem. 1985 Mar 25;260(6):3350-4.
3894345	Tiedeman AA, Smith JM, Zalkin H: Nucleotide sequence of the guaA gene encoding GMP synthetase of Escherichia coli K12. J Biol Chem. 1985 Jul 25;260(15):8676-9.
8548458	Tesmer JJ, Klem TJ, Deras ML, Davisson VJ, Smith JL: The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat Struct Biol. 1996 Jan;3(1):74-86.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9890911	Deras ML, Chittur SV, Davisson VJ: N2-hydroxyguanosine 5'-monophosphate is a time-dependent inhibitor of Escherichia coli guanosine monophosphate synthetase. Biochemistry. 1999 Jan 5;38(1):303-10.

# Drug_Target_54_HGNC_ID:
Not Available

# Drug_Target_54_HPRD_ID:
Not Available

# Drug_Target_54_ID:
4353

# Drug_Target_54_Locus:
Not Available

# Drug_Target_54_Molecular_Weight:
58680

# Drug_Target_54_Name:
GMP synthase [glutamine-hydrolyzing]

# Drug_Target_54_Number_of_Residues:
525

# Drug_Target_54_PDB_ID:
1GPM

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00117	GATase
PF00958	GMP_synt_C
PF03054	tRNA_Me_trans

# Drug_Target_54_Protein_Sequence:
>GMP synthase [glutamine-hydrolyzing]
MTENIHKHRILILDFGSQYTQLVARRVRELGVYCELWAWDVTEAQIRDFNPSGIILSGGP
ESTTEENSPRAPQYVFEAGVPVFGVCYGMQTMAMQLGGHVEASNEREFGYAQVEVVNDSA
LVRGIEDALTADGKPLLDVWMSHGDKVTAIPSDFITVASTESCPFAIMANEEKRFYGVQF
HPEVTHTRQGMRMLERFVRDICQCEALWTPAKIIDDAVARIREQVGDDKVILGLSGGVDS
SVTAMLLHRAIGKNLTCVFVDNGLLRLNEAEQVLDMFGDHFGLNIVHVPAEDRFLSALAG
ENDPEAKRKIIGRVFVEVFDEEALKLEDVKWLAQGTIYPDVIESAASATGKAHVIKSHHN
VGGLPKEMKMGLVEPLKELFKDEVRKIGLELGLPYDMLYRHPFPGPGLGVRVLGEVKKEY
CDLLRRADAIFIEELRKADLYDKVSQAFTVFLPVRSVGVMGDGRKYDWVVSLRAVETIDF
MTAHWAHLPYDFLGRVSNRIINEVNGISRVVYDISGKPPATIEWE

# Drug_Target_54_Reaction:
Not Available

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Catalyzes the synthesis of GMP from XMP

# Drug_Target_54_SwissProt_ID:
P04079

# Drug_Target_54_SwissProt_Name:
GUAA_ECOLI

# Drug_Target_54_Synonyms:
EC 6.3.5.2
GMP synthetase
GMPS
Glutamine amidotransferase

# Drug_Target_54_Theoretical_pI:
5.06

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Cytoplasm

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
AKR1B1

# Drug_Target_55_GenBank_ID_Gene:
J04795

# Drug_Target_55_GenBank_ID_Protein:
178487

# Drug_Target_55_GeneCard_ID:
AKR1B1

# Drug_Target_55_Gene_Name:
AKR1B1

# Drug_Target_55_Gene_Sequence:
>951 bp
ATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC
TGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC
CGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG
GAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG
TGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG
AAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG
GAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC
ACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC
AACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT
GCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC
CAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG
GCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG
CACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG
ATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA
CTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC
TTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA

# Drug_Target_55_General_Function:
Involved in oxidoreductase activity

# Drug_Target_55_General_References:
1447221	Borhani DW, Harter TM, Petrash JM: The crystal structure of the aldose reductase.NADPH binary complex. J Biol Chem. 1992 Dec 5;267(34):24841-7.
1621098	Wilson DK, Bohren KM, Gabbay KH, Quiocho FA: An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4.
1901857	Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem. 1991 Apr 15;266(11):6872-7.
2111143	Grundmann U, Bohn H, Obermeier R, Amann E: Cloning and prokaryotic expression of a biologically active human placental aldose reductase. DNA Cell Biol. 1990 Apr;9(3):149-57.
2112546	Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem. 1990 Jun 15;265(17):9788-92.
2492527	Morjana NA, Lyons C, Flynn TG: Aldose reductase from human psoas muscle. Affinity labeling of an active site lysine by pyridoxal 5'-phosphate and pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1989 Feb 15;264(5):2912-9.
2498333	Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989 Jun 5;264(16):9547-51.
2504709	Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem. 1989 Sep 5;264(25):14775-7.
2510130	Graham A, Hedge PJ, Powell SJ, Riley J, Brown L, Gammack A, Carey F, Markham AF: Nucleotide sequence of cDNA for human aldose reductase. Nucleic Acids Res. 1989 Oct 25;17(20):8368.
8234324	Wilson DK, Tarle I, Petrash JM, Quiocho FA: Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9847-51.
8245005	Tarle I, Borhani DW, Wilson DK, Quiocho FA, Petrash JM: Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. J Biol Chem. 1993 Dec 5;268(34):25687-93.
8281941	Jaquinod M, Potier N, Klarskov K, Reymann JM, Sorokine O, Kieffer S, Barth P, Andriantomanga V, Biellmann JF, Van Dorsselaer A: Sequence of pig lens aldose reductase and electrospray mass spectrometry of non-covalent and covalent complexes. Eur J Biochem. 1993 Dec 15;218(3):893-903.
8343525	Liu SQ, Bhatnagar A, Ansari NH, Srivastava SK: Identification of the reactive cysteine residue in human placenta aldose reductase. Biochim Biophys Acta. 1993 Aug 7;1164(3):268-72.
8435445	Ferraretto A, Negri A, Giuliani A, De Grada L, Fuhrman Conti AM, Ronchi S: Aldose reductase is involved in long-term adaptation of EUE cells to hyperosmotic stress. Biochim Biophys Acta. 1993 Feb 17;1175(3):283-8.
9195951	Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS: Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem. 1997 Jun 27;272(26):16431-7.
9405046	Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH: The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry. 1997 Dec 23;36(51):16134-40.

# Drug_Target_55_HGNC_ID:
HGNC:381

# Drug_Target_55_HPRD_ID:
00071

# Drug_Target_55_ID:
822

# Drug_Target_55_Locus:
7q35

# Drug_Target_55_Molecular_Weight:
35723

# Drug_Target_55_Name:
Aldose reductase

# Drug_Target_55_Number_of_Residues:
315

# Drug_Target_55_PDB_ID:
1T40

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_55_Protein_Sequence:
>Aldose reductase
ASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQE
KLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKE
FFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPA
VNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKH
NKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCAL
LSCTSHKDYPFHEEF

# Drug_Target_55_Reaction:
alditol + NAD(P)+ = aldose + NAD(P)H + H+

# Drug_Target_55_Signals:
None

# Drug_Target_55_Specific_Function:
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies

# Drug_Target_55_SwissProt_ID:
P15121

# Drug_Target_55_SwissProt_Name:
ALDR_HUMAN

# Drug_Target_55_Synonyms:
AR
Aldehyde reductase
EC 1.1.1.21

# Drug_Target_55_Theoretical_pI:
6.99

# Drug_Target_55_Transmembrane_Regions:
None

# Drug_Target_56_Cellular_Location:
Not Available

# Drug_Target_56_Chromosome_Location:
Not Available

# Drug_Target_56_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
Not Available

# Drug_Target_56_GenBank_ID_Gene:
Not Available

# Drug_Target_56_GenBank_ID_Protein:
Not Available

# Drug_Target_56_GeneCard_ID:
Not Available

# Drug_Target_56_Gene_Name:
ITPA

# Drug_Target_56_Gene_Sequence:
Not Available

# Drug_Target_56_General_Function:
Not Available

# Drug_Target_56_General_References:
Not Available

# Drug_Target_56_HGNC_ID:
Not Available

# Drug_Target_56_HPRD_ID:
Not Available

# Drug_Target_56_ID:
6953

# Drug_Target_56_Locus:
Not Available

# Drug_Target_56_Molecular_Weight:
Not Available

# Drug_Target_56_Name:
Inosine triphosphate pyrophosphatase

# Drug_Target_56_Number_of_Residues:
0

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Not Available

# Drug_Target_56_Pfam_Domain_Function:
Not Available

# Drug_Target_56_Protein_Sequence:
Not Available

# Drug_Target_56_Reaction:
Not Available

# Drug_Target_56_Signals:
Not Available

# Drug_Target_56_Specific_Function:
Not Available

# Drug_Target_56_SwissProt_ID:
Q9BY32

# Drug_Target_56_SwissProt_Name:
ITPA_HUMAN

# Drug_Target_56_Synonyms:
Not Available

# Drug_Target_56_Theoretical_pI:
Not Available

# Drug_Target_56_Transmembrane_Regions:
Not Available

# Drug_Target_57_Cellular_Location:
Not Available

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
Not Available

# Drug_Target_57_GenBank_ID_Gene:
Not Available

# Drug_Target_57_GenBank_ID_Protein:
Not Available

# Drug_Target_57_GeneCard_ID:
Not Available

# Drug_Target_57_Gene_Name:
CS

# Drug_Target_57_Gene_Sequence:
Not Available

# Drug_Target_57_General_Function:
Not Available

# Drug_Target_57_General_References:
Not Available

# Drug_Target_57_HGNC_ID:
Not Available

# Drug_Target_57_HPRD_ID:
Not Available

# Drug_Target_57_ID:
6969

# Drug_Target_57_Locus:
Not Available

# Drug_Target_57_Molecular_Weight:
Not Available

# Drug_Target_57_Name:
Citrate synthase, mitochondrial

# Drug_Target_57_Number_of_Residues:
0

# Drug_Target_57_PDB_ID:
Not Available

# Drug_Target_57_Pathway:
Not Available

# Drug_Target_57_Pfam_Domain_Function:
Not Available

# Drug_Target_57_Protein_Sequence:
Not Available

# Drug_Target_57_Reaction:
Not Available

# Drug_Target_57_Signals:
Not Available

# Drug_Target_57_Specific_Function:
Not Available

# Drug_Target_57_SwissProt_ID:
O75390

# Drug_Target_57_SwissProt_Name:
CISY_HUMAN

# Drug_Target_57_Synonyms:
Not Available

# Drug_Target_57_Theoretical_pI:
Not Available

# Drug_Target_57_Transmembrane_Regions:
Not Available

# Drug_Target_58_Cellular_Location:
Cytoplasmic

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
Not Available

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
Not Available

# Drug_Target_58_GenBank_ID_Gene:
X87673

# Drug_Target_58_GenBank_ID_Protein:
Not Available

# Drug_Target_58_GeneCard_ID:
Not Available

# Drug_Target_58_Gene_Name:
17

# Drug_Target_58_Gene_Sequence:
>558 bp
ATGAAGGGAAAAACAGCCGCAGGAGGCGGTGCAATTTGCGCTATCGCGGTGATGATTACC
ATCGTAATGGGTAATGGCAATGTGCGAACCAACCAGGCGGGGCTTGAGCTGATTGGTAAC
GCTGAAGGTTGCCGACGTGATCCATACATGTGCCCGGCGGGGGTATGGACTGACGGGATC
GGTAATACACACGGGGTAACGCCGGGTGTGCGAAAAACCGACCAGCAAATCGCCGCTGAT
TGGGAAAAGAATATCCTGATCGCTGAACGCTGTATTAATCAGCACTTCCGGGGCAAAGAC
ATGCCCGATAATGCCTTCAGCGCAATGACAAGCGCGGCATTCAATATGGGATGCAATAGC
TTACGGACCTACTACAGCAAAGCGCGAGGCATGCGAGTCGAAACGTCCATCCACAAGTGG
GCGCAGAAAGGGGAATGGGTGAATATGTGTAACCATCTCCCTGATTTCGTGAACAGTAAC
GGCGTGCCCCTGCGAGGTTTAAAGATTCGCCGTGAAAAAGAACGCCAGCTTTGCCTGACG
GGACTGGTCAATGAATAA

# Drug_Target_58_General_Function:
Involved in lysozyme activity

# Drug_Target_58_General_References:
8576044	Schmidt C, Velleman M, Arber W: Three functions of bacteriophage P1 involved in cell lysis. J Bacteriol. 1996 Feb;178(4):1099-104.

# Drug_Target_58_HGNC_ID:
Not Available

# Drug_Target_58_HPRD_ID:
Not Available

# Drug_Target_58_ID:
5597

# Drug_Target_58_Locus:
Not Available

# Drug_Target_58_Molecular_Weight:
20257

# Drug_Target_58_Name:
Lysozyme

# Drug_Target_58_Number_of_Residues:
185

# Drug_Target_58_PDB_ID:
1XJT

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF00959	Phage_lysozyme

# Drug_Target_58_Protein_Sequence:
>Lysozyme
MKGKTAAGGGAICAIAVMITIVMGNGNVRTNQAGLELIGNAEGCRRDPYMCPAGVWTDGI
GNTHGVTPGVRKTDQQIAADWEKNILIAERCINQHFRGKDMPDNAFSAMTSAAFNMGCNS
LRTYYSKARGMRVETSIHKWAQKGEWVNMCNHLPDFVNSNGVPLRGLKIRREKERQLCLT
GLVNE

# Drug_Target_58_Reaction:
Not Available

# Drug_Target_58_Signals:
None

# Drug_Target_58_Specific_Function:
Essential for lysis of bacterial cell wall, by showing cell wall hydrolyzing activity (By similarity)

# Drug_Target_58_SwissProt_ID:
Q37875

# Drug_Target_58_SwissProt_Name:
LYS_BPP1

# Drug_Target_58_Synonyms:
EC 3.2.1.17
Endolysin
Lysis protein
Muramidase
Protein gp17

# Drug_Target_58_Theoretical_pI:
9.15

# Drug_Target_58_Transmembrane_Regions:
None

# Drug_Target_59_Cellular_Location:
Golgi apparatus
Golgi apparatus membrane
single-pass type II membrane protein (Probable)

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
HS3ST3A1

# Drug_Target_59_GenBank_ID_Gene:
AF105376

# Drug_Target_59_GenBank_ID_Protein:
4835723

# Drug_Target_59_GeneCard_ID:
HS3ST3A1

# Drug_Target_59_Gene_Name:
HS3ST3A1

# Drug_Target_59_Gene_Sequence:
>1221 bp
ATGGCCCCTCCGGGCCCGGCCAGTGCCCTCTCCACCTCGGCCGAGCCGCTGTCCCGCAGC
ATCTTCCGGAAGTTCTTGCTGATGCTCTGCTCCCTGCTCACGTCCCTTTACGTCTTCTAC
TGCCTGGCCGAGCGCTGCCAGACCCTGTCCGGCCCCGTCGTGGGGCTGTCCGGCGGCGGC
GAGGAGGCGGGGGCCCCTGGTGGCGGCGTCCTGGCCGGAGGCCCGAGGGAGCTGGCGGTG
TGGCCGGCGGCGGCACAGAGAAAGCGCCTCCTGCAACTGCCGCAGTGGCGGAGGCGCCGG
CCGCCCGCGCCCCGCGACGACGGCGAGGAGGCGGCCTGGGAAGAAGAGTCCCCTGGCCTG
TCAGGGGGTCCGGGCGGCTCCGGGGCCGGAAGCACCGTGGCCGAGGCCCCGCCGGGGACC
CTGGCGCTGCTCCTGGACGAAGGCAGCAAGCAGCTGCCGCAGGCCATCATCATCGGAGTG
AAGAAGGGCGGCACGCGGGCGCTGCTGGAGTTCCTGCGCGTGCACCCCGACGTGCGCGCC
GTGGGCGCCGAGCCCCACTTCTTCGACCGCAGCTACGACAAGGGCCTCGCCTGGTACCGG
GACCTGATGCCCAGAACCCTGGACGGGCAGATCACCATGGAGAAGACGCCCAGTTACTTC
GTCACGCGGGAGGCCCCCGCGCGCATCTCGGCCATGTCCAAGGACACCAAGCTCATCGTG
GTGGTGCGGGACCCGGTGACCAGGGCCATCTCGGACTACACGCAGACGCTGTCCAAGCGG
CCCGACATCCCCACCTTCGAGAGCTTGACGTTCAAAAACAGGACAGCGGGCCTCATCGAC
ACGTCGTGGAGCGCCATCCAGATCGGCATCTACGCCAAGCACCTGGAGCACTGGCTGCGC
CACTTCCCCATCCGCCAGATGCTCTTCGTGAGCGGCGAGCGGCTCATCAGCGACCCGGCC
GGGGAGCTGGGCCGCGTGCAAGACTTCCTGGGCCTCAAGAGGATCATCACGGACAAGCAC
TTCTACTTCAACAAGACCAAGGGCTTCCCCTGCCTGAAGAAGGCGGAGGGCAGCAGCCGG
CCCCATTGCCTGGGCAAGACCAAGGGCAGGACCCATCCTGAGATCGACCGCGAGGTGGTG
CGCAGGCTGCGCGAGTTCTACCGGCCTTTCAACCTCAAGTTCTACCAGATGACCGGGCAC
GACTTTGGCTGGGATGGATAA

# Drug_Target_59_General_Function:
Involved in sulfotransferase activity

# Drug_Target_59_General_References:
10520990	Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG: A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999 Oct 1;99(1):13-22.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
9988767	Shworak NW, Liu J, Petros LM, Zhang L, Kobayashi M, Copeland NG, Jenkins NA, Rosenberg RD: Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem. 1999 Feb 19;274(8):5170-84.
9988768	Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, Rosenberg RD: Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem. 1999 Feb 19;274(8):5185-92.

# Drug_Target_59_HGNC_ID:
HGNC:5196

# Drug_Target_59_HPRD_ID:
04958

# Drug_Target_59_ID:
2805

# Drug_Target_59_Locus:
17p12-p11.2

# Drug_Target_59_Molecular_Weight:
44900

# Drug_Target_59_Name:
Heparan sulfate glucosamine 3-O-sulfotransferase 3A1

# Drug_Target_59_Number_of_Residues:
406

# Drug_Target_59_PDB_ID:
1T8U

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
PF00685	Sulfotransfer_1

# Drug_Target_59_Protein_Sequence:
>Heparan sulfate glucosamine 3-O-sulfotransferase 3A1
MAPPGPASALSTSAEPLSRSIFRKFLLMLCSLLTSLYVFYCLAERCQTLSGPVVGLSGGG
EEAGAPGGGVLAGGPRELAVWPAAAQRKRLLQLPQWRRRRPPAPRDDGEEAAWEEESPGL
SGGPGGSGAGSTVAEAPPGTLALLLDEGSKQLPQAIIIGVKKGGTRALLEFLRVHPDVRA
VGAEPHFFDRSYDKGLAWYRDLMPRTLDGQITMEKTPSYFVTREAPARISAMSKDTKLIV
VVRDPVTRAISDYTQTLSKRPDIPTFESLTFKNRTAGLIDTSWSAIQIGIYAKHLEHWLR
HFPIRQMLFVSGERLISDPAGELGRVQDFLGLKRIITDKHFYFNKTKGFPCLKKAEGSSR
PHCLGKTKGRTHPEIDREVVRRLREFYRPFNLKFYQMTGHDFGWDG

# Drug_Target_59_Reaction:
3'-phosphoadenylyl sulfate + [heparan sulfate]-glucosamine = adenosine 3',5'-bisphosphate + [heparan sulfate]-glucosamine 3-sulfate

# Drug_Target_59_Signals:
None

# Drug_Target_59_Specific_Function:
Transfers a sulfuryl group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate. Catalyzes the O-sulfation of glucosamine in IdoUA2S-GlcNS and also in IdoUA2S-GlcNH2. The substrate-specific O-sulfation generates an enzyme-modified heparan sulfate which acts as a binding receptor to Herpes simplex virus-1 (HSV-1) and permits its entry. Unlike 3-OST-1, does not convert non-anticoagulant heparan sulfate to anticoagulant heparan sulfate

# Drug_Target_59_SwissProt_ID:
Q9Y663

# Drug_Target_59_SwissProt_Name:
HS3SA_HUMAN

# Drug_Target_59_Synonyms:
EC 2.8.2.30
Heparan sulfate 3-O-sulfotransferase 3A1
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1
h3-OST-3A

# Drug_Target_59_Theoretical_pI:
9.98

# Drug_Target_59_Transmembrane_Regions:
25-43

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
D25414

# Drug_Target_5_GenBank_ID_Protein:
538227

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
nfnB

# Drug_Target_5_Gene_Sequence:
>654 bp
ATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAA
AAACTTACCCCGGAACAGGCCGAGCAGATCAAAACGCTACTGCAATACAGCCCATCCAGC
ACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTT
GCCAAATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCAC
GTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGAAGCTGGTTGTTGAC
CAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGT
CGCAAGTTCTTCGCTGATATGCACCGTAAAGATCTGCATGATGATGCAGAGTGGATGGCA
AAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGAC
GCGGTACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAG
AAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATCACAGCGTTGAAGATTTTAAC
GCTACGCTGCCGAAATCTCGTCTGCCGCAAAACATCACCTTAACCGAAGTGTAA

# Drug_Target_5_General_Function:
Energy production and conversion

# Drug_Target_5_General_References:
11020276	Parkinson GN, Skelly JV, Neidle S: Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J Med Chem. 2000 Oct 5;43(20):3624-31.
1472094	Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ: The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol. 1992 Dec 15;44(12):2289-95.
3060113	Vasudevan SG, Shaw DC, Armarego WL: Dihydropteridine reductase from Escherichia coli. Biochem J. 1988 Oct 15;255(2):581-8.
7813889	Michael NP, Brehm JK, Anlezark GM, Minton NP: Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiol Lett. 1994 Dec 1;124(2):195-202.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
2936

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
23905

# Drug_Target_5_Name:
Oxygen-insensitive NAD(P)H nitroreductase

# Drug_Target_5_Number_of_Residues:
217

# Drug_Target_5_PDB_ID:
1YLU

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_5_Protein_Sequence:
>Oxygen-insensitive NAD(P)H nitroreductase
MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIVASTEEGKARV
AKSAAGNYVFNERKMLDASHVVVFCAKTAMDDVWLKLVVDQEDADGRFATPEAKAANDKG
RKFFADMHRKDLHDDAEWMAKQVYLNVGNFLLGVAALGLDAVPIEGFDAAILDAEFGLKE
KGYTSLVVVPVGHHSVEDFNATLPKSRLPQNITLTEV

# Drug_Target_5_Reaction:
a 5,6,7,8-tetrahydropteridine + NAD(P)+ = a 6,7-dihydropteridine + NAD(P)H + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred. Capable of reducing nitrofurazone, quinones and the anti-tumor agent CB1954 (5- (aziridin-1-yl)-2,4-dinitrobenzamide). The reduction of CB1954 results in the generation of cytotoxic species

# Drug_Target_5_SwissProt_ID:
P38489

# Drug_Target_5_SwissProt_Name:
NFNB_ECOLI

# Drug_Target_5_Synonyms:
Dihydropteridine reductase
EC 1.-.-.-
EC 1.5.1.34
FMN-dependent nitroreductase

# Drug_Target_5_Theoretical_pI:
6.16

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_60_Cellular_Location:
Not Available

# Drug_Target_60_Chromosome_Location:
Not Available

# Drug_Target_60_Drug_References:
Not Available

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
Not Available

# Drug_Target_60_GenBank_ID_Gene:
AE000512

# Drug_Target_60_GenBank_ID_Protein:
Not Available

# Drug_Target_60_GeneCard_ID:
Not Available

# Drug_Target_60_Gene_Name:
TM_1436

# Drug_Target_60_Gene_Sequence:
>531 bp
TCATGGTAGAAACTTCATCTTCCAGAGGATTCTTGAACTTGTAGAGATCGCTGAAACGTG
TTTGAGGATTTCGCGAGCTTCTTCCTCTGTTTCAACGAGCCCGGCGGCGATCACTGTCCT
GCCGGGTATTTTTCTGGCCACTTTCGGAGCCACCGCACCTGGAAGGACTTCCACCACATC
TACCCCGAGCGTTTCTATCTGTTCGATACCTCTTTCGACCGCTTTCGAGTCGAGAGCAAA
GAATCTGAGGACAGCGGGAATTCCGTTCTTCTTTGCAACGACGTAATTTTTTGGCTTTAT
CGTGATGATACCATCGGCACCGGCCTTTTTCACAAAAAGAATCGCTTCTTCTCCCTCTCC
TAGTCCGTTCACAAAATCCATATCAACAAAAACGGTTTTTCCCCTGTCTTTGAGAATCTT
CAGATGAAACTTCAGATTCAAAATGTCGCTCTTCAAAAGGAAGACCACATCGGGTTCTAT
TTCTCCTATGGAATCCATATCCCACAGCGCAGCTATTATCCCCTTGAACAT

# Drug_Target_60_General_Function:
Involved in transcription regulator activity

# Drug_Target_60_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_60_HGNC_ID:
Not Available

# Drug_Target_60_HPRD_ID:
Not Available

# Drug_Target_60_ID:
5598

# Drug_Target_60_Locus:
Not Available

# Drug_Target_60_Molecular_Weight:
19297

# Drug_Target_60_Name:
Glycerol uptake operon antiterminator-related protein

# Drug_Target_60_Number_of_Residues:
176

# Drug_Target_60_PDB_ID:
1VKF

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
PF04309	G3P_antiterm

# Drug_Target_60_Protein_Sequence:
>Glycerol uptake operon antiterminator-related protein
MFKGIIAALWDMDSIGEIEPDVVFLLKSDILNLKFHLKILKDRGKTVFVDMDFVNGLGEG
EEAILFVKKAGADGIITIKPKNYVVAKKNGIPAVLRFFALDSKAVERGIEQIETLGVDVV
EVLPGAVAPKVARKIPGRTVIAAGLVETEEEAREILKHVSAISTSSRILWKMKFLP

# Drug_Target_60_Reaction:
Not Available

# Drug_Target_60_Signals:
None

# Drug_Target_60_Specific_Function:
Not Available

# Drug_Target_60_SwissProt_ID:
Q9X1F0

# Drug_Target_60_SwissProt_Name:
Q9X1F0_THEMA

# Drug_Target_60_Synonyms:
Not Available

# Drug_Target_60_Theoretical_pI:
8.94

# Drug_Target_60_Transmembrane_Regions:
None

# Drug_Target_61_Cellular_Location:
Cytoplasmic

# Drug_Target_61_Chromosome_Location:
Not Available

# Drug_Target_61_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_61_Essentiality:
Non-Essential

# Drug_Target_61_GenAtlas_ID:
PDE5A

# Drug_Target_61_GenBank_ID_Gene:
AF043731

# Drug_Target_61_GenBank_ID_Protein:
3420185

# Drug_Target_61_GeneCard_ID:
PDE5A

# Drug_Target_61_Gene_Name:
PDE5A

# Drug_Target_61_Gene_Sequence:
>2628 bp
ATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAG
AAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTT
ACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAG
AGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCT
TGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGTCCCTGGAACACCAACCAGGAAA
ATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGA
ACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGG
TTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCT
AGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATA
TCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTT
ATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGT
ATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTG
AACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGC
TACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGT
GTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAA
AAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTAT
GAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATT
TTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCT
TTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTT
TCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGG
GAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAA
CCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACA
GGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAG
AAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAG
GTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGC
TTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATG
GTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTA
CAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGC
TTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACT
GACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTA
AGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAAT
ACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGAC
CTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTG
AATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATC
ATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATT
CTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATT
TTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGA
AAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATG
ACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAA
CTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAA
CCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTC
ATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTC
CCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAG
GAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGA

# Drug_Target_61_General_Function:
Involved in catalytic activity

# Drug_Target_61_General_References:
10393044	Zhou L, Thompson WJ, Potter DE: Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1745-52.
12955149	Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003 Sep 4;425(6953):98-102.
9642111	Stacey P, Rulten S, Dapling A, Phillips SC: Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun. 1998 Jun 18;247(2):249-54.
9714779	Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene. 1998 Aug 17;216(1):139-47.
9716380	Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, Omori K: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem. 1998 Jul 15;255(2):391-9.

# Drug_Target_61_HGNC_ID:
HGNC:8784

# Drug_Target_61_HPRD_ID:
04497

# Drug_Target_61_ID:
204

# Drug_Target_61_Locus:
4q25-q27

# Drug_Target_61_Molecular_Weight:
100014

# Drug_Target_61_Name:
cGMP-specific 3',5'-cyclic phosphodiesterase

# Drug_Target_61_Number_of_Residues:
875

# Drug_Target_61_PDB_ID:
1T9R

# Drug_Target_61_Pathway:
Not Available

# Drug_Target_61_Pfam_Domain_Function:
PF00233	PDEase_I
PF01590	GAF

# Drug_Target_61_Protein_Sequence:
>cGMP-specific 3',5'-cyclic phosphodiesterase
MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAE
RVHTIPVCKEGIRGHTESCSCPLQQSPRADNSVPGTPTRKISASEFDRPLRPIVVKDSEG
TVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLI
SADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPL
NIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDE
KDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIIS
FMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTME
PLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGK
VKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETREL
QSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWIL
SVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGV
NNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAI
LATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAE
LVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCF
PLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN

# Drug_Target_61_Reaction:
guanosine 3',5'-cyclic phosphate + H2O = guanosine 5'-phosphate

# Drug_Target_61_Signals:
None

# Drug_Target_61_Specific_Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'- GMP

# Drug_Target_61_SwissProt_ID:
O76074

# Drug_Target_61_SwissProt_Name:
PDE5A_HUMAN

# Drug_Target_61_Synonyms:
CGB-PDE
EC 3.1.4.35
cGMP-binding cGMP-specific phosphodiesterase

# Drug_Target_61_Theoretical_pI:
6.00

# Drug_Target_61_Transmembrane_Regions:
None

# Drug_Target_62_Cellular_Location:
Cytoplasm

# Drug_Target_62_Chromosome_Location:
Not Available

# Drug_Target_62_Drug_References:
Not Available

# Drug_Target_62_Essentiality:
Non-Essential

# Drug_Target_62_GenAtlas_ID:
Not Available

# Drug_Target_62_GenBank_ID_Gene:
L17082

# Drug_Target_62_GenBank_ID_Protein:
Not Available

# Drug_Target_62_GeneCard_ID:
Not Available

# Drug_Target_62_Gene_Name:
pcaB

# Drug_Target_62_Gene_Sequence:
>1224 bp
ATGACCAACCAACTGTTCGACGCCTACTTCACCGCGCCGGCCATGCGCGAGATTTTCTCC
GACCGTGGCCGCTTGCAGGGCATGCTCGATTTCGAAGCCGCGCTGGCCCGTGCCGAAGCT
GCTGCGGGGCTGGTCCCGCACAGCGCCGTGGCCGCCATCGAGGCGGCATGCAAGGCCGAG
CGCTATGACGTGGGGGCGCTGGCCAATGCCATCGCAACCGCTGGCAACTCGGCAATCCCG
CTGGTGAAGGCGTTGGGCAAGGTGATTGCCAGTGGCGTGCCCGAGGCCGAGCGCTATGTG
CACTTGGGCGCCACCAGCCAGGACGCGATGGACACCGGTCTGGTGTTGCAGTTGCGCGAT
GCCCTCGACCTGATCGAAGCGGACCTGGGCAAACTGGCCGATACCCTGTCGCAGCAGGCA
TTGAAGCACGCCGATACGCCAATGGTGGGCCGCACCTGGCTGCAACACGCTACCCCGGTG
ACCCTGGGCATGAAACTGGCTGGCGTGCTGGGGGCATTGACCCGCCACCGTCAGCGCCTG
CAAGAGCTCGGCCCGCCCTGTTGGTGCTGCAGTTCCGGCGGCGCCTCGGGCAGCCTGGCC
GCTCTGGGCAGCAAGGCGATGCCGGTGGCCGAGGCCCTGGCCGAGCAACTGAAGCTGAGC
CTGCCCGAGCAACCCTGGCACACCCAGCGTGATCGCCTGGTGGAGTTTGCCTCGGTGCTG
GGCCTTGTGGCCGGCAGCCTGGGCAAGTTCGGCCGCGATGTCAGCCTGCTGATGCAAACC
GAGGCGGGGGAGGTGTTCGAGCCTTCTGCACCAGGCAAGGGCGGCTCCTCGACCATGCCA
CACAAGCGCAACCCGGTGGGCGCTGCGGTGCTGATCGGTGCCGCGACTCGCGTGCCGGGG
CTGGTATCGACGCTGTTCGCCGCCATGCCCCAGGAGCACGAGCGCAGCCTGGGCCTGTGG
CATGCCGAATGGGAAACCCTCCCGGACATCTGCTGCCTGGTCTCCGGCGCGCTGCGCCAG
GCCCAGGTCATTGCCGAGGGCATTGAAGTAGACGCAGCGCGCATGCGCCGTAACCTCGAC
CTGACCCAAGGGCTGGTGCTGGCAGAAGCGGTGAGTATCGTCCTGGCCCGAACGCCTGGG
CCGCGACCGTGCCCACCACTTGCTGGAGCAATGCTGCCAGCGAGCCGTGGCCGAACAGCG
GCACCTGCGTGCGGTGCTGGGTGA

# Drug_Target_62_General_Function:
Involved in catalytic activity

# Drug_Target_62_General_References:
1390752	Williams SE, Woolridge EM, Ransom SC, Landro JA, Babbitt PC, Kozarich JW: 3-Carboxy-cis,cis-muconate lactonizing enzyme from Pseudomonas putida is homologous to the class II fumarase family: a new reaction in the evolution of a mechanistic motif. Biochemistry. 1992 Oct 13;31(40):9768-76.

# Drug_Target_62_HGNC_ID:
Not Available

# Drug_Target_62_HPRD_ID:
Not Available

# Drug_Target_62_ID:
5599

# Drug_Target_62_Locus:
Not Available

# Drug_Target_62_Molecular_Weight:
44677

# Drug_Target_62_Name:
3-carboxy-cis,cis-muconate cycloisomerase

# Drug_Target_62_Number_of_Residues:
422

# Drug_Target_62_PDB_ID:
1RE5

# Drug_Target_62_Pathway:
Not Available

# Drug_Target_62_Pfam_Domain_Function:
PF00206	Lyase_1

# Drug_Target_62_Protein_Sequence:
>3-carboxy-cis,cis-muconate cycloisomerase
MTNQLFDAYFTAPAMREIFSDRGRLQGMLDFEAALARAEAAAGLVPHSAVAAIEAACKAE
RYDVGALANAIATAGNSAIPLVKALGKVIASGVPEAERYVHLGATSQDAMDTGLVLQLRD
ALDLIEADLGKLADTLSQQALKHADTPMVGRTWLQHATPVTLGMKLAGVLGALTRHRQRL
QELGPPCWCCSSGGASGSLAALGSKAMPVAEALAEQLKLSLPEQPWHTQRDRLVEFASVL
GLVAGSLGKFGRDVSLLMQTEAGEVFEPSAPGKGGSSTMPHKRNPVGAAVLIGAATRVPG
LVSTLFAAMPQEHERSLGLWHAEWETLPDICCLVSGALRQAQVIAEGIEVDAARMRRNLD
LTQGLVLAEAVSIVLARTLGRDRAHHLLEQCCQRAVAEQRHLRAVLGDDPQVSAELSAEE
LD

# Drug_Target_62_Reaction:
Not Available

# Drug_Target_62_Signals:
None

# Drug_Target_62_Specific_Function:
Catalyzes an anti cycloisomerization

# Drug_Target_62_SwissProt_ID:
P32427

# Drug_Target_62_SwissProt_Name:
PCAB_PSEPU

# Drug_Target_62_Synonyms:
3- carboxymuconate lactonizing enzyme
CMLE
EC 5.5.1.2

# Drug_Target_62_Theoretical_pI:
5.93

# Drug_Target_62_Transmembrane_Regions:
None

# Drug_Target_63_Cellular_Location:
Not Available

# Drug_Target_63_Chromosome_Location:
Not Available

# Drug_Target_63_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_63_Essentiality:
Non-Essential

# Drug_Target_63_GenAtlas_ID:
SRC

# Drug_Target_63_GenBank_ID_Gene:
AL133293

# Drug_Target_63_GenBank_ID_Protein:
10635153

# Drug_Target_63_GeneCard_ID:
SRC

# Drug_Target_63_Gene_Name:
SRC

# Drug_Target_63_Gene_Sequence:
>1611 bp
ATGGGTAGCAACAAGAGCAAGCCCAAGGATGCCAGCCAGCGGCGCCGCAGCCTGGAGCCC
GCCGAGAACGTGCACGGCGCTGGCGGGGGCGCTTTCCCCGCCTCGCAGACCCCCAGCAAG
CCAGCCTCGGCCGACGGCCACCGCGGCCCCAGCGCGGCCTTCGCCCCCGCGGCCGCCGAG
CCCAAGCTGTTCGGAGGCTTCAACTCCTCGGACACCGTCACCTCCCCGCAGAGGGCGGGC
CCGCTGGCCGGTGGAGTGACCACCTTTGTGGCCCTCTATGACTATGAGTCTAGGACGGAG
ACAGACCTGTCCTTCAAGAAAGGCGAGCGGCTCCAGATTGTCAACAACACAGAGGGAGAC
TGGTGGCTGGCCCACTCGCTCAGCACAGGACAGACAGGCTACATCCCCAGCAACTACGTG
GCGCCCTCCGACTCCATCCAGGCTGAGGAGTGGTATTTTGGCAAGATCACCAGACGGGAG
TCAGAGCGGTTACTGCTCAATGCAGAGAACCCGAGAGGGACCTTCCTCGTGCGAGAAAGT
GAGACCACGAAAGGTGCCTACTGCCTCTCAGTGTCTGACTTCGACAACGCCAAGGGCCTC
AACGTGAAGCACTACAAGATCCGCAAGCTGGACAGCGGCGGCTTCTACATCACCTCCCGC
ACCCAGTTCAACAGCCTGCAGCAGCTGGTGGCCTACTACTCCAAACACGCCGATGGCCTG
TGCCACCGCCTCACCACCGTGTGCCCCACGTCCAAGCCGCAGACTCAGGGCCTGGCCAAG
GATGCCTGGGAGATCCCTCGGGAGTCGCTGCGGCTGGAGGTCAAGCTGGGCCAGGGCTGC
TTTGGCGAGGTGTGGATGGGGACCTGGAACGGTACCACCAGGGTGGCCATCAAAACCCTG
AAGCCTGGCACGATGTCTCCAGAGGCCTTCCTGCAGGAGGCCCAGGTCATGAAGAAGCTG
AGGCATGAGAAGCTGGTGCAGTTGTATGCTGTGGTTTCAGAGGAGCCCATTTACATCGTC
ACGGAGTACATGAGCAAGGGGAGTTTGCTGGACTTTCTCAAGGGGGAGACAGGCAAGTAC
CTGCGGCTGCCTCAGCTGGTGGACATGGCTGCTCAGATCGCCTCAGGCATGGCGTACGTG
GAGCGGATGAACTACGTCCACCGGGACCTTCGTGCAGCCAACATCCTGGTGGGAGAGAAC
CTGGTGTGCAAAGTGGCGGACTTTGGGCTGGCTCGGCTCATTGAAGACAATGAGTACACG
GCGCGGCAAGGTGCCAAATTCCCCATCAAGTGGACGGCTCCAGAAGCTGCCCTCTATGGC
CGCTTCACCATCAAGTCGGACGTGTGGTCCTTCGGGATCCTGCTGACTGAGCTCACCACA
AAGGGACGGGTGCCCTACCCTGGGATGGTGAACCGCGAGGTGCTGGACCAGGTGGAGCGG
GGCTACCGGATGCCCTGCCCGCCGGAGTGTCCCGAGTCCCTGCACGACCTCATGTGCCAG
TGCTGGCGGAAGGAGCCTGAGGAGCGGCCCACCTTCGAGTACCTGCAGGCCTTCCTGGAG
GACTACTTCACGTCCACCGAGCCCCAGTACCAGCCCGGGGAGAACCTCTAG

# Drug_Target_63_General_Function:
Involved in protein kinase activity

# Drug_Target_63_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
12415108	Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.
2581127	Parker RC, Mardon G, Lebo RV, Varmus HE, Bishop JM: Isolation of duplicated human c-src genes located on chromosomes 1 and 20. Mol Cell Biol. 1985 Apr;5(4):831-8.
2582238	Anderson SK, Gibbs CP, Tanaka A, Kung HJ, Fujita DJ: Human cellular src gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-terminal two-thirds of pp60c-src. Mol Cell Biol. 1985 May;5(5):1122-9.
2681803	Pyper JM, Bolen JB: Neuron-specific splicing of C-SRC RNA in human brain. J Neurosci Res. 1989 Sep;24(1):89-96.
3299057	Tanaka A, Gibbs CP, Arthur RR, Anderson SK, Kung HJ, Fujita DJ: DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes. Mol Cell Biol. 1987 May;7(5):1978-83.
7532003	Xu RX, Word JM, Davis DG, Rink MJ, Willard DH Jr, Gampe RT Jr: Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide. Biochemistry. 1995 Feb 21;34(7):2107-21.
9024657	Xu W, Harrison SC, Eck MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature. 1997 Feb 13;385(6617):595-602.
9174343	Charifson PS, Shewchuk LM, Rocque W, Hummel CW, Jordan SR, Mohr C, Pacofsky GJ, Peel MR, Rodriguez M, Sternbach DD, Consler TG: Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural study. Biochemistry. 1997 May 27;36(21):6283-93.

# Drug_Target_63_HGNC_ID:
11283

# Drug_Target_63_HPRD_ID:
01819

# Drug_Target_63_ID:
933

# Drug_Target_63_Locus:
20q12-q13

# Drug_Target_63_Molecular_Weight:
59704

# Drug_Target_63_Name:
Proto-oncogene tyrosine-protein kinase Src

# Drug_Target_63_Number_of_Residues:
535

# Drug_Target_63_PDB_ID:
2SRC

# Drug_Target_63_Pathway:
Not Available

# Drug_Target_63_Pfam_Domain_Function:
PF00017	SH2
PF00018	SH3_1
PF07714	Pkinase_Tyr

# Drug_Target_63_Protein_Sequence:
>Proto-oncogene tyrosine-protein kinase Src
GSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAAEP
KLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDW
WLAHSLSTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNAENPRGTFLVRESE
TTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLVAYYSKHADGLC
HRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLK
PGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGETGKYL
RLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTA
RQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVERG
YRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQPGENL

# Drug_Target_63_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_63_Signals:
None

# Drug_Target_63_Specific_Function:
Not Available

# Drug_Target_63_SwissProt_ID:
P12931

# Drug_Target_63_SwissProt_Name:
SRC_HUMAN

# Drug_Target_63_Synonyms:
EC 2.7.10.2
c- Src
p60-Src
pp60c-src

# Drug_Target_63_Theoretical_pI:
7.47

# Drug_Target_63_Transmembrane_Regions:
None

# Drug_Target_64_Cellular_Location:
Not Available

# Drug_Target_64_Chromosome_Location:
Not Available

# Drug_Target_64_Drug_References:
Not Available

# Drug_Target_64_Essentiality:
Non-Essential

# Drug_Target_64_GenAtlas_ID:
Not Available

# Drug_Target_64_GenBank_ID_Gene:
M15368

# Drug_Target_64_GenBank_ID_Protein:
Not Available

# Drug_Target_64_GeneCard_ID:
Not Available

# Drug_Target_64_Gene_Name:
pdc

# Drug_Target_64_Gene_Sequence:
>1707 bp
ATGAGTTATACTGTCGGTACCTATTTAGCGGAGCGGCTTGTCCAGATTGGTCTCAAGCAT
CACTTCGCAGTCGCGGGCGACTACAACCTCGTCCTTCTTGACAACCTGCTTTTGAACAAA
AACATGGAGCAGGTTTATTGCTGTAACGAACTGAACTGCGGTTTCAGTGCAGAAGGTTAT
GCTCGTGCCAAAGGCGCAGCAGCAGCCGTCGTTACCTACAGCGTCGGTGCGCTTTCCGCA
TTTGATGCTATCGGTGGCGCCTATGCAGAAAACCTTCCGGTTATCCTGATCTCCGGTGCT
CCGAACAACAATGATCACGCTGCTGGTCACGTGTTGCATCACGCTCTTGGCAAAACCGAC
TATCACTATCAGTTGGAAATGGCCAAGAACATCACGGCCGCCGCTGAAGCGATTTACACC
CCGGAAGAAGCTCCGGCTAAAATCGATCACGTGATTAAAACTGCTCTTCGTGAGAAGAAG
CCGGTTTATCTCGAAATCGCTTGCAACATTGCTTCCATGCCCTGCGCCGCTCCTGGACCG
GCAAGCGCATTGTTCAATGACGAAGCCAGCGACGAAGCTTCTTTGAATGCAGCGGTTGAA
GAAACCCTGAAATTCATCGCCAACCGCGACAAAGTTGCCGTCCTCGTCGGCAGCAAGCTG
CGCGCAGCTGGTGCTGAAGAAGCTGCTGTCAAATTTGCTGATGCTCTCGGTGGCGCAGTT
GCTACCATGGCTGCTGCAAAAAGCTTCTTTCCAGAAGAAAACCCGCATTACATCGGCACC
TCATGGGGTGAAGTCAGCTATCCGGGCGTTGAAAAGACGATGAAAGAAGCCGATGCGGTT
ATCGCTCTGGCTCCTGTCTTCAACGACTACTCCACCACTGGTTGGACGGATATTCCTGAT
CCTAAGAAACTGGTTCTCGCTGAACCGCGTTCTGTCGTCGTTAACGGCATTCGCTTCCCC
AGCGTCCATCTGAAAGACTATCTGACCCGTTTGGCTCAGAAAGTTTCCAAGAAAACCGGT
GCATTGGACTTCTTCAAATCCCTCAATGCAGGTGAACTGAAGAAAGCCGCTCCGGCTGAT
CCGAGTGCTCCGTTGGTCAACGCAGAAATCGCCCGCCAAGTCGAAGCTCTTCTGACCCCG
AACACGACGGTTATTGCTGAAACCGGTGACTCTTGGTTCAATGCTCAGCGCATGAAGCTC
CCGAACGGTGCTCGCGTTGAATATGAAATGCAGTGGGGTCACATTGGTTGGTCCGTTCCT
GCCGCCTTCGGTTATGCCGTCGGTGCTCCGGAACGTCGCAACATCCTCATGGTTGGTGAT
GGTTCCTTCCAGCTGACGGCTCAGGAAGTCGCTCAGATGGTTCGCCTGAAACTGCCGGTT
ATCATCTTCTTGATCAATAACTATGGTTACACCATCGAAGTTATGATCCATGATGGTCCG
TACAACAACATCAAGAACTGGGATTATGCCGGTCTGATGGAAGTGTTCAACGGTAACGGT
GGTTATGACAGCGGTGCTGGTAAAGGCCTGAAGGCTAAAACCGGTGGCGAACTGGCAGAA
GCTATCAAGGTTGCTCTGGCAAACACCGACGGCCCAACCCTGATCGAATGCTTCATCGGT
CGTGAAGACTGCACTGAAGAATTGGTCAAATGGGGTAAGCGCGTTGCTGCCGCCAACAGC
CGTAAGCCTGTTAACAAGCTCCTCTAG

# Drug_Target_64_General_Function:
Involved in magnesium ion binding

# Drug_Target_64_General_References:
2838467	Reynen M, Sahm H: Comparison of the structural genes for pyruvate decarboxylase in different Zymomonas mobilis strains. J Bacteriol. 1988 Jul;170(7):3310-3.
3029037	Conway T, Osman YA, Konnan JI, Hoffmann EM, Ingram LO: Promoter and nucleotide sequences of the Zymomonas mobilis pyruvate decarboxylase. J Bacteriol. 1987 Mar;169(3):949-54.
3029726	Neale AD, Scopes RK, Wettenhall RE, Hoogenraad NJ: Nucleotide sequence of the pyruvate decarboxylase gene from Zymomonas mobilis. Nucleic Acids Res. 1987 Feb 25;15(4):1753-61.
3546263	Neale AD, Scopes RK, Wettenhall RE, Hoogenraad NJ: Pyruvate decarboxylase of Zymomonas mobilis: isolation, properties, and genetic expression in Escherichia coli. J Bacteriol. 1987 Mar;169(3):1024-8.
8645153	Candy JM, Koga J, Nixon PF, Duggleby RG: The role of residues glutamate-50 and phenylalanine-496 in Zymomonas mobilis pyruvate decarboxylase. Biochem J. 1996 May 1;315 ( Pt 3):745-51.
9655927	Candy JM, Duggleby RG: Structure and properties of pyruvate decarboxylase and site-directed mutagenesis of the Zymomonas mobilis enzyme. Biochim Biophys Acta. 1998 Jun 29;1385(2):323-38.

# Drug_Target_64_HGNC_ID:
Not Available

# Drug_Target_64_HPRD_ID:
Not Available

# Drug_Target_64_ID:
5600

# Drug_Target_64_Locus:
Not Available

# Drug_Target_64_Molecular_Weight:
60926

# Drug_Target_64_Name:
Pyruvate decarboxylase

# Drug_Target_64_Number_of_Residues:
568

# Drug_Target_64_PDB_ID:
1ZPD

# Drug_Target_64_Pathway:
Not Available

# Drug_Target_64_Pfam_Domain_Function:
PF00205	TPP_enzyme_M
PF02775	TPP_enzyme_C
PF02776	TPP_enzyme_N

# Drug_Target_64_Protein_Sequence:
>Pyruvate decarboxylase
MSYTVGTYLAERLVQIGLKHHFAVAGDYNLVLLDNLLLNKNMEQVYCCNELNCGFSAEGY
ARAKGAAAAVVTYSVGALSAFDAIGGAYAENLPVILISGAPNNNDHAAGHVLHHALGKTD
YHYQLEMAKNITAAAEAIYTPEEAPAKIDHVIKTALREKKPVYLEIACNIASMPCAAPGP
ASALFNDEASDEASLNAAVEETLKFIANRDKVAVLVGSKLRAAGAEEAAVKFADALGGAV
ATMAAAKSFFPEENPHYIGTSWGEVSYPGVEKTMKEADAVIALAPVFNDYSTTGWTDIPD
PKKLVLAEPRSVVVNGIRFPSVHLKDYLTRLAQKVSKKTGALDFFKSLNAGELKKAAPAD
PSAPLVNAEIARQVEALLTPNTTVIAETGDSWFNAQRMKLPNGARVEYEMQWGHIGWSVP
AAFGYAVGAPERRNILMVGDGSFQLTAQEVAQMVRLKLPVIIFLINNYGYTIEVMIHDGP
YNNIKNWDYAGLMEVFNGNGGYDSGAGKGLKAKTGGELAEAIKVALANTDGPTLIECFIG
REDCTEELVKWGKRVAAANSRKPVNKLL

# Drug_Target_64_Reaction:
Not Available

# Drug_Target_64_Signals:
None

# Drug_Target_64_Specific_Function:
A 2-oxo acid = an aldehyde + CO(2)

# Drug_Target_64_SwissProt_ID:
P06672

# Drug_Target_64_SwissProt_Name:
PDC_ZYMMO

# Drug_Target_64_Synonyms:
EC 4.1.1.1
PDC

# Drug_Target_64_Theoretical_pI:
5.96

# Drug_Target_64_Transmembrane_Regions:
None

# Drug_Target_65_Cellular_Location:
Secreted protein

# Drug_Target_65_Chromosome_Location:
Not Available

# Drug_Target_65_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_65_Essentiality:
Non-Essential

# Drug_Target_65_GenAtlas_ID:
RNASE1

# Drug_Target_65_GenBank_ID_Gene:
D26129

# Drug_Target_65_GenBank_ID_Protein:
Not Available

# Drug_Target_65_GeneCard_ID:
Not Available

# Drug_Target_65_Gene_Name:
RNASE1

# Drug_Target_65_Gene_Sequence:
>471 bp
ATGGCTCTGGAGAAGTCTCTTGTCCGGCTCCTTCTGCTTGTCCTGATACTGCTGGTGCTG
GGCTGGGTCCAGCCTTCCCTGGGCAAGGAATCCCGGGCCAAGAAATTCCAGCGGCAGCAT
ATGGACTCAGACAGTTCCCCCAGCAGCAGCTCCACCTACTGTAACCAAATGATGAGGCGC
CGGAATATGACACAGGGGCGGTGCAAACCAGTGAACACCTTTGTGCACGAGCCCCTGGTA
GATGTCCAGAATGTCTGTTTCCAGGAAAAGGTCACCTGCAAGAACGGGCAGGGCAACTGC
TACAAGAGCAACTCCAGCATGCACATCACAGACTGCCGCCTGACAAACGGCTCCAGGTAC
CCCAACTGTGCATACCGGACCAGCCCGAAGGAGAGACACATCATTGTGGCCTGTGAAGGG
AGCCCATATGTGCCAGTCCACTTTGATGCTTCTGTGGAGGACTCTACCTAA

# Drug_Target_65_General_Function:
Involved in nucleic acid binding

# Drug_Target_65_General_References:
1741299	Haugg M, Schein CH: The DNA sequences of the human and hamster secretory ribonucleases determined with the polymerase chain reaction (PCR). Nucleic Acids Res. 1992 Feb 11;20(3):612.
2049798	Sakakibara R, Hashida K, Tominaga N, Sakai K, Ishiguro M, Imamura S, Ohmatsu F, Sato E: A putative mouse oocyte maturation inhibitory protein from urine of pregnant women: N-terminal sequence homology with human nonsecretory ribonuclease. Chem Pharm Bull (Tokyo). 1991 Jan;39(1):146-9.
2383019	Mizuta K, Awazu S, Yasuda T, Kishi K: Purification and characterization of three ribonucleases from human kidney: comparison with urine ribonucleases. Arch Biochem Biophys. 1990 Aug 15;281(1):144-51.
3202829	Beintema JJ, Blank A, Schieven GL, Dekker CA, Sorrentino S, Libonati M: Differences in glycosylation pattern of human secretory ribonucleases. Biochem J. 1988 Oct 15;255(2):501-5.
6201087	Beintema JJ, Wietzes P, Weickmann JL, Glitz DG: The amino acid sequence of human pancreatic ribonuclease. Anal Biochem. 1984 Jan;136(1):48-64.
7649283	Russo N, de Nigris M, Ciardiello A, Di Donato A, D'Alessio G: Expression in mammalian cells, purification and characterization of recombinant human pancreatic ribonuclease. FEBS Lett. 1995 Aug 7;369(2-3):352.
8049276	Seno M, Futami J, Kosaka M, Seno S, Yamada H: Nucleotide sequence encoding human pancreatic ribonuclease. Biochim Biophys Acta. 1994 Aug 2;1218(3):466-8.
8588814	Kochetov AV, Lukasheva VV, Filipenko ML, Mertvetsov NP, Rivkin MI: [Primary structure of the coding part of the gene for human pancreatic ribonuclease and its chromosomal location] Bioorg Khim. 1995 Sep;21(9):691-4.

# Drug_Target_65_HGNC_ID:
HGNC:10044

# Drug_Target_65_HPRD_ID:
Not Available

# Drug_Target_65_ID:
5682

# Drug_Target_65_Locus:
14q11.2

# Drug_Target_65_Molecular_Weight:
17644

# Drug_Target_65_Name:
Ribonuclease pancreatic

# Drug_Target_65_Number_of_Residues:
156

# Drug_Target_65_PDB_ID:
1E21

# Drug_Target_65_Pathway:
Not Available

# Drug_Target_65_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_65_Protein_Sequence:
>Ribonuclease pancreatic
MALEKSLVRLLLLVLILLVLGWVQPSLGKESRAKKFQRQHMDSDSSPSSSSTYCNQMMRR
RNMTQGRCKPVNTFVHEPLVDVQNVCFQEKVTCKNGQGNCYKSNSSMHITDCRLTNGSRY
PNCAYRTSPKERHIIVACEGSPYVPVHFDASVEDST

# Drug_Target_65_Reaction:
Not Available

# Drug_Target_65_Signals:
1-28

# Drug_Target_65_Specific_Function:
Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single stranded and double stranded RNA

# Drug_Target_65_SwissProt_ID:
P07998

# Drug_Target_65_SwissProt_Name:
RNAS1_HUMAN

# Drug_Target_65_Synonyms:
EC 3.1.27.5
HP-RNase
RIB-1
RNase 1
RNase A
RNase UpI-1
Ribonuclease pancreatic precursor

# Drug_Target_65_Theoretical_pI:
8.94

# Drug_Target_65_Transmembrane_Regions:
None

# Drug_Target_66_Cellular_Location:
Not Available

# Drug_Target_66_Chromosome_Location:
Not Available

# Drug_Target_66_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_66_Essentiality:
Non-Essential

# Drug_Target_66_GenAtlas_ID:
Not Available

# Drug_Target_66_GenBank_ID_Gene:
U05257

# Drug_Target_66_GenBank_ID_Protein:
487434

# Drug_Target_66_GeneCard_ID:
Not Available

# Drug_Target_66_Gene_Name:
icd

# Drug_Target_66_Gene_Sequence:
>1272 bp
GTGGCACAAGGTGAAAAAATTACAGTCTCTAACGGAGTATTAAACGTACCAAACAACCCG
ATTATCCCATTTATCGAAGGAGACGGAACCGGTCCTGATATTTGGAACGCGGCTTCGAAG
GTTTTGGAAGCAGCAGTAGAAAAAGCATACAAAGGCGAAAAGAAAATTACATGGAAAGAA
GTTTACGCCGGAGAAAAGGCTTATAATAAAACAGGTGAGTGGCTCCCTGCTGAAACATTA
GATGTGATCCGCGAATATTTCATCGCGATTAAAGGCCCGTTAACGACACCTGTCGGCGGC
GGTATCCGTTCTTTGAACGTAGCGCTCAGACAAGAGCTTGACCTATTCGTCTGCTTAAGA
CCTGTAAGATACTTTACTGGAGTGCCGTCACCGGTAAAACGCCCTGAAGATACTGATATG
GTCATCTTCCGTGAAAATACAGAAGATATTTACGCAGGCATCGAGTATGCAAAAGGCTCT
GAAGAAGTGCAAAAGCTTATCAGCTTCCTTCAAAATGAGTTAAACGTCAATAAAATCCGT
TTCCCTGAGACATCAGGTATCGGCATTAAGCCTGTTTCAGAAGAAGGAACAAGCCGCTTG
GTCAGAGCTGCCATTGATTATGCGATCGAGCATGGCCGCAAATCTGTAACACTTGTTCAC
AAAGGAAACATCATGAAGTTCACAGAAGGCGCCTTCAAAAACTGGGGCTATGAACTTGCT
GAAAAAGAATACGGAGATAAAGTCTTCACATGGGCTCAATATGACCGCATTGCTGAAGAA
CAAGGAAAAGACGCTGCCAACAAAGCGCAAAGCGAAGCGGAAGCAGCAGGAAAAATCATT
ATCAAAGACAGCATTGCTGACATTTTCCTTCAGCAGATCTTAACGCGTCCAAACGAGTTT
GATGTCGTTGCGACAATGAACTTGAACGGAGATTACATTTCTGATGCTCTTGCTGCGCAA
GTCGGCGGAATCGGCATTGCTCCTGGAGCGAACATCAACTACGAAACAGGACATGCGATT
TTCGAGGCGACGCACGGAACGGCTCCTAAATATGCAGGCCTTGATAAAGTAAACCCATCT
TCAGTTATTCTTTCAGGCGTTCTGCTTCTTGAGCATTTAGGATGGAACGAAGCGGCTGAT
TTGGTTATCAAATCTATGGAAAAAACAATCGCTTCTAAAGTCGTAACTTACGATTTTGCC
AGATTAATGGACGGGGCGACTGAAGTGAAATGTTCAGAGTTCGGAGAAGAACTGATCAAA
AACATGGACTAA

# Drug_Target_66_General_Function:
Energy production and conversion

# Drug_Target_66_General_References:
11290745	Singh SK, Matsuno K, LaPorte DC, Banaszak LJ: Crystal structure of Bacillus subtilis isocitrate dehydrogenase at 1.55 A. Insights into the nature of substrate specificity exhibited by Escherichia coli isocitrate dehydrogenase kinase/phosphatase. J Biol Chem. 2001 Jul 13;276(28):26154-63. Epub 2001 Apr 4.
11751849	Singh SK, Miller SP, Dean A, Banaszak LJ, LaPorte DC: Bacillus subtilis isocitrate dehydrogenase. A substrate analogue for Escherichia coli isocitrate dehydrogenase kinase/phosphatase. J Biol Chem. 2002 Mar 1;277(9):7567-73. Epub 2002 Jan 7.
8045898	Jin S, Sonenshein AL: Identification of two distinct Bacillus subtilis citrate synthase genes. J Bacteriol. 1994 Aug;176(15):4669-79.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9387221	Lapidus A, Galleron N, Sorokin A, Ehrlich SD: Sequencing and functional annotation of the Bacillus subtilis genes in the 200 kb rrnB-dnaB region. Microbiology. 1997 Nov;143 ( Pt 11):3431-41.

# Drug_Target_66_HGNC_ID:
Not Available

# Drug_Target_66_HPRD_ID:
Not Available

# Drug_Target_66_ID:
2771

# Drug_Target_66_Locus:
Not Available

# Drug_Target_66_Molecular_Weight:
46418

# Drug_Target_66_Name:
Isocitrate dehydrogenase [NADP]

# Drug_Target_66_Number_of_Residues:
423

# Drug_Target_66_PDB_ID:
1HQS

# Drug_Target_66_Pathway:
Not Available

# Drug_Target_66_Pfam_Domain_Function:
PF00180	Iso_dh

# Drug_Target_66_Protein_Sequence:
>Isocitrate dehydrogenase [NADP]
MAQGEKITVSNGVLNVPNNPIIPFIEGDGTGPDIWNAASKVLEAAVEKAYKGEKKITWKE
VYAGEKAYNKTGEWLPAETLDVIREYFIAIKGPLTTPVGGGIRSLNVALRQELDLFVCLR
PVRYFTGVPSPVKRPEDTDMVIFRENTEDIYAGIEYAKGSEEVQKLISFLQNELNVNKIR
FPETSGIGIKPVSEEGTSRLVRAAIDYAIEHGRKSVTLVHKGNIMKFTEGAFKNWGYELA
EKEYGDKVFTWAQYDRIAEEQGKDAANKAQSEAEAAGKIIIKDSIADIFLQQILTRPNEF
DVVATMNLNGDYISDALAAQVGGIGIAPGANINYETGHAIFEATHGTAPKYAGLDKVNPS
SVILSGVLLLEHLGWNEAADLVIKSMEKTIASKVVTYDFARLMDGATEVKCSEFGEELIK
NMD

# Drug_Target_66_Reaction:
(1) isocitrate + NADP+ = 2-oxoglutarate + CO2 + NADPH

# Drug_Target_66_Signals:
None

# Drug_Target_66_Specific_Function:
Isocitrate + NADP(+) = 2-oxoglutarate + CO(2) + NADPH

# Drug_Target_66_SwissProt_ID:
P39126

# Drug_Target_66_SwissProt_Name:
IDH_BACSU

# Drug_Target_66_Synonyms:
EC 1.1.1.42
IDH
IDP
NADP(+)-specific ICDH
Oxalosuccinate decarboxylase

# Drug_Target_66_Theoretical_pI:
4.74

# Drug_Target_66_Transmembrane_Regions:
None

# Drug_Target_67_Cellular_Location:
Cytoplasm

# Drug_Target_67_Chromosome_Location:
Not Available

# Drug_Target_67_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_67_Essentiality:
Non-Essential

# Drug_Target_67_GenAtlas_ID:
GNMT

# Drug_Target_67_GenBank_ID_Gene:
AF101477

# Drug_Target_67_GenBank_ID_Protein:
8671584

# Drug_Target_67_GeneCard_ID:
GNMT

# Drug_Target_67_Gene_Name:
GNMT

# Drug_Target_67_Gene_Sequence:
>888 bp
ATGGTGGACAGCGTGTACCGGACCCGCTCCCTGGGGGTGGCGGCCGAAGGGCTCCCGGAC
CAGTACGCGGACGGGGAGGCGGCGCGCGTGTGGCAGCTGTATATCGGAGACACCCGCAGC
CGCACCGCCGAGTACAAGGCATGGCTGCTTGGGCTGCTGCGCCAGCACGGCTGCCAGCGG
GTGCTCGACGTAGCCTGTGGCACTGGGGTGGACTCCATTATGCTGGTGGAAGAGGGCTTC
AGTGTGACGAGTGTGGATGCCAGTGACAAGATGCTGAAGTATGCACTTAAGGAGCGCTGG
AACCGGCGGCACGAGCCCGCCTTCGACAAGTGGGTCATCGAAGAAGCCAACTGGATGACT
CTGGACAAAGATGTGCCCCAGTCAGCAGAGGGTGGCTTTGATGCTGTCATCTGCCTTGGA
AACAGTTTCGCTCACTTGCCAGACTGCAAAGGGGACCAGAGTGAGCACCGGCTGGCGCTG
AAAAACATTGCGAGCATGGTGCGGGCAGGGGGCCTACTGGTCATTGATCATCGCAACTAC
GACCACATCCTCAGTACAGGCTGTGCACCCCCAGGGAAGAACATCTACTATAAGAGTGAC
TTGACCAAGGACGTCACAACATCAGTGCTGATAGTGAACAACAAGGCCCACATGGTGACC
CTGGACTATACGGTGCAGGTGCCGGGGGCTGGCCAGGATGGCTCTCCTGGCTTGAGTAAG
TTCCGGCTCTCCTACTACCCACACTGTCTGGCATCCTTCACGGAGCTGCTCCAAGCAGCC
TTCGGAGGTAAGTGCCAGCACAGCGTCCTGGGCGACTTCAAGCCTTACAAGCCAGGCCAA
ACCTACATTCCCTGCTACTTCATCCACGTGCTCAAGAGGACAGACTGA

# Drug_Target_67_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_67_General_References:
10843803	Chen YM, Chen LY, Wong FH, Lee CM, Chang TJ, Yang-Feng TL: Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics. 2000 May 15;66(1):43-7.
11810299	Luka Z, Cerone R, Phillips JA 3rd, Mudd HS, Wagner C: Mutations in human glycine N-methyltransferase give insights into its role in methionine metabolism. Hum Genet. 2002 Jan;110(1):68-74. Epub 2001 Dec 7.
9495250	Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY, Chen PH: Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int J Cancer. 1998 Mar 2;75(5):787-93.

# Drug_Target_67_HGNC_ID:
HGNC:4415

# Drug_Target_67_HPRD_ID:
05970

# Drug_Target_67_ID:
411

# Drug_Target_67_Locus:
6p12

# Drug_Target_67_Molecular_Weight:
32611

# Drug_Target_67_Name:
Glycine N-methyltransferase

# Drug_Target_67_Number_of_Residues:
294

# Drug_Target_67_PDB_ID:
1R74

# Drug_Target_67_Pathway:
Not Available

# Drug_Target_67_Pfam_Domain_Function:
PF08242	Methyltransf_12

# Drug_Target_67_Protein_Sequence:
>Glycine N-methyltransferase
VDSVYRTRSLGVAAEGLPDQYADGEAARVWQLYIGDTRSRTAEYKAWLLGLLRQHGCQRV
LDVACGTGVDSIMLVEEGFSVTSVDASDKMLKYALKERWNRRHEPAFDKWVIEEANWMTL
DKDVPQSAEGGFDAVICLGNSFAHLPDCKGDQSEHRLALKNIASMVRAGGLLVIDHRNYD
HILSTGCAPPGKNIYYKSDLTKDVTTSVLIVNNKAHMVTLDYTVQVPGAGQDGSPGLSKF
RLSYYPHCLASFTELLQAAFGGKCQHSVLGDFKPYKPGQTYIPCYFIHVLKRTD

# Drug_Target_67_Reaction:
S-adenosyl-L-methionine + glycine = S-adenosyl-L-homocysteine + sarcosine

# Drug_Target_67_Signals:
None

# Drug_Target_67_Specific_Function:
Catalyzes the methylation of glycine by using S- adenosylmethionine (AdoMet) to form N-methylglycine (sarcosine) with the concomitant production of S-adenosylhomocysteine (AdoHcy). Possible crucial role in the regulation of tissue concentration of AdoMet and of metabolism of methionine

# Drug_Target_67_SwissProt_ID:
Q14749

# Drug_Target_67_SwissProt_Name:
GNMT_HUMAN

# Drug_Target_67_Synonyms:
EC 2.1.1.20

# Drug_Target_67_Theoretical_pI:
7.03

# Drug_Target_67_Transmembrane_Regions:
None

# Drug_Target_68_Cellular_Location:
Cytoplasmic granule. Note=Matrix of eosinophil's large specific granule

# Drug_Target_68_Chromosome_Location:
Not Available

# Drug_Target_68_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_68_Essentiality:
Non-Essential

# Drug_Target_68_GenAtlas_ID:
RNASE3

# Drug_Target_68_GenBank_ID_Gene:
X15161

# Drug_Target_68_GenBank_ID_Protein:
31077

# Drug_Target_68_GeneCard_ID:
RNASE3

# Drug_Target_68_Gene_Name:
RNASE3

# Drug_Target_68_Gene_Sequence:
>483 bp
ATGGTTCCAAAACTGTTCACTTCCCAAATTTGTCTGCTTCTTCTGTTGGGGCTTATGGGT
GTGGAGGGCTCACTCCATGCCAGACCCCCACAGTTTACGAGGGCTCAGTGGTTTGCCATC
CAGCACATCAGTCTGAACCCCCCTCGATGCACCATTGCAATGCGGGCAATTAACAATTAT
CGATGGCGTTGCAAAAACCAAAATACTTTTCTTCGTACAACTTTTGCTAATGTAGTTAAT
GTTTGTGGTAACCAAAGTATACGCTGCCCTCATAACAGAACTCTCAACAATTGTCATCGG
AGTAGATTCCGGGTGCCTTTACTCCACTGTGACCTCATAAATCCAGGTGCACAGAATATT
TCAAACTGCAGGTATGCAGACAGACCAGGAAGGAGGTTCTATGTAGTTGCATGTGACAAC
AGAGATCCACGGGATTCTCCACGGTATCCTGTGGTTCCAGTTCACCTGGATACCACCATC
TAA

# Drug_Target_68_General_Function:
Involved in nucleic acid binding

# Drug_Target_68_General_References:
10606511	Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR: Crystal structure of eosinophil cationic protein at 2.4 A resolution. Biochemistry. 1999 Dec 21;38(51):16794-801.
10903870	Mallorqui-Fernandez G, Pous J, Peracaula R, Aymami J, Maeda T, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Ruth FX, Coll M: Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution. J Mol Biol. 2000 Jul 28;300(5):1297-307.
11102386	Zhang J, Rosenberg HF: Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics. 2000 Dec;156(4):1949-58.
12356310	Mohan CG, Boix E, Evans HR, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR: The crystal structure of eosinophil cationic protein in complex with 2',5'-ADP at 2.0 A resolution reveals the details of the ribonucleolytic active site. Biochemistry. 2002 Oct 8;41(40):12100-6.
12508121	Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M, Barbe V, de Berardinis V, Ureta-Vidal A, Pelletier E, Vico V, Anthouard V, Rowen L, Madan A, Qin S, Sun H, Du H, Pepin K, Artiguenave F, Robert C, Cruaud C, Bruls T, Jaillon O, Friedlander L, Samson G, Brottier P, Cure S, Segurens B, Aniere F, Samain S, Crespeau H, Abbasi N, Aiach N, Boscus D, Dickhoff R, Dors M, Dubois I, Friedman C, Gouyvenoux M, James R, Madan A, Mairey-Estrada B, Mangenot S, Martins N, Menard M, Oztas S, Ratcliffe A, Shaffer T, Trask B, Vacherie B, Bellemere C, Belser C, Besnard-Gonnet M, Bartol-Mavel D, Boutard M, Briez-Silla S, Combette S, Dufosse-Laurent V, Ferron C, Lechaplais C, Louesse C, Muselet D, Magdelenat G, Pateau E, Petit E, Sirvain-Trukniewicz P, Trybou A, Vega-Czarny N, Bataille E, Bluet E, Bordelais I, Dubois M, Dumont C, Guerin T, Haffray S, Hammadi R, Muanga J, Pellouin V, Robert D, Wunderle E, Gauguet G, Roy A, Sainte-Marthe L, Verdier J, Verdier-Discala C, Hillier L, Fulton L, McPherson J, Matsuda F, Wilson R, Scarpelli C, Gyapay G, Wincker P, Saurin W, Quetier F, Waterston R, Hood L, Weissenbach J: The DNA sequence and analysis of human chromosome 14. Nature. 2003 Feb 6;421(6923):601-7. Epub 2003 Jan 1.
2387583	Hamann KJ, Ten RM, Loegering DA, Jenkins RB, Heise MT, Schad CR, Pease LR, Gleich GJ, Barker RL: Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily. Genomics. 1990 Aug;7(4):535-46.
2473157	Rosenberg HF, Ackerman SJ, Tenen DG: Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med. 1989 Jul 1;170(1):163-76.
2501794	Gabay JE, Scott RW, Campanelli D, Griffith J, Wilde C, Marra MN, Seeger M, Nathan CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5610-4.
2745977	Barker RL, Loegering DA, Ten RM, Hamann KJ, Pease LR, Gleich GJ: Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. J Immunol. 1989 Aug 1;143(3):952-5.
3458170	Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ: Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A. 1986 May;83(10):3146-50.

# Drug_Target_68_HGNC_ID:
HGNC:10046

# Drug_Target_68_HPRD_ID:
00575

# Drug_Target_68_ID:
1123

# Drug_Target_68_Locus:
14q24-q31

# Drug_Target_68_Molecular_Weight:
18386

# Drug_Target_68_Name:
Eosinophil cationic protein

# Drug_Target_68_Number_of_Residues:
160

# Drug_Target_68_PDB_ID:
1DYT

# Drug_Target_68_Pathway:
Not Available

# Drug_Target_68_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_68_Protein_Sequence:
>Eosinophil cationic protein precursor
MVPKLFTSQICLLLLLGLMGVEGSLHARPPQFTRAQWFAIQHISLNPPRCTIAMRAINNY
RWRCKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNNCHRSRFRVPLLHCDLINPGAQNI
SNCTYADRPGRRFYVVACDNRDPRDSPRYPVVPVHLDTTI

# Drug_Target_68_Reaction:
Not Available

# Drug_Target_68_Signals:
1-27

# Drug_Target_68_Specific_Function:
Cytotoxin and helminthotoxin with low-efficiency ribonuclease activity. Possesses a wide variety of biological activities. Exhibits antibacterial activity

# Drug_Target_68_SwissProt_ID:
P12724

# Drug_Target_68_SwissProt_Name:
ECP_HUMAN

# Drug_Target_68_Synonyms:
EC 3.1.27.-
ECP
Eosinophil cationic protein precursor
RNase 3
Ribonuclease 3

# Drug_Target_68_Theoretical_pI:
10.33

# Drug_Target_68_Transmembrane_Regions:
None

# Drug_Target_69_Cellular_Location:
Cell membrane
lipid-anchor (Probable)

# Drug_Target_69_Chromosome_Location:
Not Available

# Drug_Target_69_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_69_Essentiality:
Non-Essential

# Drug_Target_69_GenAtlas_ID:
Not Available

# Drug_Target_69_GenBank_ID_Gene:
V00093

# Drug_Target_69_GenBank_ID_Protein:
39575

# Drug_Target_69_GeneCard_ID:
Not Available

# Drug_Target_69_Gene_Name:
penP

# Drug_Target_69_Gene_Sequence:
>924 bp
ATGAAATTATGGTTCAGTACTTTAAAACTGAAAAAGGCTGCAGCAGTGTTGCTTTTCTCT
TGCGTCGCGCTTGCAGGATGCGCTAACAATCAAACGAATGCCTCGCAACCTGCCGAGAAG
AATGAAAAGACGGAGATGAAAGATGATTTTGCAAAACTTGAGGAACAATTTGATGCAAAA
CTCGGGATCTTTGCATTGGATACAGGTACAAACCGGACGGTAGCGTATCGGCCGGATGAG
CGTTTTGCTTTTGCTTCGACGATTAAGGCTTTAACTGTAGGCGTGCTTTTGCAACAGAAA
TCAATAGAAGATCTGAACCAGAGAATAACATATACACGTGATGATCTTGTAAACTACAAC
CCGATTACGGAAAAGCACGTTGATACGGGAATGACGCTCAAAGAGCTTGCGGATGCTTCG
CTTCGATATAGTGACAATGCGGCACAGAATCTCATTCTTAAACAAATTGGCGGACCTGAA
AGTTTGAAAAAGGAACTGAGGAAGATTGGTGATGAGGTTACAAATCCCGAACGATTCGAA
CCAGAGTTAAATGAAGTGAATCCGGGTGAAACTCAGGATACCAGTACAGCAAGAGCACTT
GTCACAAGCCTTCGAGCCTTTGCTCTTGAAGATAAACTTCCAAGTGAAAAACGCGAGCTT
TTAATCGATTGGATGAAACGAAATACCACTGGAGACGCCTTAATCCGTGCCGGTGTGCCG
GACGGTTGGGAAGTGGCTGATAAAACTGGAGCGGCATCATATGGAACCCGGAATGACATT
GCCATCATTTGGCCGCCAAAAGGAGATCCTGTCGTTCTTGCAGTATTATCCAGCAGGGAT
AAAAAGGACGCCAAGTATGATGATAAACTTATTGCAGAGGCAACAAAGGTGGTAATGAAA
GCCTTAAACATGAACGGCAAATAA

# Drug_Target_69_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_69_General_References:
11827533	Fonze E, Vanhove M, Dive G, Sauvage E, Frere JM, Charlier P: Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin. Biochemistry. 2002 Feb 12;41(6):1877-85.
1856867	Knox JR, Moews PC: Beta-lactamase of Bacillus licheniformis 749/C. Refinement at 2 A resolution and analysis of hydration. J Mol Biol. 1991 Jul 20;220(2):435-55.
2326252	Moews PC, Knox JR, Dideberg O, Charlier P, Frere JM: Beta-lactamase of Bacillus licheniformis 749/C at 2 A resolution. Proteins. 1990;7(2):156-71.
3260234	Wittman V, Wong HC: Regulation of the penicillinase genes of Bacillus licheniformis: interaction of the pen repressor with its operators. J Bacteriol. 1988 Jul;170(7):3206-12.
5353499	Meadway RJ: The amino acid sequence of penicillinase from Bacillus licheniformis. Biochem J. 1969 Nov;115(3):12P-13P.
6269055	Neugebauer K, Sprengel R, Schaller H: Penicillinase from Bacillus licheniformis: nucleotide sequence of the gene and implications for the biosynthesis of a secretory protein in a Gram-positive bacterium. Nucleic Acids Res. 1981 Jun 11;9(11):2577-88.
6966510	Izui K, Nielsen JB, Caulfield MP, Lampen JO: Large exopenicillinase, initial extracellular form detected in cultures of Bacillus licheniformis. Biochemistry. 1980 Apr 29;19(9):1882-6.
6977472	Kroyer J, Chang S: The promoter-proximal region of the Bacillus licheniformis penicillinase gene: Nucleotide sequence and predicted leader peptide sequence. Gene. 1981 Dec;15(4):343-7.

# Drug_Target_69_HGNC_ID:
Not Available

# Drug_Target_69_HPRD_ID:
Not Available

# Drug_Target_69_ID:
2700

# Drug_Target_69_Locus:
Not Available

# Drug_Target_69_Molecular_Weight:
33996

# Drug_Target_69_Name:
Beta-lactamase

# Drug_Target_69_Number_of_Residues:
307

# Drug_Target_69_PDB_ID:
1I2W

# Drug_Target_69_Pathway:
Not Available

# Drug_Target_69_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_69_Protein_Sequence:
>Beta-lactamase precursor
MKLWFSTLKLKKAAAVLLFSCVALAGCANNQTNASQPAEKNEKTEMKDDFAKLEEQFDAK
LGIFALDTGTNRTVAYRPDERFAFASTIKALTVGVLLQQKSIEDLNQRITYTRDDLVNYN
PITEKHVDTGMTLKELADASLRYSDNAAQNLILKQIGGPESLKKELRKIGDEVTNPERFE
PELNEVNPGETQDTSTARALVTSLRAFALEDKLPSEKRELLIDWMKRNTTGDALIRAGVP
DGWEVADKTGAASYGTRNDIAIIWPPKGDPVVLAVLSSRDKKDAKYDDKLIAEATKVVMK
ALNMNGK

# Drug_Target_69_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_69_Signals:
1-26

# Drug_Target_69_Specific_Function:
A beta-lactam + H(2)O = a substituted beta- amino acid

# Drug_Target_69_SwissProt_ID:
P00808

# Drug_Target_69_SwissProt_Name:
BLAC_BACLI

# Drug_Target_69_Synonyms:
Beta-lactamase precursor
EC 3.5.2.6
Penicillinase

# Drug_Target_69_Theoretical_pI:
5.61

# Drug_Target_69_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
M37980

# Drug_Target_6_GenBank_ID_Protein:
210273

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
gag-pro-pol

# Drug_Target_6_Gene_Sequence:
>2688 bp
ACTGTTGCGCTACATCTGGCTATTCCGCTCAAATGGAAGCCAGACCACACGCCTGTGTGG
ATTGACCAGTGGCCCCTTCCTGAAGGTAAACTTGTAGCGCTAACGCAATTAGTGGAAAAA
GAATTACAGTTAGGACATATAGAACCTTCACTTAGTTGTTGGAACACACCTGTCTTTGTG
ATCCGGAAGGCTTCCGGGTCTTATCGCTTATTGCATGACTTGCGCGCTGTTAACGCCAAG
CTTGTTCCTTTTGGGGCCGTCCAACAGGGGGCGCCAGTTCTCTCCGCGCTCCCGCGTGGC
TGGCCCCTGATGGTCCTAGACCTCAAGGATTGCTTCTTTTCTATTCCTCTTGCGGAACAA
GATCGCGAAGCTTTTGCATTTACGCTCCCCTCTGTGAATAACCAGGCCCCCGCTCGAAGA
TTCCAATGGAAGGTCTTGCCCCAAGGGATGACCTGTTCTCCCACTATCTGTCAGTTGGTG
GTGGGTCAGGTACTTGAGCCCTTGCGACTCAAGCACCCATCTCTGCGCATGTTGCATTAT
ATGGATGATCTTTTGCTAGCCGCCTCAAGTCATGATGGGTTGGAAGCGGCAGGGGAGGAG
GTTATCAGTACATTGGAAAGAGCCGGGTTCACCATTTCGCCTGATAAGATCCAGAGGGAA
CCCGGAGTACAATATCTTGGGTACAAGTTAGGCAGTACGTATGTAGCACCCGTAGGCCTG
GTAGCAGAACCCAGGATAGCCACCTTGTGGGATGTTCAAAAGCTGGTGGGGTCACTTCAG
TGGCTTCGCCCAGCGTTAGGAATCCCGCCACGACTGATGGGCCCCTTCTATGAGCAGTTA
CGAGGGTCAGATCCTAACGAGGCGAGGGAATGGAATCTAGACATGAAAATGGCCTGGAGA
GAGATCGTACAGCTTAGCACCACTGCTGCCTTGGAACGATGGGACCCTGCCCTGCCTTTG
GAGGGAGCGGTCGCTAGGTGTGAACAGGGGGCAATAGGGGTCCTGGGACAGGGACTGTCC
ACACACCCAAGGCCATGTTTGTGGTTATTCTCCACCCAACCCACCAAGGCGTTTACTGCT
TGGTTAGAAGTGCTCACCCTTTTGATTACTAAGCTACGCGCTTCGGCAGTGCGAACCTTT
GGCAAGGAGGTTGATATCCTCCTGTTGCCTGCATGCTTTCGGGAGGACCTTCCGCTCCCG
GAGGGGATCCTGTTAGCCCTTAGGGGGTTTGCAGGAAAAATCAGGAGTAGTGACACGCCA
TCTATTTTTGACATTGCGCGTCCACTGCATGTTTCTCTGAAAGTGAGGGTCACCGACCAC
CCTGTACCGGGACCCACTGCCTTTACCGACGCCTCCTCAAGCACCCATAAAGGGGTGGTA
GTCTGGAGGGAGGGCCCAAGGTGGGAGATAAAAGAAATAGCTGATTTGGGGGCAAGTGTA
CAACAACTGGAAGCACGCGCTGTGGCCATGGCACTTCTGCTGTGGCCGACAACGCCCACT
AATGTAGTGACTGACTCCGCGTTTGTCGCGAAAATGTTACTCAAGATGGGACAGGAGGGA
GTCCCGTCTACAGCGGCGGCTTTTATTTTAGAGGATGCGTTAAGCCAAAGGTCAGCCATG
GCCGCCGTTCTCCACGTGCGGAGTCATTCTGAAGTGCCAGGGTTTTTCACAGAAGGAAAT
GACGTGGCAGATAGCCAAGCCACCTTTCAAGCGTATCCCTTGAGAGAGGCTAAAGATCTT
CATACTGCTCTCCATATTGGACCCCGCGCGCTATCCAAAGCGTGTAATATATCTATGCAG
CAGGCTAGGGAGGTTGTTCAGACCTGCCCGCATTGTAATTCAGCCCCTGCGTTGGAGGCC
GGGGTAAACCCTAGGGGTTTGGGACCCCTACAGATATGGCAGACAGACTTTACGCTTGAG
CCTAGAATGGCCCCCCGTTCCTGGCTCGCTGTTACTGTGGATACCGCCTCATCGGCGATA
GTCGTAACTCAGCATGGCCGTGTCACATCGGTTGCTGCACAACATCATTGGGCCACGGCT
ATCGCCGTTTTGGGAAGACCAAAGGCCATAAAAACAGATAATGGGTCCTGTTTCACGTCT
AAATCCACGCGAGAGTGGCTCGCGAGATGGGGGATAGCACACACCACCGGGATTCCGGGT
AATTCCCAGGGTCAAGCTATGGTAGAGCGGGCCAACCGGCTCCTGAAAGATAAGATCCGT
GTGCTTGCGGAGGGGGACGGCTTTATGAAAAGAATCCCCACCAGCAAACAGGGGGAACTA
CTAGCCAAGGCAATGTATGCCCTCAATCACTTTGAGCGCGGTGAAAACACAAAAACACCG
ATTCAAAAACACTGGAGACCTACCGTTCTTACAGAAGGACCCCCGGTTAAAATACGAATA
GAGACAGGGGAGTGGGAAAAAGGATGGAATGTGCTGGTCTGGGGACGAGGTTATGCAGCT
GTGAAAAACAGGGACACTGATAAGGTTATTTGGGTACCCTCTCGGAAAGTTAAACCGGAT
GTCACCCAAAAGGATGAGGTGACTAAGAAAGATGAGGCGAGCCCTCTTTTTGCAGGCATT
TCTGACTGGATACCCTGGGAAGACGAGCAAGAAGGACTCCAAGGAGAAACCGCTAGCAAC
AAGCAAGAAAGACCCGGAGAAGACACCCTTGCTGCCAACGAGAGTTAA

# Drug_Target_6_General_Function:
Involved in RNA binding

# Drug_Target_6_General_References:
1311072	Bieth E, Darlix JL: Complete nucleotide sequence of a highly infectious avian leukosis virus. Nucleic Acids Res. 1992 Jan 25;20(2):367.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3471

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
98631

# Drug_Target_6_Name:
Pol polyprotein

# Drug_Target_6_Number_of_Residues:
895

# Drug_Target_6_PDB_ID:
1C1A

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00075	RnaseH
PF00078	RVT_1
PF00552	Integrase
PF00665	rve
PF02022	Integrase_Zn
PF06817	RVT_thumb

# Drug_Target_6_Protein_Sequence:
>Pol polyprotein [Contains: Reverse transcriptase/ribonuclease H
TVALHLAIPLKWKPDHTPVWIDQWPLPEGKLVALTQLVEKELQLGHIEPSLSCWNTPVFV
IRKASGSYRLLHDLRAVNAKLVPFGAVQQGAPVLSALPRGWPLMVLDLKDCFFSIPLAEQ
DREAFAFTLPSVNNQAPARRFQWKVLPQGMTCSPTICQLVVGQVLEPLRLKHPSLRMLHY
MDDLLLAASSHDGLEAAGEEVISTLERAGFTISPDKIQREPGVQYLGYKLGSTYVAPVGL
VAEPRIATLWDVQKLVGSLQWLRPALGIPPRLMGPFYEQLRGSDPNEAREWNLDMKMAWR
EIVQLSTTAALERWDPALPLEGAVARCEQGAIGVLGQGLSTHPRPCLWLFSTQPTKAFTA
WLEVLTLLITKLRASAVRTFGKEVDILLLPACFREDLPLPEGILLALRGFAGKIRSSDTP
SIFDIARPLHVSLKVRVTDHPVPGPTAFTDASSSTHKGVVVWREGPRWEIKEIADLGASV
QQLEARAVAMALLLWPTTPTNVVTDSAFVAKMLLKMGQEGVPSTAAAFILEDALSQRSAM
AAVLHVRSHSEVPGFFTEGNDVADSQATFQAYPLREAKDLHTALHIGPRALSKACNISMQ
QAREVVQTCPHCNSAPALEAGVNPRGLGPLQIWQTDFTLEPRMAPRSWLAVTVDTASSAI
VVTQHGRVTSVAAQHHWATAIAVLGRPKAIKTDNGSCFTSKSTREWLARWGIAHTTGIPG
NSQGQAMVERANRLLKDKIRVLAEGDGFMKRIPTSKQGELLAKAMYALNHFERGENTKTP
IQKHWRPTVLTEGPPVKIRIETGEWEKGWNVLVWGRGYAAVKNRDTDKVIWVPSRKVKPD
VTQKDEVTKKDEASPLFAGISDWIPWEDEQEGLQGETASNKQERPGEDTLAANES

# Drug_Target_6_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
During replicative cycle of retroviruses, the reverse- transcribed viral DNA is integrated into the host chromosome by the viral integrase enzyme. RNase H activity is associated with the reverse transcriptase

# Drug_Target_6_SwissProt_ID:
Q04095

# Drug_Target_6_SwissProt_Name:
POL_RSVSA

# Drug_Target_6_Synonyms:
EC 2.7.7.49
EC 3.1.26.4
IN
Integrase
Pol polyprotein [Contains: Reverse transcriptase/ribonuclease H
RT
pp32]

# Drug_Target_6_Theoretical_pI:
8.10

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Not Available

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
IL4I1

# Drug_Target_7_Gene_Sequence:
Not Available

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
7076

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
Not Available

# Drug_Target_7_Name:
L-amino-acid oxidase

# Drug_Target_7_Number_of_Residues:
0

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
Not Available

# Drug_Target_7_Protein_Sequence:
Not Available

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
Not Available

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Q96RQ9

# Drug_Target_7_SwissProt_Name:
OXLA_HUMAN

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
Not Available

# Drug_Target_7_Transmembrane_Regions:
Not Available

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
MIF

# Drug_Target_8_GenBank_ID_Gene:
M25639

# Drug_Target_8_GenBank_ID_Protein:
188556

# Drug_Target_8_GeneCard_ID:
MIF

# Drug_Target_8_Gene_Name:
MIF

# Drug_Target_8_Gene_Sequence:
>348 bp
ATGCCGATGTTCATCGTAAACACCAACGTGCCCCGCGCCTCCGTGCCGGACGGGTTCCTC
TCCGAGCTCACCCAGCAGCTGGCGCAGGCCACCGGCAAGCCCCCCCAGTACATCGCGGTG
CACGTGGTCCCGGACCAGCTCATGGCCTTCGGCGGCTCCAGCGAGCCGTGCGCGCTCTGC
AGCCTGCACAGCATCGGCAAGATCGGCGGCGCGCAGAACCGCTCCTACAGCAAGCTGCTG
TGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCCCGGACAGGGTCTACATCAACTATTAC
GACATGAACGCGGCCAGTGTGGGCTGGAACAACTCCACCTTCGCCTAA

# Drug_Target_8_General_Function:
Involved in cytokine activity

# Drug_Target_8_General_References:
10353846	Lubetsky JB, Swope M, Dealwis C, Blake P, Lolis E: Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry. 1999 Jun 1;38(22):7346-54.
11089976	Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000 Nov 9;408(6809):211-6.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
12681488	Shen L, Hu J, Lu H, Wu M, Qin W, Wan D, Li YY, Gu J: The apoptosis-associated protein BNIPL interacts with two cell proliferation-related proteins, MIF and GFER. FEBS Lett. 2003 Apr 10;540(1-3):86-90.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
2552447	Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7522-6.
7679497	Wistow GJ, Shaughnessy MP, Lee DC, Hodin J, Zelenka PS: A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1272-5.
7683862	Zeng FY, Weiser WY, Kratzin H, Stahl B, Karas M, Gabius HJ: The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys. 1993 May 15;303(1):74-80.
7947826	Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 1994 Nov 29;33(47):14144-55.
8188240	Paralkar V, Wistow G: Cloning the human gene for macrophage migration inhibitory factor (MIF). Genomics. 1994 Jan 1;19(1):48-51.
8234256	Mikayama T, Nakano T, Gomi H, Nakagawa Y, Liu YC, Sato M, Iwamatsu A, Ishii Y, Weiser WY, Ishizaka K: Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10056-60.
8610159	Kato Y, Muto T, Tomura T, Tsumura H, Watarai H, Mikayama T, Ishizaka K, Kuroki R: The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3007-10.
8643551	Sun HW, Bernhagen J, Bucala R, Lolis E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5191-6.
8766818	Sugimoto H, Suzuki M, Nakagawa A, Tanaka I, Nishihira J: Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 A resolution. FEBS Lett. 1996 Jul 1;389(2):145-8.

# Drug_Target_8_HGNC_ID:
HGNC:7097

# Drug_Target_8_HPRD_ID:
01091

# Drug_Target_8_ID:
3384

# Drug_Target_8_Locus:
22q11.23

# Drug_Target_8_Molecular_Weight:
12476

# Drug_Target_8_Name:
Macrophage migration inhibitory factor

# Drug_Target_8_Number_of_Residues:
115

# Drug_Target_8_PDB_ID:
1GIF

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01187	MIF

# Drug_Target_8_Protein_Sequence:
>Macrophage migration inhibitory factor
MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALC
SLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA

# Drug_Target_8_Reaction:
keto-phenylpyruvate = enol-phenylpyruvate

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
The expression of MIF at sites of inflammation suggest a role for the mediator in regulating the function of macrophage in host defense. Also acts as a phenylpyruvate tautomerase

# Drug_Target_8_SwissProt_ID:
P14174

# Drug_Target_8_SwissProt_Name:
MIF_HUMAN

# Drug_Target_8_Synonyms:
EC 5.3.2.1
GIF
Glycosylation-inhibiting factor
MIF
Phenylpyruvate tautomerase

# Drug_Target_8_Theoretical_pI:
8.05

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
Not Available

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
CTDSP1

# Drug_Target_9_Gene_Sequence:
Not Available

# Drug_Target_9_General_Function:
Not Available

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
7061

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
Not Available

# Drug_Target_9_Name:
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1

# Drug_Target_9_Number_of_Residues:
0

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
Not Available

# Drug_Target_9_Protein_Sequence:
Not Available

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
Not Available

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
Q9GZU7

# Drug_Target_9_SwissProt_Name:
CTDS1_HUMAN

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
Not Available

# Drug_Target_9_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB04272
